Organization of GABA [sub A] receptor subtypes in spinal nociceptive pathways by Paul, Jolly
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Organization of GABA [sub A] receptor subtypes in spinal nociceptive
pathways
Paul, Jolly
Abstract: Im Rückenmark sind GABAAR sowohl postsynaptisch auf intrinsischen Neuronen des Hinter-
horns als auch auf den Terminalen primär afferenter Nozizeptoren exprimiert, wo sie durch primäraffer-
ente Depolarisation (engl. primary afferent depolrization, PAD) zur präsynaptischen Hemmung beitra-
gen. Die meisten dieser präsynaptischen GABAAR gehören zum 2 Typ. Im ersten Teilprojekt der
vorliegenden Dissertation untersuchten wir Mäuse, deren Nozizeptoren entweder keine 2 GABAAR ex-
primierten (sns-2-/-) oder aufgrund einer Punktmutation insensitiv gegenüber Diazepam waren (sns-
2R/-). Basale Schmerzschwellen sowie entzündliche und neuropathische Neuropathie waren in beiden
Mausstämmen unverändert. Im Entzündungsschmerzmodell war jedoch der antihyperalgetische Effekt
von intrathekal injiziertem Diazepam signifikant vermindert. Im zweiten Teilprojekt sollte der mögliche
Beitrag supraspinaler 2 GABAAR zur Antihyperalgesie untersucht werden. Ein solcher Beitrag kön-
nte etwa in einer Aufhebung angstvermittelter Hyperalgesie oder in einem genuinen antihyperalgetis-
chen Effekt bestehen. Hierzu wurden HoxB8-2-/- Mäuse, denen 2 GABAAR im Rückenmark und in
der Peripherie fehlen, systemisch mit HZ166 behandelt. HZ166 ist ein neu entwickelter Agonist an
der Benzodiazepin-Bindungsstelle von GABAAR mit reduzierten sedativen Eigenschaften. Die selek-
tive Ablation spinaler und peripherer GABAAR führte zu einem kompletten Verlust der 2-vermittelten
Komponente der HZ166-induzierten Antihyperalgesie im Neuropathiemodell. Diese Ergebnisse zeigen,
dass supraspinale 2 GABAAR nicht wesentlich zur HZ166- vermittlelten Antihyperalgesie beitragen,
und legen damit auch nahe, dass indirekte Effekte, die z.B. durch die anxiolytische Wirkung zustande
kommen könnten, keine wesentliche Rolle spielen. Im dritten Teilprojekt wurde daher die molekulare
Zusammensetzung der GABAAR-Subtypen im Hinterhorn des Rückenmarks einer detaillierten Analyse
unterzogen. Histologische Färbung von verschiedenen Markerproteinen im selben Schnitt und hochsen-
sitive Detektionsmethoden zeigten, dass die Verteilung der GABAAR im Hinterhorn des Rückenmarks
einen sehr hohen Organisationgrad aufweist. Insbesondere 2 und 3 GABAAR zeigten eine strategisch
äusserst effektive Verteilung auf Nociceptorterminalen und auf exzitatorischen und inhibitorischen In-
terneuronen. Die Ergebnisse dieser Untersuchungen belegen, dass 2, 3 und 5 GABAAR auf prä- und
postsynaptischen Kompartimenten spezifischer Neuronentypen lokalisiert sind, die eine zentrale Rolle für
die GABAerge Kontrolle der Nociception spielen.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-164135
Dissertation
Published Version
Originally published at:
Paul, Jolly. Organization of GABA [sub A] receptor subtypes in spinal nociceptive pathways. 2012,
University of Zurich, Faculty of Science.
2
 
 
ORGANIZATION OF GABAA RECEPTOR SUBTYPES IN 
SPINAL NOCICEPTIVE PATHWAYS 
 
 
Dissertation 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
 
von 
Jolly Paul 
aus 
Kerala, India 
 
Promotionkomitee 
Prof. Dr. Jean-Marc Fritschy, examiner 
Prof. Dr. Hanns Ulrich Zeilhofer, co-examiner 
Prof. Dr. Esther Stöckli, co-examiner 
 
Zurich, 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to 
 
Mamma and Shank
 
 
 
 
Acknowledgements 
 
Pursuing a PhD project was an incomparable experience in life that in fact shaped me as a 
person. It was like climbing a peak, step by step, accompanied with joy, bitterness, hardships, 
frustration, encouragement and trust and with so many people’s kind help. I am truly 
privileged to thank all of them for their unequivocal roles in facilitating an efficient team work 
for these projects.  
 
First of all, I would like to extend my heart-felt gratitude to my honorific supervisors, Prof. Dr. 
Hanns Ulrich Zeilhofer and Prof. Dr. Jean-Marc Fritschy for giving me the great opportunity to 
conduct this challenging research project at the Institute of Pharmacology and Toxicology, with 
its excellent infrastructure. I would like to express my sincere gratefulness to Prof. Dr. Hanns 
Ulrich Zeilhofer for his excellent co-supervision in the collaborative projects given to me. Thank 
you for giving me the responsibility of multiple projects, thus helping me to grow as an efficient 
and sharp minded person. I am extremely grateful for his foresights, intensive encouragement 
and constructive feedback for the accomplishment of my thesis.  
 
Prof. Dr. Jean-Marc Fritschy has been the most encouraging supervisor and a great teacher 
guiding me patiently with advices, fruitful discussions and timely interventions. During these 
years, he passed on to me his fascination and enthusiasm for microscopy and morphology. I 
have learned a lot from his expertise and experience in neuroscience and without his help I 
could not have finished my dissertation successfully. Thank you Prof. Dr. Jean-Marc Fritschy 
and Prof. Dr. Hanns Ulrich Zeilhofer for creating an excellent collaborative project team with 
your unequivocal expertise from which I could tremendously benefit.  
 
I would also like to thank Prof. Dr. Esther Stöckli for agreeing to be co-reviewer of this PhD 
thesis and my thesis committee member within the Zurich Neuroscience Center (ZNZ). I have 
greatly benefited from her advices and critical comments during these four years. I would also 
like to thank Prof. Dr. Stephen B. McMahon, Prof. Dr. Andrew Todd and Dr. Ping Yip for their 
inputs and guidance for the experiments.  
 
Corinne Sidler, Dr. Robert Witschi and Dr. Caroline Petitjean introduced me to 
immunohistochemistry, behavioral experiments and confocal microscopy and I would like to 
extend my sincere thanks to all of them. I am gratefully indebted to Prof. Dr. Patrizia 
 
 
Panzanelli, Dr. Dietmar Benke and Dr. Florence Crestani for their help with electron 
microscopy, biochemical, behavioral experiments and fruitful discussions. Many thanks to 
Isabelle Camenisch, Christina Köster, Thomas Grampp, Louis Scherrer and Ruth Keist without 
whom I would not have had such a smooth path towards the completion of my dissertation.   
 
My sincere gratitude goes to Christel Genoud, Jana Döhner, Gery Barmettler and Therese 
Bruggmann for sharing your great knowledge in the amazing area of electron microscopy. 
Thank you for all the advice and professional support throughout my PhD. I am deeply grateful 
to Cornelia Leuzinger, Ana Hemmersbach and Edward Apau for their unlimited assistance in 
the animal house facility. My sincere thanks also go to Romy Gisler, Katrin Uster, Verena 
Duenki and Stefanie Rebstein for their administrative support during all these years.   
 
Special thanks go to William Ralvenius, Sabine Haueter, Alessandra Di Lio, Dr. 
Gonzalo Yévenes and Dr. Pradeep Punnakkal for being excellent team mates and friends in 
various projects. I am blessed with excellent lab mates, office mates and desi mates and I would 
like to thank all of them for making my life much easier. A special and warm thanks to Dr. 
Helge Johannssen, Dr. Lena Matveeva, Dr. Marta Grabiec, Nandkishore Mule and Dr. Shanker 
Jha for their help in time at the various stages of this thesis preparation. I would like to thank all 
the other members of Fritschy and Zeilhofer groups and of the institute, for discussion and 
support, and for providing me with a nice working atmosphere.  
 
Last but not least, I would like to thank my parents (especially Mamma and Pappa) for their 
excellent support throughout my whole life. Big thanks to my husband Bijoy for his support, 
encouragement and advices during these years.  It is also a great pleasure to thank my sincere 
and dedicated friends Shank, Hari and Mabel for their inspiring and illimitable friendship. 
 
Thank you all………. 
 
Jolly Paul 
Zurich, January 2012   
 
 
 
 
 
Table of Contents 
 I  Summary ...............................................................................................................................1 
II  Zusammenfassung ..............................................................................................................3 
1  Introduction..........................................................................................................................7 
1.1           Pain .......................................................................................................................7 
1.2            Nociception..........................................................................................................8 
1.2.1       Peripheral Components of Nociception..........................................................8 
1.2.2        Spinal Components of Nociceptive Regulation...........................................10 
1.2.2.A  Nociceptor Terminals in the Spinal Dorsal Horn ........................................10 
1.2.2.B  Interneurons ......................................................................................................11 
1.2.2.C  Projection Neurons ...........................................................................................12 
1.2.2.D  Descending Inputs ............................................................................................13 
1.2.3       Supraspinal Components of Nociception.....................................................14 
1.3           Animal Pain Models.........................................................................................15 
1.4.           Mechanisms of Hyperalgesia and Allodynia ...............................................17 
1.4.1       Spinal Disinhibition in Inflammatory Hyperalgesia...................................18 
1.4.2       Spinal Disinhibition in Neuropathic Hyperalgesia.....................................19 
1.4.3      Acute and Chronic Pain Treatment ................................................................20 
1.5           GABA  Receptors...............................................................................................21 
1.5.1       GABAA  Receptors ............................................................................................21 
1.5.2      GABAA Receptor-Mediated Regulation of Neurotransmission ................22 
1.5.3      Functional Analysis of GABAA Receptors Using In vitro                          
and In vivo Tools ...............................................................................................23 
1.5.4       Distribution of GABAA  Receptor Subtypes in Rodent Brain.....................25 
1.5.5      Distribution of GABAA Receptor Subtypes in Rodent Spinal Cord..........26 
1.5.6       Interaction of Gephyrin with GABAA Receptor Subtypes .........................26 
1.5.7       Role of GABAA Receptor Subtypes in Nociception ....................................27 
 
 
 
 
 
 
 
 
2  Aims..................................................................................................................................... 31 
2.1           Contribution of Presynaptic α2 GABAA Receptors Located on                 
the Central Terminals of Primary Nociceptive Afferents to the Spinal 
Nociceptive Processing.................................................................................... 31 
2.2           Contribution of Spinal GABAA Receptor α2 Subtype to the       
Nociceptive Regulation. .................................................................................. 32 
2.3           Molecular Organization of GABAA Receptor Subtypes in the             
Spinal Dorsal Horn........................................................................................... 32 
3  Results ................................................................................................................................. 35 
3.1           Presynaptic α2 GABAA Receptors in Primary Afferent              
Depolarization and Spinal Pain Control ....................................................... 35 
3.2           Antihyperalgesic Actions of α2 GABAA Receptors  Occur Through  a 
Spinal Site of Action......................................................................................... 69 
3.3           Selective Distribution of GABAA Receptor Subtypes in Mouse Spinal 
Dorsal Horn Neurons and Primary Afferents.............................................. 93 
4  Discussion and Future Perspectives............................................................................ 131 
5  References......................................................................................................................... 136 
6  Appendices....................................................................................................................... 153 
6.1         Abbreviations .................................................................................................. 153 
6.2           Curriculum Vitae............................................................................................ 155 
6.3           Publications ..................................................................................................... 156 
6.4         Poster Presentations ....................................................................................... 157 
Summary 
 
 
 
I Summary 
 
Chronic pain is a frequent neurological condition occurring at least in part as the 
consequence of progressive changes in the nociceptive circuits of the peripheral and 
central nervous system. It frequently arises from tissue damage, inflammation or from 
damage of neurons and nerves. Diminished synaptic inhibition in the spinal dorsal horn 
is a major contributor to chronic pain syndromes. Classical benzodiazepines (BDZ) 
facilitate synaptic inhibition through a positive allosteric modulation of GABAA 
receptors (GABAAR). They exert antihyperalgesic actions after spinal application in 
rodents and humans, but lack general analgesic activity in humans after systemic 
administration. Furthermore, in particular their long-term use is limited by unwanted 
drug effects such as sedation, memory impairment, tolerance development and 
addiction. GABAAR form multiple pharmacologically and functionally distinct subtypes, 
best differentiated by the type of α subunit. The spinal antihyperalgesic effect of BDZ in 
rodents is mediated mainly by α2 and α3 containing GABAAR (α2 and α3 GABAAR), 
while most of the adverse effects are caused by α1 GABAAR located at supraspinal sites. 
Novel subtype-selective GABAAR ligands sparing α1 GABAAR might thus exert 
antihyperalgesia in the absence of major unwanted effects. To strengthen the scientific 
basis for such an approach, we aimed at a better understanding of the GABAergic 
circuits responsible for the antihyperalgesic effects of dorsal horn GABAAR.  
 
In the spinal dorsal horn, GABAAR are expressed not only postsynaptically on intrinsic 
neurons, but are also found at the spinal terminals of primary afferent nociceptors where 
they contribute to presynaptic inhibition through primary afferent depolarization (PAD). 
Many of these presynaptic GABAAR belong to the α2 GABAAR. In the first project of this 
thesis, experiments were performed with nociceptor-specific α2 GABAAR-deficient (sns-
α2 −/−) mice and conditional (sns- α2R/-) point-mutated mice, whose primary nociceptor 
α2 GABAAR subunits have been rendered diazepam-insensitive. The results revealed 
unchanged baseline nociceptive thresholds, and unchanged inflammatory and 
neuropathic hyperalgesia, but decreased antihyperalgesia evoked by intrathecally 
applied diazepam in an inflammatory pain model.  
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The second project aimed at the identification of a possible contribution of supraspinal 
α2 GABAAR to antihyperalgesia, e.g. through a reversal of anxiety-induced hyperalgesia 
or through a genuine antihyperalgesic effect. To this end, Hoxb8-α2−/−  mice which lack 
α2 GABAAR specifically from spinal and peripheral sites, were treated systemically with 
HZ166, a novel BDZ site agonist with reduced sedative properties. Specific ablation of 
α2 GABAAR from all spinal and peripheral sites completely abolished the α2 mediated 
component of HZ166-induced antihyperalgesia in a neuropathic pain model, indicating 
that α2 GABAAR in the brain did neither contribute to or influence HZ166-induced 
antihyperalgesia. These results also rule out indirect antihyperalgesic effects resulting 
e.g. from central anxiolytic actions and a reversal of anxiety-induced hyperalgesia.  
 
Results from project 1 and 2 provide clear evidence that at least the α2 mediated 
component of GABAAR-induced antihyperalgesia results from a direct interaction with 
spinal nociceptive circuits and does not involve secondary effects originating from 
higher CNS areas. The third project therefore addressed the molecular organization of 
GABAAR subtypes in nociceptive circuits of spinal dorsal horn. Multiple-labeling 
experiments that combined different markers and very sensitive immunofluorescence 
assays revealed a highly organized GABAAR subtype distribution with α2  and 
α3  GABAAR being strategically located at excitatory and inhibitory interneurons and 
nociceptors terminals in the superficial dorsal horn laminae I-III. This study revealed 
GABAAR α2 , α3   and α5  subtypes localized to specific presynaptic and postsynaptic 
terminals and thus to sites critically involved in the GABAergic control of nociception. In 
summary, the combination of highly sophisticated genetic mouse models and of novel 
pharmacological tools together with anatomical, electrophysiological and behavioral 
approaches significantly extends the rational basis for the development of subtype-
selective GABAAR ligands as novel spinally acting antihyperalgesic agents.
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II Zusammenfassung  
 
Chronische Schmerzen sind ein weitverbreitetes neurologisches Leiden, das wesentlich 
auf Veränderungen nociceptiver Schaltkreise im peripheren und zentralen 
Nervensystem beruht. Chronische Schmerzen treten häufig als Folge von 
Gewebeschädigung, chronischen Entzündungen oder Nervenschädigungen auf. 
Verminderte synaptische Hemmung im Hinterhorn des Rückenmarks trägt wesentlich 
zur Entstehung chronischer Schmerzen bei. Klassische Benzodiazepine (BDZ) verstärken 
synaptische Hemmung durch positive allosterische Modulation von GABAA-Rezeptoren 
(GABAAR). Ihre spinale Applikation wirkt in Nagern und im Menschen 
antihyperalgetisch, nach systemischer Gabe bewirken sie jedoch zumindest beim 
Menschen keine generelle Schmerzhemmung. Zudem ist insbesondere die langfristige 
Anwendung klassischer BDZ durch Nebenwirkungen wie Sedierung, Einschränkung 
der Gedächtnisleistung, Toleranzentwicklung und Abhängigkeit wesentlich 
eingeschränkt. GABAAR existieren in verschiedenen Subtypen, die sich in ihren 
funktionellen und pharmakologischen Eigenschaften unterscheiden. Sie werden 
typischerweise anhand ihrer α Untereinheit klassifiziert. Die antihyperalgetische 
Benzodiazepin-Wirkung wird hauptsächlich durch GABAAR vermittelt, die α2 bzw. α3 
Untereinheiten enthalten (α2 bzw. α3 GABAAR). Die meisten unerwünschten Effekte 
werden hingegen von supraspinalen α1 GABAAR vermittelt. Neue Subtyp-spezifische 
GABAAR-Liganden könnten demnach schmerzlindernde Eigenschaften haben, ohne die 
typischen Nebenwirkungen klassischer BDZ aufzuweisen. Um dieses Konzept weiter zu 
untermauern, wurden in der vorliegenden Arbeit die an der spinalen Naociception 
beteiligten GABAergen Netzwerke einer vertieften Analyse unterzogen.  
 
Im Rückenmark sind GABAAR sowohl postsynaptisch auf intrinsischen Neuronen des 
Hinterhorns als auch auf den Terminalen primär afferenter Nozizeptoren exprimiert, wo 
sie durch primärafferente Depolarisation (engl. primary afferent depolrization, PAD) zur 
präsynaptischen Hemmung beitragen. Die meisten dieser präsynaptischen GABAAR 
gehören zum α2 Typ. Im ersten Teilprojekt der vorliegenden Dissertation untersuchten 
wir Mäuse, deren Nozizeptoren entweder keine α2 GABAAR exprimierten (sns-α2-/-) 
oder aufgrund einer Punktmutation insensitiv gegenüber Diazepam waren (sns-α2R/-). 
Basale Schmerzschwellen sowie entzündliche und neuropathische Neuropathie waren in 
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beiden Mausstämmen unverändert. Im Entzündungsschmerzmodell war jedoch der 
antihyperalgetische Effekt von intrathekal injiziertem Diazepam signifikant vermindert.   
 
Im zweiten Teilprojekt sollte der mögliche Beitrag supraspinaler α2 GABAAR zur 
Antihyperalgesie untersucht werden. Ein solcher Beitrag könnte etwa in einer 
Aufhebung angstvermittelter Hyperalgesie oder in einem genuinen antihyperalgetischen 
Effekt bestehen. Hierzu wurden HoxB8-α2-/- Mäuse, denen α2 GABAAR im Rückenmark 
und in der Peripherie fehlen, systemisch mit HZ166 behandelt. HZ166 ist ein neu 
entwickelter Agonist an der Benzodiazepin-Bindungsstelle von GABAAR mit 
reduzierten sedativen Eigenschaften. Die selektive Ablation spinaler und peripherer α2 
GABAAR führte zu einem kompletten Verlust der α2-vermittelten Komponente der 
HZ166-induzierten Antihyperalgesie im Neuropathiemodell. Diese Ergebnisse zeigen, 
dass supraspinale α2 GABAAR nicht wesentlich zur HZ166-vermittlelten 
Antihyperalgesie beitragen, und legen damit auch nahe, dass indirekte Effekte, die z.B. 
durch die anxiolytische Wirkung zustande kommen könnten, keine wesentliche Rolle 
spielen. 
 
Im dritten Teilprojekt wurde daher die molekulare Zusammensetzung der GABAAR-
Subtypen im Hinterhorn des Rückenmarks einer detaillierten Analyse unterzogen. 
Histologische Färbung von verschiedenen Markerproteinen im selben Schnitt und 
hochsensitive Detektionsmethoden zeigten, dass die Verteilung der GABAAR im 
Hinterhorn des Rückenmarks einen sehr hohen Organisationgrad aufweist. 
Insbesondere α2 und α3 GABAAR zeigten eine strategisch äusserst effektive Verteilung 
auf Nociceptorterminalen und auf exzitatorischen und inhibitorischen Interneuronen. 
Die Ergebnisse dieser Untersuchungen belegen, dass α2, α3 und α5 GABAAR auf prä- 
und postsynaptischen Kompartimenten spezifischer Neuronentypen lokalisiert sind, die 
eine zentrale Rolle für die GABAerge Kontrolle der Nociception spielen.  
 
Zusammenfassend konnte in dieser Arbeit durch die Kombination von transgenen 
Mausmodellen mit neu entwickelten GABAergen Wirkstoffen und mit Hilfe von 
anatomischen, elektrophysiologischen und verhaltensbasierten Methoden die 
neurobiologische Basis für Entwicklung von Subtyp-spezifischen GABAAR-Liganden mit 
antihyperalgetischen Eigenschaften deutlich erweitert werden.  
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Introduction 
1.1 Pain  
The survival and welfare of higher organisms critically depend on the ability to detect 
noxious environmental factors and to respond properly. Exposure to noxious stimuli 
evokes a protective response action resulting in the immediate withdrawal from the 
stimulus. Conversely, humans who suffer from congenital insensitivity to pain have a 
reduced life expectancy due to recurrent trauma and infections (Cox et al., 2006). Acute 
pain hence serves an important protective function. However, when pain persists 
beyond the actual threat, it severely interferes with the wellbeing of organisms. 
 
The International Association for the Study of Pain (www.iasp-pain.org) defines pain as 
“an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage”. The prevalence of chronic pain 
and pain-related impairments were surveyed in European (Breivik et al., 2006), 
American (www.theacpa.org) and Canadian (Reitsma et al., 2011) populations. These 
studies indicated that chronic pain represents a challenging and debilitating condition 
contributing to major medical and socio-economic problems; it has even been suggested 
that relief from pain should be recognized as a human right (IASP, 2010).  
 
Chronic pain is primarily distinguished from acute pain by its long duration. It can be 
further sub-classified based on its spatial and temporal pattern, its intensity and etiology. 
On this basis, a detailed classification of chronic pain has been established by the IASP 
(Merskey and Bogduk, 1994). Chronic pain often involves plasticity in the nociceptive 
stimuli processing that can occur at all levels of the neuraxis. The complexity of these 
changes is probably a major reason for the difficulties in the management of chronic pain 
syndromes. Typical symptoms of chronic pain include hyperalgesia (increased pain to 
noxious stimuli), allodynia (pain due to a stimulus which does not normally provoke 
pain) and spontaneous pain (pain felt in the absence of sensory stimulation). 
Hyperalgesia occurring at the site of injury is called primary hyperalgesia, while 
enhanced pain sensitivity in uninjured healthy tissue is termed secondary hyperalgesia. 
Both peripheral and central components can contribute to primary hyperalgesia and 
probably also to spontaneous pain, whereas secondary hyperalgesia and allodynia 
originate exclusively from central sensitization. On the basis of its pathophysiology, pain 
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can be classified into (1) nociceptive (transient pain in response to noxious stimulus), (2) 
inflammatory (initiated by tissue damage and/or inflammation), (3) neuropathic (caused 
by a primary lesion in the nervous system), and (4) dysfunctional pain (hypersensitivity 
to pain resulting from abnormal central processing of normal input) (Woolf, 2010). 
 
While our knowledge of the molecular and cellular mechanisms of acute pain has 
increased significantly during the last decades, our understanding of the mechanisms of 
chronic pain is still incomplete. Accordingly, chronic pain treatment, which still relies 
mainly on opioids and cyclooxygenase inhibitors, is very often insufficient. Both families 
of analgesics lack efficacy particularly in neuropathic pain and often result in major side 
effects when taken for prolonged periods of time. Therefore, novel therapeutic 
approaches are required. A large number of genetic, electrophysiological, 
neuroanatomical and pharmacological studies are currently undertaken to elucidate the 
molecular mechanisms that underlie chronic pain with the ultimate aim to improve pain 
treatment. 
1.2  Nociception 
According to IASP, nociception is defined as “The neural processes of encoding and 
processing of noxious stimuli”(Loeser and Treede, 2008). It has three components: (1) 
peripheral, where the afferent activity is initiated by a subpopulation of peripheral nerve 
fibers called nociceptors, (2) spinal, where most of the nociceptors terminate and 
transmit signals to second order neurons and (3) supraspinal, where neural processes 
result in conscious pain perception. These pathways are schematically represented 
below (fig. 1). 
1.2.1 Peripheral Components of Nociception 
Nociceptors are sensory nerve cells activated by mechanical, thermal or chemical stimuli 
that reach the noxious stimulation strength range. They have peripheral and central 
axonal branches that innervate their target organs (skin, visceral organs and skeletal and 
cardiac muscle) and the spinal cord or brain stem, respectively. The cell bodies of the 
nociceptors innervating the head reside in trigeminal ganglia (TG), while those of 
nociceptors innervating the rest of the body are located in the dorsal root ganglia (DRG). 
Upon exposure to noxious stimuli, nociceptors produce inward (depolarizing) currents 
within their peripheral terminals, which evoke action potentials (AP) when the 
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depolarizations become suprathreshold. These signals are then transmitted to second 
order neurons located in the ipsilateral trigeminal nucleus or the spinal dorsal horn. 
Nociceptors release L-glutamate from their central terminals to excite second order 
dorsal horn neurons. 
 
 
 
 
Based on their conduction velocity, nociceptors are categorized into two classes: (1) 
medium diameter myelinated Aδ afferents that mediate acute, sharp and well-localized 
fast pain and (2) small diameter unmyelinated C fibers that convey poorly localized, 
prolonged, dull and burning slow pain sensation. The latter are further subdivided into  
peptidergic and non-peptidergic nociceptors. The former release neuropeptides 
(substance P and calcitonin-gene related peptide, CGRP),  in addition to glutamate. 
These neuropeptides are absent in non-peptidergic nociceptors. Release of CGRP and 
substance P from the peripheral terminals causes vasodilation and the so called flare 
response (Basbaum et al., 2009). Peptidergic and non-peptidergic fibers not only differ in 
their neuropeptide content but also in other neuroanatomical and molecular 
characteristics (Snider and McMahon, 1998). Peptidergic nociceptors express the TrkA 
neurotrophin receptor, which responds to nerve growth factor (NGF). Non-peptidergic 
fibers produce chondroitin sulfate proteoglycans and express the c-Ret neurotrophin 
receptor targeted by glial-derived neurotrophic factor (GDNF), neurturin and artemin.   
Fig. 1. Schematic of afferent pathways 
underlying the sensation of pain.		
Activated nociceptors convey noxious 
information to projection neurons 
within the dorsal horn of the spinal 
cord. A subset of these projection 
neurons transmits information about 
the location and intensity to the 
somatosensory cortex via the thalamus. 
Other projection neurons engage the 
cingulate and insular cortices via 
connections in the brainstem 
(parabrachial nucleus) and amygdala, 
contributing to the affective component 
of the pain experience. This ascending 
information also accesses neurons of 
the rostral ventral medulla and 
midbrain periaqueductal gray to 
engage descending feedback systems 
that regulate the output from the spinal 
cord. Reproduced from Basbaum et al. 
(2009). 
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1.2.2  Spinal Components of Nociceptive Regulation 
1.2.2.A Nociceptor Terminals in the Spinal Dorsal Horn  
The central axons of nociceptors terminate in various laminae of the spinal dorsal horn 
with a specific distribution pattern (Rexed, 1952). Mechanoreceptive myelinated primary 
afferent fibers arborize in an area extending from lamina III–V, whereas nociceptive C 
afferents innervate lamina I – II. Recent studies have identified a group of cooling-
specific C afferents that terminate in lamina I (Dhaka et al., 2008) and two possible 
candidates for low-threshold mechanoreceptive C fibers that also project to lamina II, 
(Liu et al., 2007; Seal et al., 2009). The outer half of lamina II (lamina IIo) distinctly 
harbors peptidergic fiber terminals whereas the inner half (lamina IIi) contains non-
peptidergic terminals (Hunt and Mantyh, 2001; Zylka, 2005) (fig. 2). The terminals of 
unmyelinated and myelinated primary afferents form the central axons of type I and 
type II synaptic glomeruli respectively, as shown by early ultrastructural studies 
(Ribeiro-da-Silva and Coimbra, 1982; Ribeiro-da-Silva et al., 1985). In lamina II, the 
densities of type I and type II synaptic glomeruli are 2.58 and 0.32. Within central lamina 
II region, around 79% of glomeruli are of type I whereas in the ventral lamina II region 
approximately 66% are of type II. 
 
Recent studies have explored the possibility of distinct pain modalities being conveyed 
by specific classes of nociceptors hosting specific molecules (Abrahamsen et al., 2008). 
Scherrer et al (2009) analyzed the differential distribution of- and -opioid receptors in 
distinct populations of peptidergic and non-peptidergic nociceptors, respectively, and 
showed that they control either thermal or mechanical pain. Similarly, the ablation of 
Mas-related G-protein-coupled receptor member D (MRGPRD)-containing 
nonpeptidergic fibers resulted in a selective loss of sensitivity to noxious mechanical (but 
not thermal) stimuli (Cavanaugh et al., 2009). Recently, the expression of transient 
receptor potential vanilloid-1 (TRPV-1) receptors, critical for the development of thermal 
hyperalgesia (Caterina et al., 2000), has been found to be restricted to a subset of 
peptidergic nociceptors (Cavanaugh et al., 2009). Mechanical nociception depends on the 
Nav1.8 nociceptors expressing the vesicular glutamate transporter VGluT2 (Lagerström 
et al., 2011).  
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1.2.2.B   Interneurons 
Virtually all neurons in lamina II and most of those in lamina I (excluding the projection 
neurons) and lamina III have axons that remain in the spinal cord and arborize locally 
(thus called interneurons). They can be divided into two main classes: 1) excitatory 
(glutamatergic) and 2) inhibitory (GABAergic and/or glycinergic). Excitatory 
interneuron terminals in the dorsal horn can be identified by the presence of VGLUT2 
(Todd et al., 2003; Maxwell et al., 2007; Yasaka et al., 2007). VGLUT2-containing boutons 
are numerous in laminae I–III, most of which originate from local excitatory 
interneurons. About 25%, 30% and 40% of neurons are GABAergic in laminae I, II and 
III, respectively (Polgar et al., 2003), a subpopulation of those is, in addition, glycinergic. 
Very few neurons have been found to be only glycinergic and not GABAergic (Todd and 
Sullivan, 1990). Nevertheless, electrophysiological studies have identified synapses in 
lamina I-III that are purely glycinergic (Keller et al., 2001; Yasaka et al., 2007). The axons 
of inhibitory interneurons can be identified with antibodies against the vesicular 
inhibitory amino acid transporter (VIAAT, which transports GABA and glycine into 
presynaptic vesicles), glutamate decarboxylase (GAD, the GABA-synthesizing enzymes) 
or the glycine transporter type 2 (GLYT2, which transports glycine into presynaptic 
terminals).  
 
A nociceptors (I) 
C peptidergic fibers (I-IIo) 
C non-peptidergicfibers (IIi) 
Ahair follicle afferents (III) 
A hair follicle and tactile afferents (IIi-V) 
 
 Fig. 2. Laminar organization of the dorsal horn and 
primary afferent inputs. 
Primary afferents arborize within the dorsal horn in a 
distinct fashion: a laminar termination pattern based on fiber 
diameter and function is superimposed on a somatotopic 
distribution that determines mediolateral and rostrocaudal 
location. Projection neurons in lamina I receive direct input 
from A and C nociceptors. Lamina V neurons are 
predominantly of the wide dynamic-range type. They 
receive input from low-threshold large-diameter myelinated 
fibers (Aβ) of mechanoreceptors as well as both direct and 
indirect input from nociceptive afferent fibers (A and C) 
Modified from Todd (2010). 
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In some respects, the inhibitory action of GABA in the spinal cord is more complex than 
in many parts of the brain (see section 1.5.7). In brain, postsynaptic GABAAR activation 
reduces neuronal excitability primarily through hyperpolarization and the activation of a 
shunting conductance, and presynaptic GABAAR activation facilitates transmitter release 
and LTP induction (Ruiz et al., 2010). In the spinal cord, GABAAR on the terminals of 
primary afferent fibers contribute to presynaptic inhibition through primary afferent 
depolarization (Eccles et al., 1961). Primary nociceptors exhibit a high expression of 
sodium-potassium-chloride transporter NKCC1 (transports chloride, sodium and 
potassium into the cell) along with a low to nil expression of potassium chloride co-
transporter KCC2 (extrudes chloride and potassium out of the cell) (Rivera et al., 1999; 
Sung et al., 2000) giving rise to sub-threshold primary afferent depolarization (PAD). 
Bicuculline-sensitive GABAergic inhibition has a major role in creating PAD (Nishi et al., 
1974; Mokha et al., 1983). Activity-related increases in the concentration of glutamate 
(Rees et al., 1995) and potassium (Heinemann et al., 1990) also contribute to PAD. PAD 
inhibits transmitter release from the primary afferent terminal possibly through 
inactivation of voltage-gated Ca2+ and/or Na+ channels or through activation of a 
shunting conductance (Kullmann et al., 2005). Under certain conditions, PAD may 
become suprathreshold and would then facilitate chronic pain through the so called 
dorsal root potentials resulting in hyperalgesia and allodynia (Willis Jr, 1999). 
 
Lamina II interneurons can also be classified based on the morphology of their dendritic 
trees. Most authors distinguish islet, central, vertical and radial cells (Grudt and Perl, 
2002; Lu and Perl, 2003; Hantman et al., 2004), but a generally accepted classification that 
covers all interneurons in laminae I–III does still not exist. Furthermore, these 
morphologically defined groups do not represent homogeneous functional 
subpopulations (Todd, 2010).  
1.2.2.C  Projection Neurons 
Dorsal horn projection neurons have axons that cross the midline, project rostrally, run 
in the contralateral white matter, and terminate in various brain stem and thalamic 
nuclei. They are mainly concentrated in lamina I but exist also in all other dorsal horn 
laminae, at least at lumbar levels. Quantitative retrograde tracing studies in the rat 
suggest that in the fourth lumbar segment (L4), projection neurons constitute ~5% of 
lamina I neurons (Spike et al., 2003). Attempts to classify projection neurons into discrete 
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categories were not successful yet. The neurokinin 1 receptor (NK1R)-containing lamina 
I neurons have been extensively studied because of their relevance in nociception (fig. 3). 
NK1R is the main target of substance P and is in the dorsal horn selectively expressed in 
neurons that respond to noxious stimuli (Salter and Henry, 1991). The ablation of these 
projection neurons prevents the development of hyperalgesia in inflammatory and 
neuropathic pain models (Mantyh et al., 1997; Nichols et al., 1999). 
  
 
 
 
 
1.2.2.D Descending Inputs 
Serotonergic and noradrenergic systems contribute to descending monaminergic 
pathways projecting to the dorsal horn. Serotonergic pathways originate mainly from 
the nucleus raphe magnus whereas noradrenergic projections descend from the locus 
coeruleus. Axons of both systems terminate diffusely throughout the dorsal horn, and 
although some form synapses, much of their action is mediated through volume 
transmission (Zoli et al., 1999). Another descending pathway that may have a role in 
spinal pain control consists of GABAergic axons that descend from the rostral 
ventromedial medulla, arborize widely in the dorsal horn (Antal et al., 1996; Kato et al., 
2006) and synapse with lamina II interneurons (Kato et al., 2006). The consequences of 
Fig. 3. Synaptic circuits in the superficial dorsal horn laminae I-III. Two NKIR-positive projection neurons in 
laminae I and III are densely innervated by substance P-containing primary afferents (SP). Additionally, the 
lamina III neurons receive an input from myelinated low threshold mechanoreceptive (LTM) afferents and 
GABAergic interneurons that contain neuropeptide Y (GABA/NPY interneuron). A giant lamina I neuron 
receive a substantial input from inhibitory GABA/nNOS interneuron. Lamina I projection neurons receive high 
density innervations from two glutamatergic interneuronal populations (Unknown subtype containing VGLUT2 
(?GLU interneuron) and GLU vertical cells). GLU vertical cell are innervated by glutamatergic central cells (GLU 
central cell) and A and C fibers expressing TRPA1 and TRPV1. Reproduced from Todd (2010). 
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activation of monaminergic neurons are determined largely by the distribution of 1 and 
2 adrenergic receptors and 5-hydroxytryptamine (5-HT; serotonin) 1A (5HT1A) and 
5HT3 receptors. Most neurons hyperpolarize in response to both monamines but some 
islet and central cells are depolarized by 5-HT, and some GABAergic neurons (including 
islet cells) are depolarized by noradrenaline (Abe et al., 2009; Gassner et al., 2009). 
Additionally, monamines can suppress primary afferent inputs to superficial dorsal horn 
neurons through a presynaptic mechanism (Lu et al., 2002). 
1.2.3 Supraspinal Components of Nociception  
Anterograde tracing experiments from the spinal dorsal horn have shown that ascending 
projections terminate in the caudal ventrolateral medulla (CVLM), the nucleus of the 
solitary tract (NTS), the lateral parabrachial area (LPb), the periaqueductal grey matter 
(PAG) and certain nuclei in the thalamus (Gauriau and Bernard, 2004). Extensive 
collateralization of axons, with some lamina I neurons projecting to at least three targets 
(e.g., LPb, PAG and thalamus) has also been observed (Al Khater and Todd, 2009). Most 
of the projection neurons have only contralateral projections, but some exhibit bilateral 
projections, as well (Spike et al., 2003). Quantitative retrograde tracing studies in the rat 
indicated that 95% of all lamina I projection neurons project to the LPb, around a third to 
the PAG, a quarter to the NTS and <5% to the thalamus (Spike et al., 2003). Thus, the low 
number of lamina I spinothalamic cells seem to give raise to pathways essential for 
conscious pain perception. The perception of pain involves sensory-discriminative, 
affective-motivational and cognitive-evaluative dimensions represented in distinct pain 
pathways and brain regions activated during the experience of pain (pain matrix). The 
primary (S1) and secondary (S2) somatosensory cortices that receive input from the 
ventrolateral thalamic nuclei constitute the lateral pain system. This system affects the 
sensory and discriminative components (location and intensity) of pain. The medial pain 
system branches at the level of the medulla and ascends via the medial thalamus to 
hypothalamic nuclei, limbic regions (mainly anterior cingulate cortex (ACC)), the insular 
cortex (IC) and prefrontal areas. These regions control emotion, arousal and attention. 
This medial pain pathway is therefore proposed to mediate the unpleasant, affective 
imensions of pain and the motivation to escape from the noxious event (Treede et al., 
1999; Price, 2000; Brooks and Tracey, 2005; Bushnell and Apkarian, 2006). 
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1.3 Animal Pain Models 
Most of our knowledge of the molecular mechanisms of acute nociceptive and 
pathological pain has been obtained from experiments in animal models of pain.  
 
Acute nociceptive pain 
Classical tests of nociception in rodents involve the quantification of sensitivities to 
noxious heat, punctate mechanical stimuli, pressure and chemical activators of 
nociceptors. Frequently used tests include the tail flick test, the hot plate test and the 
plantar (Hargreaves et al., 1988) test. In the tail flick and plantar test a radiant heat 
stimulus of pre-defined intensity is directed onto the tail or plantar surface of one 
hindpaw, respectively. In the hot plate test, the animal is placed onto a heated surface. In 
all these tests, the typical read-out is the time interval (latency) between the application 
of the noxious stimulus and a withdrawal or escape response of the animal. One 
advantage of the plantar test is that it allows the comparison of responses elicited in 
inflamed and non-inflamed paws.  
 
Sensitivity to punctate mechanical stimuli is typically measured with calibrated von Frey 
filaments which are applied on the plantar surface of one hind paw and which exert a 
defined pressure upon bending. More recently developed versions include force 
transducers (electronic von Fey filaments) or filaments which are moved at a pre-defined 
and electronically-controlled speed towards the animal paw (dynamic von Frey 
filaments). In all these tests, sensitivity is measured as the threshold force at which an 
animal withdraws the stimulated paw.  
 
Chemical sensitivity is typically assessed by injecting compounds, which directly 
activate nociceptor terminals. Such compounds include the TRPV1 agonist capsaicin, the 
TRPA1 agonist mustard oil, or formalin, which at low concentrations is also a selective 
activator of TRPA1. The animal’s sensitivity is measured in most cases by counting the 
number of nociceptive responses e.g. of flexor responses (so called flinches).  
 
Hyperalgesia and allodynia 
In mice, inflammatory pain can be generated by injecting pro-inflammatory agents (e.g., 
complete Freund's adjuvant, zymosan A, carrageenan) into one hind paw (Meller and 
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Gebhart, 1997). All these agents induce a robust heat and mechanical hyperalgesia of the 
inflamed paw within hours. 
 
Neuropathic pain can be induced by peripheral nerve injuries, injections of neurotoxic 
drugs or by inducing diabetic syndrome. The most frequently used models involve 
partial mechanical injuries of peripheral nerves.  
 
In the chronic constriction injury model (CCI model; Bennett and Xie, 1988; Sugimoto et 
al., 1990) a partial nerve damage is induced through loose ligations put around the 
sciatic nerve. The constriction results from intraneural edema within the nerve leading to 
a preferential loss of myelinated afferents. Mice exposed to CCI develop robust 
mechanical and heat hyperalgesia, and cold allodynia. These symptoms develop over 
the first post-operative week, peak during the second week, and gradually disappear by 
around 4-5 weeks. 
 
In the spinal nerve ligation (SNL; Kim and Chung, 1992) model, tight ligatures are 
placed around the L5 and L6 spinal nerves before these join the lumbosacral plexus. 
Animals exposed to SNL rapidly develop signs of tactile allodynia, which appear within 
the first post-operative day and last for several months. In addition, they show a thermal 
hyperalgesia that starts during the first week and lasts for around 1 month.  
 
In the spared nerve injury (SNI) model two of the three terminal branches of the sciatic 
nerve (tibial and common peroneal nerves) are ligated and cut, leaving only the sural 
nerve intact (Decosterd and Woolf, 2000). Like the SNL model, this also results in a 
rapidly developing and prolonged tactile and cold allodynia in the affected hind limb, 
and comparatively minor increases in heat sensitivity. 
 
Mechanical sensitization in neuropathy manifests not only in increased responses to 
punctate mechanical stimuli (static allodynia) and pressure, but also in dynamic 
allodynia which can be tested by stroking an animal’s flank with a paint brush.  
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1.4. Mechanisms of Hyperalgesia and Allodynia 
Similar to many other neurological diseases such as epilepsy, sleep disorders and 
anxiety, pathological pain is believed to originate from an imbalance of excitatory and 
inhibitory drive. Examples for increase excitation in spinal dorsal horn include short 
term and long term increases in the strength of synaptic transmission between primary 
nociceptors and dorsal horn second order neurons. Repetitive stimulation of C fibers 
leads to a transient homosynaptic activity-dependent progressive enhancement of the 
postsynaptic potentials, which results in an increased excitability of dorsal horn neurons 
called wind up (Mendell, 1984; Herrero et al., 2000). This phenomenon results in 
progressive increase in pain sensitivity to repetitive noxious heat or mechanical stimuli 
(Price et al., 1977; Staud et al., 2003). A prolonged form of homosynaptic activity-
dependent plasticity (long term potentiation; LTP) has been identified at the excitatory 
synapses between C fibers and NK1R-expressing lamina I projection neurons. Both high 
and low frequency stimulation can induce LTP in these neurons probably through Ca2+-
dependent postsynaptic mechanisms (Ikeda et al., 2003; Ikeda et al., 2006). As 
NK1R-expressing projection neurons have an important role in the development of 
chronic pain states, LTP of their nociceptive inputs is likely a major mechanism of 
hyperalgesia (Mantyh et al., 1997; Nichols et al., 1999; Sandkühler, 2009). 
 
Facilitated transmission between intrinsic excitatory dorsal horn neurons may enhance 
activation of lamina I projection cells through polysynaptic pathways. This mechanism 
has been shown to involve phosphorylation of Kv4.2 (at position S616), a downstream 
target for phosphorylated extracellular signal-regulated kinases (ERKs), expressed in 
excitatory interneurons in lamina II. This phosphorylation results in a reduction of A-
type potassium currents, leading to an increase in excitability (Hu et al, 2006). Since 
ERKs are activated in many neurons following noxious stimulation, this mechanism 
could also contribute to hyperalgesia (Todd, 2010; Yasaka et al., 2010).  
 
An imbalance of excitatory and inhibitory drive can also be caused by diminished 
inhibition. This concept dates back to the gate control theory of pain (Melzack and Wall, 
1965), which proposed that inhibitory interneurons would regulate the strength of 
nociceptive inputs transmitted from the periphery to higher CNS areas through the 
spinal cord. It has been shown that spinal pharmacological antagonism of GABAA and 
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glycine receptors with bicuculline or strychnine induces tactile allodynia and 
hyperalgesia (Beyer et al., 1985; Roberts et al., 1986) and intrathecal application of GABA 
reversed thermal and mechanical sensitivity in rats with chronic constriction nerve 
injury (Eaton et al., 1999). Many studies from different groups published in last decade 
have shown that a reduction in dorsal horn synaptic inhibition occurs also endogenously 
in the natural course of inflammatory and neuropathic diseases (Zeilhofer and Zeilhofer, 
2008).  
1.4.1 Spinal Disinhibition in Inflammatory Hyperalgesia 
Inflammation is a complex defense reaction orchestrated by components of the innate 
and acquired immune system. Many mediators, including bradykinin, substance P, ATP, 
prostaglandins (mainly PGE2 and PGI2), growth factors (e.g., NGF), proteases, protons, 
nitric oxide (NO), pro-inflammatory cytokines and chemokines contribute to an 
increased excitability of nociceptors. These algogens activate three classes of receptors: 
(1) G-protein coupled receptors for prostaglandin (EP2, EP4, IP and DP1) and histamine 
(H1); (2) Tyrosine kinase receptors (TrkA and TrkB); (3) ligand gated ion channels (TRPV 
and P2X receptors. For detailed review see (Linley et al., 2010).  
 
Peripheral inflammation induces secondary changes in the CNS, particularly in the 
spinal dorsal horn. The following example illustrates how signaling cascades are 
interlinked to alter neuronal excitability. Inflammation causes an increase in the 
expression of cyclooxygenase-2 (COX-2) and inducible microsomal prostaglandin E 
synthase 1 (mPGES-1), enzymes required for prostaglandin E2 (PGE2) synthesis (Beiche 
et al., 1996; Murakami et al., 2000; Samad et al., 2001; Claveau et al., 2003). The resulting 
increased EP2 receptor activation stimulates Gs/PKA pathway leading to the PKA 
phosphorylation and inhibition of 3 subunit containing glycine receptors (GlyRα3). 
These receptors are densely expressed in the superficial laminae concentrating in lamina 
IIi (Harvey et al., 2004). PGE2 thus reduces glycinergic transmission in the majority of 
superficial dorsal horn neurons resulting in central inflammatory hyperalgesia (Ahmadi 
et al., 2002; Reinold et al., 2005) (fig. 4A). Mice lacking either EP2-receptor or GlyRα3 or 
carrying a mutated PKA regulatory subunit exhibit strongly reduced inflammatory pain 
indicating a near absence of pro-nociceptive actions of PGE2 (Harvey et al., 2004; Reinold 
et al., 2005; Hösl et al., 2006). Interestingly, the development of neuropathic pain in CCI 
model is not altered in these mice (Hösl et al., 2006).  
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1.4.2 Spinal Disinhibition in Neuropathic Hyperalgesia 
Mechanisms of disinhibition resulting in neuropathic pain have been extensively 
in rodents. A reduction in the proportion of lamina II neurons exhibiting primary 
afferent-evoked inhibitory postsynaptic currents has been detected (Moore et al., 
2002), supporting the view that disinhibition contributes to neuropathic pain 
symptoms. Earlier studies have reported an almost complete loss of GABA-
immunoreactivity in dorsal horn neurons at around two weeks after CCI (Ibuki 
et al., 1996; Eaton et al., 1998). Others have, in addition, found that GAD-65 
expression was down-regulated after CCI or SNI (Moore et al., 2002). An 
apoptotic cell death of GABAergic interneurons has been proposed as an 
underlying mechanism (Moore et al., 2002), but more recent evidence suggests 
that CCI does not cause a loss of neurons in the dorsal horn and does not alter the 
portion of GABA- or glycine-immunoreactive neurons (Polgar et al., 2003; Polgar 
et al., 2004). Alternative explanations of reduced inhibitory control after 
peripheral nerve injury include a depletion of GABA (or glycine) from 
presynaptic terminals. However, following SNI, the level of GABA in GABAergic 
boutons in lamina I-III and the number of GABAAR were similar in neuropathic 
and intact sides (Polgár et al., 2008). The possibility of disinhibition by the 
reduction of the number of GABAAR has also been investigated, but the number 
of GABAAR was not altered in neuropathic mice (Moore et al., 2002, Polgar et al., 
2008).  
 
Peripheral nerve injury leads to microglia-dependent central sensitization and this 
pathway, leading to diminished synaptic inhibition, has been recognized as a key event 
in the generation of neuropathic pain following SNI (Tsuda et al., 2003; Scholz and 
Woolf, 2007). The damage of nerve fiber leads to the release of cytokine CCL2 that 
mediates microglial recruitment and activation. The activated microglial cells release 
brain derived neurotrophic factor (BDNF) and subsequently result in TrkB-mediated 
down-regulation of the potassium chloride co-transporter KCC2 in dorsal horn neurons 
(Coull et al., 2003; Coull et al., 2005) (fig. 4B). P2X family receptors are thought to be 
involved in the release of BDNF and are thus considered potential targets for novel 
analgesics (Chessell et al., 2005; Honore et al., 2005). 
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1.4.3 Acute and Chronic Pain Treatment 
At present the most frequently used drugs in chronic pain treatment are opioids and 
cyclooxygenase inhibitors. Opioids are very effective in the treatment of acute pain and 
of certain chronic pain states, in particular of cancer associated pain. They are however 
less effective (and less well tolerated) in patients with chronic inflammatory pain. 
Cyclooxygenase inhibitors on the other hand are highly effective against inflammatory 
pain, while both opioids and cyclooxygenase inhibitors are poorly effective in 
neuropathic pain patients (Malmberg and Yaksh, 1992; Lashbrook et al., 1999). 
Neuropathic pain is at present most frequently treated with anticonvulsive drugs, which 
either block voltage gated Na+ channels (carbamazepine or oxcarbazepine; Ilyin et al., 
2006) or modulate voltage gated Ca2+ channel (gabapentin and pregabalin; Tanabe et al., 
2008). Both of these drug classes reduce neuronal excitability and synaptic transmission. 
The clinical efficacy of the more recently developed gabapentin and pregabalin has been 
proven in a large number of clinical studies, but their efficacy with numbers needed to 
treat (NNT) between 5 and 6 is still far from being optimal (Moore et al, 2011).   
 
A
      
B 
Fig. 4. Diminished synaptic GABAergic and glycinergic control. (A) Disinhibition in inflammatory 
hyperalgesia. Cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase (mPGES1) become 
induced in response to inflammation in peripheral tissues and produce PGE2 in the spinal cord. PGE2 
binds to PGE2 receptors of the EP2 subtype, which increase cAMP levels and activate protein kinase A 
(PKA). PKA then phosphorylates and inhibits a specific subtype of glycine receptors containing the 3 
subunit, which regulate the excitability of superficial dorsal horn neurons. This disinhibition facilitates the 
firing of these neurons and promotes transmission of nociceptive signals through the spinal cord to higher 
brain areas where pain becomes conscious. (B) Disinhibition in neuropathic pain states. Peripheral nerve 
damage activates spinal microglia which releases brain-derived neurotrophic factor (BDNF). BDNF 
subsequently down-regulates the potassium-chloride cotransporter (KCC-2), reducing the inhibitory 
action of GABAA and glycine receptors. Reproduced from Zeilhofer and Zeilhofer (2008).  
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As outlined above, an alternative approach to neuropathic or chronic pain in general 
could be the strengthening of synaptic inhibition. Although gabapentin and pregabalin 
contain “gaba” in their names and gabapentin has even structural similarity with GABA, 
neither gabapentin nor pregabalin act on GABAAR (Coderre et al., 2005; Li et al., 2011) 
but bind instead to an accessory subunit of certain voltage-gated Ca2+ channels (Gee et 
al., 1996; Marais et al., 2001). The therapeutic option of increasing inhibition is therefore 
totally unexplored so far. The following chapters hence discuss GABAAR in general and 
specifically in the spinal cord.  
1.5 GABA  Receptors 
In mammalian central nervous system, more than one third of synapses release the 
inhibitory neurotransmitter GABA that activates GABAAR. These receptors are classified 
into two types based on their biochemical, pharmacological and physiological properties 
(Bowery et al., 1980): 1) The ionotropic GABAAR, a member of the Cys-loop ligand-gated 
ion channel superfamily, which also includes nicotinic acetylcholine, glycine and 5-HT3 
receptors and 2) the metabotropic GABAB receptors (GABABR), a member of the group C 
family of G-protein-coupled receptors including metabotropic glutamate receptors. 
GABABR mediate slow inhibition of neuronal excitability through the opening of 
inwardly rectifying K+ channels and the inhibition of voltage-gated calcium channels 
(VGCCs). They also inhibit adenylyl cyclase (Pan et al., 2008). GABAAR mediating fast 
synaptic inhibition are permeable to chloride (Cl-) and to a lesser extent, to bicarbonate 
(HCO3-) (Farrant and Kaila, 2007). Increased inhibition by GABAAR causes behavioral 
changes, including sedation, anxiolysis, anterograde amnesia, muscle relaxation and 
increased seizure threshold.  
1.5.1 GABAA  Receptors  
GABAAR are heteropentameric ion channels assembled from at least 19 subunits (6, 
1-3, 1-3, , , θ, π, 1-3). The most common subtype in the CNS is composed of two , 
two , and one subunit. Structurally, they are composed of a central pore for anion flux, 
two GABA binding sites  (each formed by an and  interface) and one BDZ -ligand 
binding site at the and subunit interface (Möhler, 2006). GABAAR can be composed of 
varying combinations of different  subunits (fig. 5).  
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1.5.2  GABAA Receptor-Mediated Regulation of Neurotransmission 
The first and foremost significant action of GABA in CNS is to decrease neuronal 
excitation by increasing the conductance for chloride ions. In neurons, depending on the 
intracellular anion concentration and the membrane potential, GABAAR can mediate 
chloride (Cl-) current which is either hyperpolarizing (inward) or depolarizing (outward) 
and depolarizing HCO3- current. Activation of GABAAR by GABA and other agonists 
(such as muscimol) leads to an increase in Cl- conductance driving the membrane 
potential towards the chloride equilibrium potential. Most adult CNS neurons have 
negative chloride equilibrium at around -65 mV. In these neurons GABAAR activation 
results in a decreased neuronal excitability thereby reducing the probability for an action 
potential in the postsynaptic neuron. However, excitatory effects of GABAAR activation 
by the net effluxes of Cl- and K+ ions have also been reported, notably during 
development (Ben-Ari et al., 1997; Taketo and Yoshioka, 2000), as well as in certain cell 
populations, such as some hippocampal interneurons (Lamsa and Taira, 2003) and in 
DRG neurons (see 1.2.3). 
 
GABA mainly mediates phasic (transient) inhibition through the synaptically localized 
GABAAR. These receptors are composed of , ,  or subunits in combination 
with the ubiquitous 2-subunit that drives receptor clustering at the synapse (Essrich et 
al., 1998). Activation of extrasynaptic GABAAR by the GABA spilled over from the 
synaptic cleft has been shown to cause tonic (persistent) inhibition (Brickley et al., 1996). 
These extrasynaptic GABAAR contain 4 and 6 subunits as well as  subunit. 
GABAAR are found both at the synaptic and extrasynaptic sites. Tonic inhibition is 
Fig. 5. GABAA receptor with its 
major ligand binding sites. 
Schematic illustration of a GABAAR 
protein formed from five subunits 
((1)2 (2)2 (2)). It also depicts 
chloride (Cl-) ion channel pore, two 
GABA active binding sites at the 1 
and 2 interfaces, and BDZ allosteric 
binding-site at the 1 and 2 interface.  
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distinct from the transient activation of synaptic GABAAR that result in classical 
inhibitory postsynaptic currents and from the slow and transient response of the 
metabotropic GABABR. The generation of tonic inhibition upon activation of slowly 
desensitizing extrasynaptic receptors by low concentrations of GABA is attributed to the 
presence of the  subunit (Haas and Macdonald, 1999; Bianchi et al., 2002). Recently 
extrasynaptic GABAAR have been identified as novel targets for endogenous and 
clinically relevant molecules such as neuroactive steroids (Lambert and Belelli, 2002), 
ethanol (Sundstrom-Poromaa et al., 2002), analgesics (Krogsgaard-Larsen et al., 2004) 
and anticonvulsant drugs (Cheng et al., 2006). Neurosteroids (e.g., the progesterone 
metabolite allopregnanolone) have been shown to specifically modulate neuronal 
excitability through endocrine, paracrine, or autocrine actions at extrasynaptic GABAAR 
in neurons (Belelli et al., 2005). 
 
GABAAR contain several allosteric binding sites for multiple ligands, in particular BDZ -
site ligands, barbiturates, ethanol, neuroactive steroids, volatile and intravenous 
anesthetics. Classical BDZ are positive allosteric modulators of GABAAR and enhance 
the apparent affinity of GABA, whereas inverse agonists (e.g., Ro 15-4513) have the 
opposite effect. The action of both agonists and inverse agonists can be blocked by the 
antagonist flumazenil, which lacks intrinsic activity (Hunkeler et al., 1981; Möhler, 2006). 
1.5.3  Functional Analysis of GABAA Receptors Using In vitro and In vivo 
Tools 
In the last two decades, the functional significance of the molecular diversity of GABAAR 
has been unraveled by novel genetic and pharmacological tools employed to study the 
functions of specific GABAAR isoforms in vitro and in vivo. GABAAR subunit specific 
knock-out mice were generated, but the applicability of these mice in studies to 
understand the functions of GABAAR subtypes had been limited by the compensatory 
up- or down- regulations of other GABAAR subunits (1 knock-out, Sur et al., 2001, 
Vicini et al., 2001), lethal phenotype (2 knock-out, Gunther et al, 1995) or absence of 
detectable behavioral effects (2 knock-out, Sur et al., 2001). The presence of a histidine 
residue at a conserved location in the genes encoding , ,  or subunit has 
been shown to be critical for diazepam sensitivity of the corresponding GABAAR 
subtypes. 4 and 6 GABAA R  have an arginine residue at this site, which renders them 
insensitive to diazepam and other classical BDZ (Wieland et al., 1992). Recombinant 
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receptor studies done by replacing the histidine residue with an arginine residue 
confirmed the loss of potentiating effect of diazepam without affecting the receptor 
sensitivity to GABA (Benson et al., 1998; Dixon et al., 2011). 
 
This knowledge helped to generate GABAAR subunit point-mutated (“knock-in”) 
mice, which were rendered insensitive to diazepam by replacing the histidine residue 
with arginine (Rudolph et al., 2001). Knock-in mice carrying these point-mutations 
(1(H101R), 2(H101R), 3(H126R), 5(H105R)) enabled the characterization of defined 
GABAAR subtypes mediating the sedative, anxiolytic, anticonvulsant and myorelaxant 
actions of diazepam (Rudolph et al., 1999; Löw et al., 2000; Crestani et al., 2001; Crestani 
et al., 2002), as well as its antinociceptive effects in models of chronic pain. Thus,  
GABAAR mediate sedative, anticonvulsant, anterograde amnesic effects of diazepam 
(Rudolph et al., 1999; McKernan et al., 2000; Crestani et al., 2002; Savic et al., 2006); 
whereas  GABAAR selectively mediate anxiolytic and alcohol potentiating effects of 
diazepam, as well as parts of its antihyperalgesic action.  and  GABAAR contribute 
moderate-low modulations in nociception (Löw et al., 2000; Täuber et al., 2003; Knabl et 
al., 2008). At the same time, the muscle relaxant effect is primarily mediated by  and 
 GABAAR with  GABAAR and shown to be effective at higher doses of diazepam 
(Crestani et al., 2001; Crestani et al., 2002). Sedative tolerance to diazepam administration 
depends on  GABAAR (van Rijnsoever et al., 2004). More importantly, the knock-in 
mouse lines did not show a decrease in the mutated subunit or apparent compensatory 
regulations of other GABAAR subunits (Möhler et al., 2002) except in 5 (H105R) mice 
with a reduced expression of subunit in the medial temporal lobe (Crestani et al., 
2002; Prut et al., 2010). 
 
The availability of cre/loxP system that provides site-specific gene recombination (Sauer 
et al., 1987; Sauer and Henderson, 1988a, 1988b) was also employed for mutating 
GABAAR subunits. Cre/loxP recombination targets a specific sequence of DNA and its 
splicing is achieved with cre recombinase enzyme (38-kDa). It recognizes a 34-bp DNA 
segment called “locus of crossing-over of P1” (loxP) which was first described in the 
bacteriophage P1 (Orban et al., 1992; Lakso et al., 1996). This site is unlikely to occur 
randomly in the mouse genome and is small enough to be "neutral" when integrated into 
chromosomal DNA. When two loxP sites are located on the same DNA molecule, cre 
causes inversion or excision of the intervening DNA segment based on their respective 
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orientation. Two transgenic mouse lines are required to generate tissue-specific gene 
deletions. The first mouse line expresses the cre recombinase under the control of a 
tissue-specific promoter. The second carries loxP sites flanking around the gene (essential 
exon) of interest ("floxed gene"). In the offspring from these two lines, the gene (or exons) 
of interest will be removed selectively from cells expressing cre recombinase. This system 
was employed in creating the transgenic mouse line carrying a specific spinal deletion of 
GABAAR subtypes using a mouse line that expresses the Cre recombinase under the 
transcriptional control of the spinally expressed Hoxb8 gene (Witschi et al., 2010).   
1.5.4 Distribution of GABAA  Receptor Subtypes in Rodent Brain  
Previous studies have revealed the distinct distribution pattern of GABAAR subtypes in 
the murine brain (Fritschy et al., 1992; Fritschy and Mohler, 1995; Pirker et al., 2000; 
Möhler et al., 2002). Diazepam-sensitive GABAAR are the most abundant in the brain 
altogether constituting 90% of the total GABAR. GABAAR alone represent 60% out of 
the total GABAAR (Benke et al., 1991). The subunit is abundantly present in the 
cerebral cortex, hippocampus, thalamus, cerebellum and olfactory bulb at both synaptic 
and extrasynaptic sites, whereas it is absent in a few brain regions including the granule 
cell layer of olfactory bulb and the reticular nucleus of the thalamus. The subtypes 
contribute to 15-20% GABAAR, which are present at synaptic locations of cerebral cortex, 
hippocampus and striatum. The subtypes are located mainly in synapses of cerebral 
cortex, thalamic reticular nucleus, as well as in monaminergic cells of brain stem and 
cholinergic neurons, accounting for up to 10-15% of the total GABAAR. The subunit is 
less abundant in the rat brain (< 5%) except in hippocampus. A rough complementary 
pattern of distribution is observed with  versus  and GABAAR. Diazepam-
insensitive GABAAR represent 6% of the total GABAAR. The 6 subunit is present 
exclusively in cerebellar granule cells, both at synaptic and extrasynaptic locations 
whereas the 4 subunit has been found only extrasynaptically. 
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1.5.5  Distribution of GABAA Receptor Subtypes in Rodent Spinal Cord  
Compared to brain, distribution of GABAAR subtypes in spinal dorsal horn is relatively 
less well explored.  In rat spinal cord, in situ hybridization studies detected strong 
signals for GABAAR 2, 3, 3 and 2 subunit mRNA, weak expression for 1, 5, 1, 2, 
1 and 3, but could not detect andsubunits (Persohn et al., 1991; Wisden et al., 
1991; Ma et al., 1993). Immunohistochemical analysis has shown that 1, 2 and 5 
subunit show restricted lamina-specific distribution whereas the 3 subunit is more 
widely expressed (Bohlhalter et al., 1996). Previous work in our laboratory showed that 
2 and 3 subunit correspond to the most abundant diazepam-sensitive GABAAR 
subtypes in the mouse spinal dorsal horn and that intrinsic dorsal horn neurons express 
mainly the 2 and 3 subunits (Knabl et al., 2008).  
1.5.6 Interaction of Gephyrin with GABAA Receptor Subtypes  
Gephyrin was first discovered as a glycine receptor subunit (Pfeiffer et al., 1982) and was 
later recognized as a scaffolding protein that interacts with polymerized tubulin and 
anchors glycine receptors in the membrane (Kirsch et al., 1991). In 1995, gephyrin was 
Fig. 6. Distinct subunit distribution 
pattern, reflecting the distribution of 
diazepam-sensitive GABAA receptors in 
the murine brain. 
 The GABAA receptor 1 subunit is 
abundant in cerebral cortex, cerebellar 
cortex, thalamus and pallidum. The 2 
subunit is localized to striatum, 
hippocampus, amygdala and 
hypothalamus. The 3 subunit is 
expressed in the monaminergic and 
serotonergic neurons of the brain stem 
and the cholinergic neurons of the basal 
forebrain. The subunit is found 
predominantly in the hippocampus and 
olfactory bulb. Adapted from Mohler et 
al. (2002).  
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discovered to be present in GABAergic synapses of retina and later in brain (Sassoè 
Pognetto et al., 1995; Sassoè Pognetto et al., 2000). Antisense treatment against gephyrin 
in hippocampal cultures resulted in a significant decrease of postsynaptic subunit 
containing GABAAR clusters, indicating that gephyrin is involved in GABAAR clustering 
(Essrich et al., 1998). Furthermore, in hippocampal cultures, transfected with GFP-tagged 
GABAAR, the receptors were found to be more mobile in the plasma membrane when 
gephyrin is silenced by RNA interference, suggesting that GABAAR clusters are 
stabilized via gephyrin (Jacob et al., 2005). Besides this, GABAAR subtype 
accumulation  in inhibitory postsynaptic sites directly correlates with their ability to bind 
to gephyrin (Tretter et al., 2008). Thus, in analogy with PSD-95 in excitatory synapses, 
gephyrin is thought to be a scaffolding protein holding glycine/GABAAR at inhibitory 
postsynaptic sites.  
1.5.7 Role of GABAA Receptor Subtypes in Nociception  
Several lines of evidence indicate that GABAAR present in the spinal dorsal horn are the 
major regulators of the normal and pathological form of pain, notably in comparison to 
supraspinal GABAAR (Jasmin et al., 2003; Knabl et al., 2008; Munn et al., 2009; Munro et 
al., 2011). In principle, GABAAR modulate spinal nociceptive processing via at least two 
sites. Postsynaptic GABAAR directly reduce the excitability of central dorsal horn 
neurons, while GABAAR located on the spinal nociceptive terminals mediate presynaptic 
inhibition. Morphological data employing immunofluorescence and in situ hybridization 
support the possibility that GABAAR mediate most of the analgesic effects of BDZ 
applied intrathecally (Knabl et al., 2008) and are the major GABAAR isoform in DRG 
neurons (Ma et al., 1993). Besides, co-staining experiments with antibody against 
substance P revealed that 2, but not 1, 3 or 5 GABAAR were extensively colocalized 
with peptidergic nociceptive terminals in lamina II.  GABAAR containing 3 subunit 
were also identified as a component of the spinal pain control and were found 
colocalized with NK1-receptor-positive lamina I neurons (Knabl et al., 2008). Negative 
allosteric modulation of GABAAR using systemic 5IA-II resulted in analgesia, 
suggesting a potential role of these receptors in activation of spinally-mediated 
antihyperalgesic effects (Munro et al., 2011). So far, the neuroanatomical locations of 
GABAAR 1, 4, and 5 subunit containing neurons and afferent terminals in the spinal 
dorsal horn are rather unclear.  
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The inhibitory interneurons in the spinal dorsal horn serve important functions in the 
central processing of sensory information. The available literature points towards a 
prominent role of GABAAR subunit containing subtypes in the regulations of 
antihyperalgesia in the dorsal horn. Thus, the projects detailed in this dissertation aim to 
explore the contribution of nociceptive versus non-nociceptive terminal residing 
GABAAR. Besides, the contribution of spinally versus supraspinally 
locatedGABAAR towards antihyperalgesia in inflammatory and neuropathic models 
is also investigated. Ultimately, this dissertation contributes to the knowledge pool that 
might result in the development of novel pharmacological approaches to pain treatment. 
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2 Aims 
 
Despite numerous advances in our understanding of the functional diversity of GABAAR 
subtypes and their profound influence on nociception, their exact cellular distribution 
pattern in the spinal dorsal horn is largely unknown. Several lines of evidence suggest 
that pathological pain of inflammatory or neuropathic origin converge onto a loss of 
synaptic inhibition in the spinal cord, which should be reversible through the 
potentiation of GABAergic neurotransmission. In line with this hypothesis, BDZ, which 
facilitate the action of GABA at GABAAR, exert clear antihyperalgesic actions after local 
spinal application, both in animal models (Clavier et al., 1992; Sumida et al., 1995) and in 
patients (Tucker et al., 2004). This thesis combines pharmacological, behavioral, 
electrophysiological, and morphological experiments in wild type and genetically 
modified mice to unravel the localization of the GABAAR α subtypes in the mouse spinal 
cord and to identify the specific sites of action of α2 GABAAR-mediated 
antihyperalgesia.  
 
2.1 Contribution of Presynaptic α2 GABAA Receptors Located on the 
Central Terminals of Primary Nociceptive Afferents to the Spinal 
Nociceptive Processing. 
At the spinal cord level, GABAAR can in principle modulate nociceptive processing via 
at least two sites. Postsynaptically located GABAAR directly reduce the excitability of 
central dorsal horn neurons, while GABAAR located presynaptically on the spinal 
terminals of primary afferent nociceptors cause presynaptic inhibition. Morphological 
data employing immunofluorescence and in-situ hybridization have suggested that 
α2 GABAAR, which mediate most of the analgesic effects of spinal BDZ (Knabl et al., 
2008), are the major if not the only GABAAR isoform in dorsal root ganglion neurons (Ma 
et al., 1993). In addition, co-staining experiments with antibodies against substance P 
revealed that α2 GABAAR were extensively colocalized with peptidergic primary 
afferent nociceptive terminals in lamina II. α3  GABAAR were also identified as a critical 
component of the spinal pain control and were present in NK1-receptor-positive lamina I 
neurons (Knabl et al., 2008). To address the contribution of presynaptic α2 GABAAR to 
the analgesic effects of spinal BDZ, mice were generated carrying targeted deletions or 
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mutations of the GABAAR α2 subunit in primary nociceptive neurons. Behavioral, 
morphological and electrophysiological experiments were performed to analyze the 
phenotype of GABAAR mutant mice in different models of inflammatory and 
neuropathic pain in absence of treatment and after intrathecal injection of diazepam. 
2.2 Contribution of Spinal GABAA Receptor α2 Subtype to the Nociceptive 
Regulation.  
This project aims to distinguish the contribution of spinal versus supraspinal 
α2 GABAAR to antihyperalgesia induced by BDZ-site ligands using a mouse line 
expressing the Cre recombinase under the transcriptional control of the homeobox gene 
Hoxb8 (Witschi et al., 2010), together with a floxed Gabra2 gene. Within the neuraxis, 
Hoxb8-Cre expression is restricted to spinal cord neurons and glial cells, as well as dorsal 
root ganglion neurons, allowing selective excision of a floxed gene in these cells. Since 
Hoxb8 is expressed only up to the mid cervical segments during development, Gabra2 is 
not affected in the supraspinal cells. Behavioral, biochemical, morphological and 
electrophysiological experiments were performed to analyze the phenotype of these 
mutant mice in a neuropathic pain model in the absence of treatment and after systemic 
injection of HZ166, a less sedating BDZ-binding site ligand with preferential affinity for 
α2  and α3 GABAAR. 
2.3 Molecular Organization of GABAA Receptor Subtypes in the Spinal 
Dorsal Horn. 
This study aims to analyze immunohistochemically the molecular organization of 
GABAAR in identified intrinsic dorsal horn neurons and primary afferents in layers I-III 
of the dorsal horn, using high resolution immunofluorescence staining combined with 
specific neuronal and axonal markers (Schneider Gasser et al., 2006). 
 
32
  
 
 
 
 
 
 
 
EXPERIMENTAL SECTION 
 
 
 
 
33
  
34
                                                                                                                  Results (Paper 1) 
 
 
 
3 Results 
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Abstract 
 
Spinal dorsal horn GABAA receptors are found both postsynaptically on central neurons 
and presynaptically on axons and/or terminals of primary sensory neurons, where they 
mediate primary afferent depolarization (PAD) and presynaptic inhibition. Both 
phenomena have been studied extensively on a cellular level, but their role in sensory 
processing in vivo has remained elusive, due to inherent difficulties to selectively 
interfere with presynaptic receptors. Here, we address the contribution of a major 
subpopulation of GABAAR (those containing the α2 subunit) to spinal pain control in 
mice lacking α2  GABAAR specifically in primary nociceptors (sns-α2−/− mice). sns-α2−/− 
mice exhibited GABAAR currents and dorsal root potentials of normal amplitude in vitro, 
and normal response thresholds to thermal and mechanical stimulation in vivo, and 
developed normal inflammatory and neuropathic pain sensitization. However, the 
positive allosteric GABAAR modulator diazepam (DZP) had almost completely lost its 
potentiating effect on PAD and presynaptic inhibition in vitro, and a major part of its 
spinal antihyperalgesic action against inflammatory hyperalgesia in vivo. Our results 
thus show that part of the antihyperalgesic action of spinally applied DZP occurs 
through facilitated activation of GABAAR residing on primary nociceptors.  
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Introduction  
 
GABAA receptors mediate fast synaptic inhibition throughout the adult mammalian 
CNS. They are also densely expressed in the spinal dorsal horn (Bohlhalter et al., 1996) 
where they control the propagation of nociceptive signals (Roberts et al., 1986; Ishikawa 
et al., 2000). Diminished GABAergic and glycinergic inhibition at this site is a major 
factor in chronic pain syndromes (for a review see (Zeilhofer, 2008)). Conversely, 
hyperalgesia originating from inflammatory and neuropathic diseases can be reversed 
by local spinal or systemic administration of benzodiazepines (BDZ) such as diazepam 
(DZP) (Knabl et al., 2008) and midazolam (Kontinen and Dickenson, 2000), which 
enhance GABAAR activation. GABAAR are heteropentameric ligand-gated ion channels, 
most of which are composed of α, β and γ subunits (Olsen and Sieghart, 2008). BDZ-
sensitive subtypes contain one γ2 subunit, which together with an α1, α2, α3, or α5 
subunit forms the BDZ binding site (Pritchett et al., 1989; Wieland et al., 1992). For each 
of these subunits, point mutated mice have been generated which carry a histidine to 
arginine (H/R) substitution that destroys the DZP-sensitivity of the mutated α subunit 
without changing its responses to GABA (Mohler et al., 2002). Using these mice it has 
become possible to attribute to α2  GABAAR most of the antihyperalgesic effect of spinal 
DZP (Knabl et al., 2008).  
 
In the spinal cord α2  GABAAR are densely expressed in the superficial layers of the 
dorsal horn, the main termination area of primary nociceptors (Bohlhalter et al., 1996). At 
this site, α2  GABAAR are found not only postsynaptically on central neurons, where 
they cause classical hyperpolarization, but most likely also presynaptically on the 
terminals of primary sensory neurons (discussed in Persohn et al., 1991, and Bohlhalter 
et al., 1996). These terminals are depolarized by GABAAR (Labrakakis et al., 2003), 
because their intracellular chloride concentration is kept above electrochemical 
equilibrium by the chloride importer NKCC1 (Alvarez-Leefmans, 2009). This primary 
afferent depolarization (PAD) causes presynaptic inhibition, i.e. a reduction in synaptic 
glutamate release, possibly through inactivation of presynaptic sodium channels and/or 
through activation of a shunting conductance, both of which can result in inhibition of 
action potential propagation into presynaptic terminals (Kullmann et al., 2005). Both 
processes will result in reduction of nociceptive input to the spinal cord. However, if 
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PAD becomes sufficiently strong to trigger action potentials, it may also elicit so called 
dorsal root reflexes, and exaggerate pain and neurogenic inflammation (Willis, 1999). 
 
The contribution of PAD to the processing of nociceptive signals and to the 
antihyperalgesic effect GABAAR modulators is unknown, mainly due to the lack of 
suitable tools for the specific targeting of presynaptic GABAAR. Here, we used a genetic 
approach and investigated conditional nociceptor-specific α2  GABAAR-deficient and 
point mutated mice in morphological, electrophysiological and behavioral experiments. 
Deletion of α2  GABAAR in nociceptive primary afferents reduced DZP sensitivity of 
GABAergic membrane currents in nociceptive dorsal root ganglion (DRG) neurons and 
GABAAR-mediated presynaptic inhibition, and led to a reduction in the antihyperalgesic 
effect of spinal DZP.  
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Materials and Methods 
 
Mice 
To generate a floxed Gabra2 allele, a 6.3 kb PstI-NcoI genomic fragment containing exons 
5 (221 bp) and 6 (83 bp) together with 2 SphI sites was isolated. The 1 kb SphI-SphI 
fragment was removed from the 6.3 kb PstI-NcoI fragment and replaced by an oligo 
hybrid containing a loxP site with adjacent KpnI and SalI sites, recreating a single SphI 
site, into which the 1 kb SphI-SphI fragment containing exon 5 was reinserted. A 
neomycine resistance cassette (FRT-Pol2-neo-bpA-FRT-loxP) was then subcloned into the 
SalI site. The vector was linearized at the 5’ end of the genomic homology at a NotI site 
and electroporated into embryonic stem (ES) cells (C57BL/6N, Eurogentec). Clones 
harboring a single targeting event (“targeted allele” in fig. 1A) were injected into 
blastocysts (Polygene, Ruemlang, Switzerland). The neomycine resistance cassette was 
bred out using ACTFlpe mice (Jackson Laboratories, Bar Harbor, ME, USA) to obtain the 
floxed allele (Gabra2tm2.1Uru). Floxed mice were crossed with EIIa-cre mice (Jackson 
Laboratories) to obtain Gabra2 global knock-out mice (allele designated Gabra2tm2.2Uru). 
Nociceptor specific sns-α2−/−  mice and sns-α2 −/R point mutated mice were generated 
from sns-cre transgenic mice (Agarwal et al., 2004) crossed with α2fl/fl and  or α2R/R mice 
(Low et al., 2000) (for the designations of the different genotypes see Tab. 1). All mice 
were maintained on a C57BL/6 background.  
 
mRNA quantification 
 4 - 6 lumbar DRGs, lumbar spinal cords, and cerebral cortices were rapidly removed 
from euthanized adult sns-α2−/− mice and α2fl/fl littermates, as well as from global α2 /- 
mice. mRNA expression of GABAAR α subunits was quantified with quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR) using β-actin as reference gene (for 
Taqman® assays see Tab. 2). 
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Genotype   Gabra2 phenotype 
Gabra2 
allele 1 
Gabra2 
allele 2 
sns-cre  
transgene 
Primary 
nociceptors 
All other cell 
types 
Designation 
(short) 
Fl fl - wt / wt wt / wt 
α2fl/fl_sns-cretg- 
(α2fl/fl) 
Fl fl + - / - wt / wt 
α2fl/fl_sns-cretg+ 
(sns-α2 /-) 
Fl H - wt / wt wt / wt 
α2fl/H_sns-cretg- 
(α2fl/H) 
Fl H + - / wt wt / wt 
α2fl/H_sns-cretg+ 
(sns-α2 /H) 
Fl R - wt / R wt / R 
α2fl/R_sns-cretg- 
(α2fl/R) 
Fl R + - / R wt / R 
α2fl/R_sns-cretg+ 
(sns-α2 /R) 
R R - R / R R / R (α2R/R) 
- - - - / - - / - (α2 /-) 
 
Tab. 1. Genotypes and cell type-specific phenotypes of the mouse lines analyzed. Phenotypically,  
 floxed alleles are regarded as wild-type in the absence of cre.  
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assay ID context sequence  
(including the probe sequence) 
Gene 
Mm00607939_s1 CTGTTACTGAGCTGCGTTTTACACC Actb 
Mm00439046_m1 TTCCAGAAAAGCCAAAGAAAGTAAA gabra1 
Mm00433435_m1* TATATACCATGAGGCTTACAGTCCA gabra2 
Mm00433440_m1 AGTGACTGTGACACTCGATCTCACA gabra3 
Mm00802631_m1 GAAACATCCCTTCAGAATACACATG gabra4 
Mm00621092_m1 ACACCATGCGTCTGACAATCTCTGC gabra5 
Mm01227754_m1 CCAGGATTTGGGGGTGCTGTAACAG gabra6 
Mm01266203_g1 TCTCAGAGGCAAACATGGAATACAC Gabrd 
Mm00489932_m1 CCAGACATGGAATATTCCATTGACA Gabre 
Mm01193033_m1 GTAACATGGACTACACAGCCACTAT Gabrp 
Mm00445057_m1 AGCAAATGTGCAGGATGGCCTGATT Gabrq 
Mm00433499_m1 GCAAGGCAGCCCAATCCTGAGACGA gabrr1 
Mm00433507_m1 TCCAAGCCAAGCCATTTGTATAAAA gabrr2 
Mm01344096_m1 GTTTCCCTGGGGATCACGACGGTGC gabrr3 
 
Tab. 2.  qRT-PCR (Taqman) assays used to quantify GABAAR α subunit expression. * This assay 
amplifies a gene segment including the floxed gabra2 exon 5 and therefore does not yield a PCR 
product from chromosomes which have undergone cre-mediated excision of exon 5.  
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Morphology 
 Lumbar spinal cords prepared from 6 - 8 week old sns-α2−/−  mice and α2fl/fl littermates 
were cut into 300 µm thick parasagittal slices, fixed in 4% paraformaldehyde for 10 min 
and subsequently cut into 14 µm thick sections using a cryostat. Immunofluorescence 
staining was performed to study the colocalization of GABAAR α2 and α3 subunits using 
guinea pig affinity purified antisera (guinea pig affinity purified antisera (Knabl et al., 
2008) with markers of primary afferent nociceptive fibers (CGRP and IB4). A polyclonal 
rabbit antiserum against CGRP (Chemicon, cat. no. AB 15360) and an IB4-Alexa 488 
conjugate (Molecular Probes, cat. no. 121411) were used to label spinal axons and 
terminals of peptidergic and nonpeptidergic nociceptors, respectively. Thick myelinated 
(non-nociceptive) fiber terminals were labeled with a rabbit antiserum against VGluT1 
(Synaptic Systems, Göttingen). High-resolution confocal images were processed and 
analyzed with Imaris (Bitplane) software. Double-immunofluorescence staining was 
visualized by confocal microscopy (Zeiss LSM-710 Meta; Jena, Germany) using a 63x 
Plan-Apochromat objective (NA 1.4). The pinhole was set to 1 Airy unit for each channel 
and separate color channels were acquired sequentially. The acquisition settings were 
adjusted to cover the entire dynamic range of the photomultipliers. High-resolution 
confocal images were processed and analyzed with Imaris (Bitplane) with minimal 
adjustments of contrast and brightness. Images from both channels were overlaid 
(maximal intensity projection) and background was subtracted, when necessary. A low-
pass ‘edge preserving’ filter was used for images displaying α2 or α3 staining. 
Colocalization of α2 subunit immunoreactivity with primary afferent terminals was 
quantified from single confocal sections (1024×1024 pixels) at a magnification of 56 μm / 
pixel in 8 bit grayscale images, using a threshold segmentation algorithm (minimal 
intensity, 90 – 130; size 0.08 – 0.8 μm2).  Colocalizations were counted in 6 fields per slide 
each from a different mouse. 3 mice per genotype were analyzed. Colocalizations were 
considered to be true, only if (a) the α subunit staining appeared completely inside the 
primary afferent staining, (b) covered an area > 0.057 μm2, and (c) the colocalization was 
visible in the previous and next images of the Z-stack. 
 
Electrophysiology 
 Whole-cell patch-clamp recordings were made at room temperature from acutely 
isolated nociceptive DRG neurons and from superficial dorsal horn neurons. DRG 
neurons were prepared from 3 - 4 week old mice (Knabl et al., 2008). Nociceptive DRG 
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neurons were identified by the presence of Na+ currents resistant to TTX (0.3 µM) and 
exhibiting pronounced reduction in amplitudes during repetitive (5 Hz) depolarizations 
for 30 ms to 0 mV (Blair and Bean, 2003). Transverse spinal cord slices with short dorsal 
roots attached were prepared from 2 - 3 week old mice (Ahmadi et al., 2002). Dorsal 
roots were stimulated electrically (duration ≥ 100 µs; 17 - 70 V) at a frequency of 0.07 Hz 
to elicit primary afferent-evoked EPSCs. DRP recordings were made from isolated spinal 
cords of 18 - 27 day old mice at 28.5°C (Martinez-Gomez and Lopez-Garcia, 2005). Dorsal 
roots S2 or S3 were stimulated and the cranially adjacent root was recorded. Suction 
electrodes were used for both stimulation and recording.  
 
Behavior 
 Experiments were done in 7 - 10 week old mice. Care was taken to ensure equal 
numbers of male and female mice in all experiments. Inflammatory and neuropathic 
pain induction, thermal and mechanical testing, and intrathecal (i.t.) injections, i.e. 
injections into the subarachnoid space of the spinal canal, of diazepam and vehicle were 
done as described previously (Knabl et al., 2008). Capsaicin was dissolved in Tween 80 
(10%), ethanol (10%), saline (80%). Permission for the animal experiments was obtained 
from the Veterinäramt des Kantons Zürich (ref. no. 121/2006 and 34/2007). 
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Results 
 
Nociceptor-specific α2 GABAA receptor-deficient mice.  
Conditional nociceptor-specific  α2  GABAAR -deficient mice (α2fl/fl_sns-cretg+; short sns-
α2−/− mice) were generated by crossing mice carrying a floxed α2  GABAAR (Gabra2) gene 
(fig. 1A) to transgenic mice expressing the cre recombinase under the transcriptional 
control of the sensory neuron specific sodium channel (sns) gene (Agarwal et al., 2004).  
 
The expression of the other BDZ-sensitive GABAAR subunits was not significantly 
changed in DRGs of sns-α2−/− mice (fig. 1C). We also analyzed possible changes in the 
expression of the BDZ-insensitive GABAAR subunits α4, α6, δ, ε, π, θ, and ρ1-ρ3 (Tab. 3). 
Transcripts encoding for six of these subunits (α4, δ, ε, θ, ρ1, and ρ3) were reliably 
detected in DRGs of both α2fl/fl and sns-α2−/− mice. mRNA encoding for the α4 subunit 
was significantly up-regulated in sns-α2−/− mice by 44.5 ± 9.5% (mean ± sem). Up-
regulations by between 20 and 40% were also found for δ, θ, and ρ1 but these did not 
reach statistical significance. 
 
No detectable levels of α2 subunit mRNA were found in global α2 /- mice (generated 
from α2fl/fl mice crossed to EIIa-cre mice (Lakso et al., 1996) verifying the specificity of 
the assay and suggesting that the α2 mRNA remaining in DRGs of sns-α2−/− mice derived 
most likely from non-nociceptive (sns-cre negative) DRG neurons.  
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Fig. 1. Generation of GABAAR α2fl/fl mice and qRT-PCR analyses. (A) Generation of mice carrying 
a floxed Gabra2 allele. For details see Materials and Methods. (B) Quantification (mean ± sem) of 
Gabra2 transcript numbers (relative to β-actin) in lumbar DRGs, spinal cords and cerebral cortices 
of sns-α2 /- mice (n = 7) and wild-type (α2fl/fl) littermates (n = 9) with qRT-PCR. (C) Quantification 
of gabra1, Gabra2, Gabra3 and Gabra5 gene transcripts (encoding for the BDZ-sensitive subunits α1, 
α2, α3, and α5) in the DRGs of sns-α2 /- mice and wild-type (α2fl/fl) littermates. ***, P ≤ 0.001. 
Statistical comparisons between wild-type and sns-α2−/− were made with unpaired t tests followed 
by Bonferroni corrections for 3 (B) and 4 (C) independent comparisons. 
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GABAA receptor  
subunit (gene) 
expression relative to 
β-actin in α2fl/fl mice 
(mean ± sem) 
expression ratio  
(sns-α2-/- / α2fl/fl) 
(mean ± sem) 
P 
α4 (Gabra4) 7.6 ± 0.34·10-5 1.45 ± 0.25 0.004 
α6 (Gabra6) n.d.   
δ (Gabrd) 2.9 ± 0.45·10-4 1.41 ± 0.45 n.s. 
ε (Gabre) 2.2 ± 0.21·10-4 1.10 ± 0.26 n.s. 
π (Gabrp) n.d.   
θ (Gabrq) 2.5 ± 0.41·10-4 1.37 ± 0.29 n.s. 
ρ1 (Gabrr1) 2.6 ± 0.39·10-4 1.23 ± 0.14 n.s. 
ρ2 (Gabrr2) n.d.   
ρ3 (Gabrr3) 1.8 ± 0.33·10-4 0.90 ± 0.11 n.s. 
 
Tab. 3. Changes in gene expression in sns-α2−/− mice compared to α2fl/fl mice. Gene expression for 
both genotypes was first calculated relative to β-actin expression, and then compared between 
sns-α2−/− and α2fl/fl mice. n.d., not detectable. α6 transcripts were not detectable in any of the 
samples, and transcripts for π and ρ2 were only found in 2 out of 16 samples. P, significance 
calculated by ANOVA followed by Bonferroni correction for 6 independent samples. n.s., not 
significant after Bonferroni correction. Number of mice, n = 8 and 7, for α2fl/fl and sns-α2−/−, 
respectively.  
 
 
 α2 GABAA receptors expressed in spinal terminals of primary afferent sensory 
fibers. 
 High resolution confocal microscopy was used in parasagittal sections of the lumbar 
spinal cord to quantify the expression of α2  GABAAR in the three major subpopulations 
of primary afferent fibers. Peptidergic and nonpeptidergic nociceptive fiber axons and 
terminals were labeled with antiserum against calcitonin gene related peptide (CGRP) 
and with a fluorescent isolectin B4 (IB4) conjugate, respectively, while non-nociceptive 
fiber terminals were labeled with an antiserum against the vesicular glutamate 
transporter 1 (VGluT1), which is in the dorsal horn selectively expressed by thick 
myelinated (non-nociceptive) primary afferent fiber terminals (Todd et al., 2003). All 
sections were counterstained with an antiserum against the GABAAR α2 subunit (fig. 
2A,B). In the major termination area of nociceptive fibers (laminae I and II of the spinal 
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dorsal horn), about one third and one fourth of CGRP and IB4 positive structures stained 
also positive for α2  GABAAR in wild-type (α2fl/fl) mice. These colocalizations were 
virtually absent in sns-α2−/−mice (fig. 2C,D). As expected, VGluT1 positive structures 
were mainly located in the deep dorsal horn (lamina III and deeper). They also showed a 
considerable but lower degree of colocalization with α2  GABAAR, which was 
unchanged in sns-α2−/− mice. We also found a significant expression of α3 GABAAR in all 
three types of primary afferent fibers (52 ± 12%, 41 ± 16%, 27 ± 4% (mean ± SD) with 
CGRP, IB4 and VGluT1, respectively). The distribution of α3 GABAAR was not altered in 
sns-α2−/− mice. 
 
Electrophysiological analysis of sns-α2−/− mice.  
To analyze functional consequences of sns-α2 gene deletion at the cellular level, we first 
made whole-cell recordings from acutely isolated nociceptive DRG neurons identified by 
the presence of tetrodotoxin (TTX)-resistant Na+ currents with pronounced use-
dependent inactivation upon repetitive stimulation (Pearce and Duchen, 1994; Arbuckle 
and Docherty, 1995; Blair and Bean, 2003). Amplitudes of GABAergic membrane 
currents evoked by exogenous application of muscimol remained unchanged in sns-
α2−/− mice, but their facilitation by DZP (1 μM) was significantly reduced (fig. 3A).  
 
 
 
 
 
 
 
 
Fig. 2. α2 GABAAR in the spinal dorsal horn. (A) Colocalization of α2 GABAAR (red) with peptidergic 
(CGRP positive, lamina II outer) and nonpeptidergic (IB4 positive, lamina II inner) axons and terminals 
(green) in parasagittal sections of lumbar spinal cord of adult wild-type (α2fl/fl) and sns-α2−/−mice. (B, C) 
Higher magnification of the areas indicated in (A) showing the α2 subunit immunoreactivity alone (B) or 
superimposed with colocalized pixels (yellow, C). Arrows in C point to the terminals containing the α2 
GABAAR. (B) α2 GABAAR immunoreactivity. (C) Colocalization (indicated by arrows). (D) Statistical 
analysis. Percent colocalization (mean ± sd) of CGRP (lamina IIo), IB4 (lamina IIi) and VGluT1 (lamina III) 
positive axons and terminals with α2 GABAAR. Colocalizations (for criteria see methods) were counted in 6 
fields per slide each from a different mouse. 3 mice per genotype were analyzed. ANOVA followed by 
Bonferroni post hoc test F(5,12) = 47.0; ***, P ≤ 0.001. Scale bars 5 µm (A) and 0.5 µm (B,C). 
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 We next analyzed the modulation of primary afferent-evoked synaptic transmission by 
presynaptic GABAAR in transverse spinal cord slices. AMPA receptor-mediated 
excitatory postsynaptic currents (EPSC) were evoked by electrical stimulation of 
attached dorsal rootlets and recorded from visually identified superficial (laminae I/II) 
dorsal horn neurons. Electrical stimulation thresholds of AMPA-EPSCs were virtually 
identical in wild-type and sns-α2−/− mice (32.4 ± 2.9 V [n = 17] and 34.1 ± 2.8 V [n = 10], 
means ± sem). In the absence of muscimol or DZP, the vast majority of AMPA-EPSCs 
were reliably triggered by dorsal root stimulation and occurred with constant latencies. 
They therefore most likely represented monosynaptic events. After a stable AMPA-EPSC 
was established slices were superfused with different concentrations of muscimol to 
activate GABAAR. To avoid confounding effects arising from activation of postsynaptic 
GABAAR, we replaced in the intracellular recording solution Cl- with F- (Turecek and 
Trussell, 2001), which does not permeate GABAAR channels (Bormann et al., 1987). 
AMPA-EPSC amplitudes were not significantly different between sns-α2−/−  mice and 
α2fl/fl littermates, and were similarly decreased with the GABAAR agonist muscimol in 
both genotypes (fig. 3B). However, when DZP (1 μM) was applied in addition to a low 
concentration (0.1 µM) of muscimol, the rate of successful transmissions (i.e. of 
presynaptic stimulations eliciting EPSCs) dropped significantly in α2fl/fl mice as expected 
for a presynaptic site of action. This increased inhibition was not observed in sns-α2 /- 
mice (fig. 3C).  
 
 
 
 
Fig. 3. GABAergic membrane currents and primary afferent-evoked synaptic transmission in 
wild-type (α2fl/fl) and sns-α2−/−  mice. (A) GABAergic membrane currents recorded from 
nociceptive DRG neurons. Left: individual current traces evoked through puffer application of 
GABA (1 mM) to the soma of the recorded DRG neuron in α2fl/fl and sns-α2−/−  mice in the absence 
(black) or presence (red) of DZP (1 µM). Right: statistical analysis (mean ± sem). n = 26 (α2fl/fl) and 
14 (sns-α2−/−). *, P < 0.05 (unpaired t test). (B, C) Primary afferent-evoked EPSCs recorded from 
lamina I/II neurons in transverse spinal cord slices. (B) left: current traces under control 
conditions (black) and in the presence of muscimol (musc, 5 µM, red). Right: statistical analysis 
(mean ± sem). EPSC amplitudes: unpaired t test, n = 19 (α2fl/fl), n = 18 (sns-α2 /-); inhibition by 
muscimol, n = 6 - 17. (C) Analyses of synaptic failure rates. Left: superposition of 10 consecutive 
primary afferent-evoked EPSCs under control conditions, in the presence of muscimol (0.1 µM), 
and in the additional presence of DZP (1 µM). Right: statistics (mean ± sem). n = 17 (α2fl/fl) and 10 
(sns-α2−/−). ANOVA (genotype * treatment); F (3,81) = 3.96; *, P = 0.03; **, P < 0.01 significant 
against α2fl/fl; +++, P < 0.001 significant against control.  
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The functioning of GABAAR on the presynaptic terminals of primary nociceptors was 
also assessed through the analysis of dorsal root potentials (DRPs). These are local field 
potentials generated by GABAergic interneurons and occurring in one dorsal root after 
electrical stimulation of another dorsal root in a neighboring segment. We compared 
DRPs of sns-α2−/−  and α2fl/fl mice in terms of amplitude, sensitivity to the GABAAR 
blocker bicuculline, and DZP sensitivity. DRPs of sns-α2−/−  mice were of similar size and 
similarly sensitive to bicuculline (1 and 3 µM), but their potentiation by DZP was 
strongly reduced (0.3 – 3 µM) (fig. 4). 
 
Acute nociception and inflammatory and neuropathic hyperalgesia in sns-
α2−/− mice.  
Before analyzing conditional α2  GABAAR mutant mice, we verified that the presence of 
the sns-cre transgene alone did not affect the development of hyperalgesia or the 
responsiveness of mice to diazepam. sns-cre mice with no mutations in the Gabra2 gene 
developed normal hyperalgesia and responded normally to spinal DZP (Tab. 4). We then 
continue with the analysis of sns-α2−/−  mice. These mice responded normally to acute 
noxious heat and to mechanical stimulation with von Frey filaments and exhibited 
normal nociceptive responses (flinches) after chemical activation of nociceptors through 
subcutaneous capsaicin injection into one hind paw (Tab. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Dorsal root potentials. (A) Left, average traces of DRPs recorded at threshold stimulation 
(1T) and at 5-fold (5T) and 10-fold (10T) higher stimulation intensities in wild-type (α2fl/fl) and 
sns-α2−/−  mice. Right, statistical analysis (mean ± sem). n = 18 (α2fl/fl) and 14 (sns-α2−/−). (B) Same 
as (A), but inhibition by bicuculline (bic, 1.0 µM, red) of DRPs elicited at 5T. n = 9 (α2fl/fl) and 7 
(sns-α2−/−). (C) Same as (B) but potentiation by DZP (1 µM, red). n = 9 (α2fl/fl) and 5 (sns-α2−/−). *, P 
< 0.05 (unpaired t test) significant against α2fl/fl. 
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Tab. 4. Baseline nociceptive sensitivity, inflammatory hyperalgesia (48 h after subcutaneous zymosan A injection) and antihyperalgesic effect of 
diazepam (0.09 mg / kg, i.t.) in wild-type and sns-cre transgenic mice. Paw withdrawal latencies (PWL; s) in response to stimulation with defined 
radiant heat, mechanical thresholds (PWT; g) to stimulation with dynamic von Frey filaments in wild-type and sns-cre+ littermates. Antihyperalgesia 
was quantified as the area under the curve (AUC) of the change from before-drug baseline plotted versus time. All values mean ± sem.  
 
 
 
 
 
 
 
 
 Acute nociception Inflamed antihyperalgesia by diazepam  
 thermal  
(PWL, s) 
mechanical 
(PWT, g) 
thermal 
(PWL, s) 
mechanical 
(PWT, g) 
thermal  
(AUC, s·h) 
mechanical  
(AUC, g·h) 
wild-type  14.8 ± 0.8  
(n = 7) 
3.5 ± 0.06  
(n = 9) 
5.65 ± 0.19 
(n = 7) 
0.94 ± 0.10 
(n = 9) 
19.9 ± 2.9  
(n = 7) 
6.55 ±1.0 
(n = 9) 
sns-cre+ 14.4 ± 2.6  
(n = 8) 
3.6 ± 0.09  
(n = 7) 
5.73 ± 0.91 
(n = 8) 
1.02 ± 0.06 
(n = 7) 
20.4 ±3.0 
(n = 8) 
6.34 ± 0.3 
(n = 7) 
P (unpaired 
t-test) 
0.71 0.63 0.95 0.58 0.91 0.83 
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 acute nociception inflammatory hyperalgesia / paw 
swelling 
neuropathic 
hyperalgesia 
capsaicin-
induced 
sensitization 
 thermal  
(PWL, s) 
mechanical 
(PWT, g) 
chemical 
(flinches 
/ 5 min) 
thermal 
(AUC, 
s·d) 
mechanical 
(AUC, g·d) 
paw 
swelling 
(AUC, 
ml·h) 
thermal 
(AUC, 
s·d) 
mechanical 
(AUC, g·d) 
mechanical 
(AUC, g·h) 
α2fl/fl 15.0 ± 
0.6 
(n = 6) 
3.0 ± 0.1 
(n = 6) 
49.5 ± 6.6 
(n = 6) 
33.3 ± 
4.6 
(n = 6) 
9.1 ± 0.3 
(n = 6) 
3.62 ± 0.42  
(n = 6) 
224 ± 9 
(n = 6) 
47.3 ± 1.5 
(n = 6) 
4.6 ± 0.24 
(n = 5) 
sns-
α2−/− 
14.5 ± 
0.8 
(n = 10) 
3.1 ± 0.1  
(n = 10) 
49.0 ± 7.1 
(n = 6) 
33.0 ± 
4.6  
(n = 10) 
10.6 ± 0.7 
(n = 10) 
3.25 ± 0.31 
(n = 10) 
230 ± 8 
(n = 6) 
44.8 ± 1.4 
(n = 6) 
4.5 ± 0.22 
(n = 6) 
 
Tab. 5. Baseline nociceptive sensitivity and inflammatory and neuropathic hyperalgesia in wild-type and sns-α2−/− mice. Paw withdrawal latencies (PWL; 
s) in response to stimulation with defined radiant heat, mechanical thresholds (PWT; g) to stimulation with electronic von Frey filaments, and numbers of 
flinches within 5 min after subcutaneous injection of capsaicin (1.6 µg in 10 µl) in sns-α2−/− mice and in wild-type (α2fl/fl) littermates. Hyperalgesia was 
quantified as the area under the curve (AUC) of the change from baseline sensitivity plotted versus time. P>0.1 (unpaired t test) for all comparisons 
between genotypes. All values mean ± sem.  
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 When tested in an inflammatory pain model (subcutaneous injection of the yeast extract 
zymosan A into one hind paw), sns-α2−/− and α2fl/fl mice developed virtually extract 
zymosan A into one hind paw), sns-α2−/− and α2fl/fl mice developed virtually identical 
thermal and mechanical hyperalgesia and similar paw swelling (fig. 5A-C). Likewise, 
sns-α2−/− and α2fl/fl mice responded with nearly identical thermal and mechanical 
hyperalgesia after chronic constriction injury (CCI) of the left sciatic nerve (fig. 5D,E), 
and developed unchanged mechanical hyperalgesia after subcutaneous capsaicin 
injection (fig. 5F). 
 
 
Fig. 5. Nociceptive behavior in sns-α2−/− mice. Inflammation induced by subcutaneous zymosan 
A injection (0.06 mg / 10 μl) into the plantar side of the left hind paw. Thermal hyperalgesia (paw 
withdrawal latencies, s) (A), mechanical sensitization (paw withdrawal thresholds, g) (B), and 
paw swelling (C) in sns-α2−/− and wild-type (α2fl/fl) littermates. n = 6 - 10 mice / group. (D, E) 
Same as B, C, but neuropathic pain induced through CCI surgery of the left sciatic nerve. n = 6 
mice / group. (F) Secondary hyperalgesia induced through subcutaneous injection of capsaicin 
(30 μg in 10 μl) into the plantar left hind paw. Mechanical withdrawal thresholds (g). n = 5 - 6 
mice / group. For statistics see Tab. 5. 
 
 
    .                                                              
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In separate experiments, we assessed the consequences of sns-α2 gene deletion for the 
antihyperalgesic effects of spinal DZP in inflammatory and neuropathic pain. DZP (0.09 
mg/kg body weight, compare Knabl et al. (2008) was injected i.t. at the level of the lower 
lumbar spine. Injections were made 2 days after zymosan A injection and 7 days after 
CCI surgery, when inflammatory or neuropathic hyperalgesia had reached a maximum 
(for the time course of sensitization compare Reinold et al., 2005, and Hösl et al., 2006). 
DZP reversibly reduced thermal and mechanical hyperalgesia to similar degrees in both 
pain models. This antihyperalgesia was profoundly reduced in global α2 GABAA point 
mutated mice (α2R/R mice) confirming the dominant contribution of α2  GABAAR (fig. 6). 
In the inflammatory pain model, the antihyperalgesic effect of i.t. DZP in sns-α2−/−  mice 
fell between those of wild-type (α2fl/fl) and α2R/R mice for thermal and mechanical 
hyperalgesia indicating that presynaptic α2  GABAAR contributed significantly to 
α2 dependent antihyperalgesia (fig. 6A,B). Although i.t. DZP was similarly effective 
against neuropathic hyperalgesia and although this antihyperalgesia was also mainly 
mediated by α2  GABAAR, neuropathic sns-α2−/− mice responded normally to i.t. DZP 
(fig. 6C,D).  
 
Because compensatory processes are of major concern in gene deletion studies (Rudolph 
and Möhler, 2004), we included nociceptor-specific α2 point mutated mice (sns-α2 /R) in 
addition to sns-α2−/− and α2R/R mice in a subset of experiments (those on mechanical 
hyperalgesia; fig. 6B, D). 
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Fig. 6. Antihyperalgesic effects of DZP. Antihyperalgesic effects of intrathecally injected DZP 
(0.09 mg / kg body weight) on thermal (A, C) and mechanical (B, D) hyperalgesia expressed as 
percent maximum possible analgesia (mean ± sem). AUC (0 - 4 h after DZP injection). (A, B) 
Inflammatory hyperalgesia induced by subcutaneous zymosan A injection (0.06 mg in 10 μl) into 
the left hind paw. DZP was given 48 hours after zymosan A injection Left: time course; Right: 
statistics. AUC expressed as percent of wild-type littermates (α2fl/fl mice). ANOVA F (2,25) = 8.71 
followed by Bonferroni post hoc text, n = 8 - 10 mice / group (thermal hyperalgesia); ANOVA F 
(3,33) = 36.82, n = 7 - 12 mice / group (mechanical hyperalgesia). (C, D) Same as (A, B) but 
neuropathic pain 7 days after CCI surgery of the left sciatic nerve. ANOVA followed by 
Bonferroni post hoc test F (2,21) = 5.18, n = 7 - 9 mice / group (thermal hyperalgesia); F (3,23) = 
11.16, n = 5 - 10 mice/group (mechanical hyperalgesia). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001, 
significant against α2fl/fl, +, P ≤ 0.05; +++, P ≤ 0.001, against α2R/R. 
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These “tissue-specific point-mutated” mice carry a point-mutated and a floxed (wild-
type) allele in all cells of the body with the exception of primary nociceptors which only 
express the mutated allele after cre-mediated deletion of the wild-type allele. In all tests 
performed, the phenotypes of these sns-α2 /R mice closely resembled those of sns-α2−/− 
mice. Because heterozygous nociceptor-specific α2 deficient (sns-α2 −/+) mice and 
heterozygous α2 point mutated (α2H/R) mice showed no behavioral changes compared to 
wild-type (α2fl/fl) mice (Tab. 6), the phenotype of sns-α2 /R mice clearly originated from 
the presence of the point mutation in primary nociceptors. These experiments therefore 
render compensatory up-regulations of other DZP-sensitive GABAAR in the sns-α2−/− 
mice unlikely.  
 
 Acute 
nociception 
(PWT, g) 
Inflammatory 
hyperalgesia 
(PWT, g) 
Antihyperalgesia 
by diazepam  
(AUC, g·h) 
α2fl/H (n = 7) 3.59 ± 0.06 0.82 ± 0.11 7.80 ± 2.95 
sns-α2− /H(n = 6) 3.55 ± 0.13 1.02 ± 0.08 7.59 ± 0.35 
α2R/H (n = 6) 3.50 ± 0.11 0.99 ± 0.08 8.12 ± 0.63 
P (ANOVA) 0.56 0.90 0.76 
 
Tab. 6. Baseline mechanical sensitivity, inflammatory hyperalgesia and antihyperalgesic effect of 
diazepam (0.09 mg / kg, i.t.) in heterozygous nociceptor-specific a2-deficient (sns-α2−/H) mice, 
heterozygous point mutated (a2H/R) mice, and heterozygous a2-floxed (wild-type) mice. 
Antihyperalgesia was quantified as the area under the curve (AUC) of the change from before-
drug baseline sensitivity plotted versus time. All three genotypes had virtually identical baseline 
mechanical sensitivities, developed similar mechanical hyperalgesia and responded normally to 
DZP (0.09 mg / kg i.t.). Because the floxed Gabra2 allele behaves as a wild-type allele in the 
absence of cre expression, α2fl/H mice can be considered as wild-type mice. Hence, these 
experiments demonstrate that the histidine to arginine point mutation of only one Gabra2 allele 
(α2H/R mice) has no apparent consequences for pain control or for the anti-hyperalgesic effect of 
intrathecal DZP. Similarly, the nociceptor specific deletion of one gabra2 allele (in sns-α2−/H mice) 
affected neither baseline mechanical sensitivity nor the development of mechanical hyperalgesia 
or its reversal by intrathecal DZP. The phenotype described for the nociceptor specific α2 point 
mutated (sns-α2−/R) mice can thus be specifically attributed to the lack of DZP sensitive α2 
GABAAR in primary nociceptors. All values mean ± sem.  
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Discussion 
 
Although presynaptic GABAAR have been extensively studied in various CNS areas 
(Kullmann et al., 2005), their roles in integrative CNS functions and as targets for 
GABAergic drugs have remained difficult to assess. Here, we have used a genetic 
approach to selectively interfere with presynaptic GABAAR on spinal nociceptor 
terminals and to investigate their contribution to spinal pain control. We used confocal 
double labeling experiments to study the expression pattern of α2  GABAAR in the spinal 
dorsal horn, electrophysiological recordings in spinal cord slices and isolated spinal 
cords to assess their contribution to the modulation of primary afferent-evoked synaptic 
transmission, and finally behavioral experiments to study their role in pain control.  
 
Previous in situ hybridization (Persohn et al., 1991; Ma et al., 1993), immunofluorescence 
(Bohlhalter et al., 1996; Knabl et al., 2008), and electrophysiological (Knabl et al., 2008) 
experiments have suggested that GABAAR on primary sensory neurons are mainly, if 
not exclusively, of the α2 subtype. Our confocal double labeling experiments confirm the 
presence of α2  GABAAR on peptidergic and nonpeptidergic nociceptors as well as on 
non-nociceptive fibers. The additional presence of α3 subunits found in all three fiber 
types is consistent with our electrophysiological results, which demonstrate that 
GABAergic membrane currents in nociceptive DRG neurons and DRPs were still 
potentiated by DZP in sns-α2−/−  mice, albeit to a lesser extent than in wild-type mice.  
 
GABAergic axo-axonic synapses onto the presynaptic terminals of primary afferent 
nerve fibers have been extensively investigated in monkey (Alvarez et al., 1993) and cat 
(Alvarez et al., 1992), but data in mice is spares. In monkey and cat electron microscopy 
studies, GABAergic terminals were found presynaptic to Aδ fiber terminals but not to C 
fiber terminals. Our study however provides clear evidence for the presence of GABAAR 
on the intra-spinal segments of peptidergic and nonpeptidergic C fibers in mice, and also 
for their functionality as ablation of α2 GABAAR in the sns-α2−/− mice almost completely 
abolished the potentiating effect of DZP on DRPs. Although the sns-cre is active not only 
in C fiber nociceptors but also in Aδ nociceptors (Gangadharan et al., 2009), these actions 
cannot be ascribed to α2 GABAAR on Aδ fibers alone, because recent evidence indicates 
that in particular heat hyperalgesia is largely if not exclusively mediated by peptidergic 
C fibers (Abrahamsen et al., 2008; Cavanaugh et al., 2009). Provided that the absence in 
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monkey and cat of GABAergic terminals presynaptic to C fiber endings translates to 
mice, our findings may prompt for structural arrangements of the GABAergic input 
different from classical axo-axonic synapses. In such an alternative scenario, GABAergic 
inhibition of C fiber nociceptors might not originate from GABAAR located at the 
presynaptic terminal itself but from axonal receptors located farther away from the 
terminals. Such an arrangement would impair action potential propagation rather than 
directly interfere with transmitter release, and would be similar to what has been 
described for muscle spindle afferents in the rat brain stem (Verdier et al., 2003). These 
axonal receptors might become activated through ambient GABA rather than through 
GABA released directly onto these receptors.  
 
The most obvious behavioral phenotype observed in sns-α2−/− mice was a reduction in 
the antihyperalgesic effect of spinal DZP against inflammatory hyperalgesia. At least for 
inflammatory hyperalgesia, this phenotype unambiguously indicates that the 
antihyperalgesic action of spinal BDZ is largely due to a direct action on the sensory pain 
pathway and not due to indirect effects such as a reduction in anxiety-induced 
hyperalgesia. It also indicates that the enhancement on primary afferent depolarization 
by spinally applied BDZs increases presynaptic inhibition in primary nociceptors and 
thereby reduces nociceptive input to the spinal dorsal horn. Diminished DZP-induced 
antihyperalgesia in sns-α2−/− mice correlates well with the decreased ability of DZP to 
facilitate GABAAR-mediated inhibition of synaptic transmission between primary 
nociceptors and second order neurons, and with the diminished DZP-sensitivity of 
GABAergic DRPs in these mice. About one third of the α2  GABAAR-mediated 
antihyperalgesia was maintained in sns-α2−/− mice. This part may originate from α2  
GABAAR expressed by intrinsic dorsal horn neurons. Expression of α2  GABAAR on 
intrinsic dorsal horn neurons has not been generally accepted previously, because in situ 
hybridization studies had revealed significant amounts of α2 mRNA in the ventral but 
not in the dorsal horn (Ma et al., 1993). Our experiments demonstrate that much of the 
α2 immunofluorescence is retained in sns-α2−/− mice consistent with our previous 
electrophysiological data showing reduced DZP-sensitivity in dorsal horn neurons of 
α2R/R mice (Knabl et al., 2008). Alternatively, the remaining α2  GABAAR-mediated 
antihyperalgesia could come from α2  GABAAR residing on primary sensory neurons 
which do not express the sns-cre. 
 
61
Results (Paper 1) 
 
 
In contrast to the antihyperalgesic activity of spinal DZP against inflammatory pain, its 
activity against neuropathic pain was not changed in sns-α2−/− or sns-α2 −/R mice. It is 
tempting to speculate that presynaptic inhibition by α2  GABAAR might be less 
important under neuropathic conditions. However, Abrahamsen et al (2008) 
demonstrated that different types of primary afferent sensory fibers mediate 
inflammatory and neuropathic hyperalgesia. In fact, neuropathic hyperalgesia 
developed normally in mice lacking sns-positive primary nociceptors, whereas 
inflammatory hyperalgesia was largely abolished (Abrahamsen et al., 2008). It is 
therefore possible that the antihyperalgesic action of intrathecal diazepam against 
neuropathic pain also occurred through presynaptic α2  GABAAR but residing on 
primary afferent sensory fibers which did not express sns-cre. 
 
GABAAR on spinal nociceptor terminals have been suggested to inhibit the transmission 
of nociceptive signals through PAD and subsequent presynaptic inhibition (Willis, 1999). 
The sns-α2−/− mice studied here had normal baseline nociceptive sensitivities and 
developed normal inflammatory or neuropathic hyperalgesia. Very intense nociceptor 
stimulation and inflammation may however enhance PAD to levels sufficient to trigger 
action potentials and to elicit so called dorsal root reflexes (Cervero and Laird, 1996; 
Willis, 1999). Input from primary afferent nerve fibers could then, via interconnected 
GABAergic interneurons, elicit action potentials in other primary afferent fiber 
terminals, from which excitation could spread both anterogradely and retrogradely, to 
exaggerate pain and inflammation. Again, sns-α2−/− mice exhibited unaltered 
hyperalgesia after capsaicin injection and unchanged hyperalgesia or paw swelling after 
zymosan A injection. Nevertheless, our findings do not exclude a contribution of 
GABAergic PAD to presynaptic inhibition or dorsal root reflexes, because the GABAAR 
remaining in nociceptors of sns-α2−/− mice were apparently sufficient to sustain 
GABAergic membrane currents and DRPs of nearly normal amplitude. Reduced BDZ 
sensitivity of GABAAR currents in nociceptive DRG neurons and of dorsal root 
potentials but nearly unchanged amplitudes and unaffected bicuculline sensitivity may 
be explained by the up-regulation of BDZ-insensitive GABAAR subunits. A significant 
up-regulation was found for α4. In addition, other BDZ-insensitive but bicuculline-
sensitive subunits (δ and θ) showed a trend towards increased expression in sns-α2−/− 
mice. One might speculate that a facilitation of GABAAR -mediated dorsal root reflexes 
by BDZs could also counteract antihyperalgesia by spinal BDZs. However, although 
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DRPs in sns-α2−/− mice were less sensitive to DZP, these mice did not show increased 
antihyperalgesia. 
 
In summary, the generation of mice with a genetic ablation of a specific GABAAR 
subtype in primary nociceptors allowed us to attribute to presynaptic GABAAR residing 
on the axons or terminals of primary nociceptors a significant role in spinal pain control, 
namely a contribution to antihyperalgesia mediated by spinal DZP.  
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Abstract 
 
Enhancing GABAergic inhibition at the spinal level alleviates inflammatory and 
neuropathic pain through specific subtypes of GABAA receptors (GABAAR). Most of 
these GABAAR contain the GABAAR subunit α2. Their specific activation should evoke 
profound antihyperalgesia while avoiding most of the unwanted effects of classical 
benzodiazepine (BDZ) site agonists. While the relevance of spinal GABAAR in this 
process is firmly established, possible contributions of supraspinal receptors are less 
clear. These might exert a genuine antihyperalgesic action similar to that of spinal 
GABAAR or might contribute to pain relief through reversing anxiety-induced 
hyperalgesia. To address these potential roles, we generated two lines of GABAAR 
mutated mice which either lack α2 GABAAR specifically in the spinal cord and in all 
primary sensory neurons up to the mid cervical level, or which carry only BDZ-
insensitive α2 GABAAR at these sites. We analyzed the consequences of these mutations 
for antihyperalgesia evoked by systemic treatment with the novel non-sedative BDZ site 
agonist HZ166 in the chronic constriction injury model of neuropathic pain. Wild-type 
mice and both types of mutated mice did not differ in their baseline nociceptive 
thresholds and developed similar neuropathic hyperalgesia. However, the 
antihyperalgesic responses to systemic HZ166 were reduced in both mutated mouse 
lines by about 70% and virtually indistinguishable from that of point-mutated mice, in 
which all α2 GABAAR had been rendered BDZ-insensitive. These results indicate that the 
antihyperalgesic actions of systemically administered BDZ site ligands do not require 
supraspinal α2 GABAAR and are thus independent of anxiolysis. 
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Introduction 
 
Chronic neuropathic pain syndromes are frequently unresponsive to classical analgesic 
drugs including cyclooxygenase inhibitors and opioids. Drugs most effective in these 
pain conditions include anticonvulsants that modulate or block voltage-gated Na+ or 
Ca2+ channels (Sang and Hayes, 2006). Other anticonvulsive drugs with a different mode 
of action include the benzodiazepine (BDZ) site agonists, which enhance neuronal 
inhibition through a facilitation of GABAAR -mediated neurotransmission. Diminished 
GABAergic inhibition at the spinal cord level has in fact been shown to be a major 
contributor to chronic pain syndromes (Ahmadi et al., 2002; Coull et al., 2003) suggesting 
that drugs facilitating spinal inhibition might indeed correct a major component of the 
maladaptive neuroplasticity underlying chronic pain (Zeilhofer, 2008; Munro et al., 
2009). In line with this concept, previous work has shown that spinal injection of BDZ 
site agonists provide pain relief in a number of rodent models of inflammatory and 
neuropathic pain (Luger et al., 1995; Kontinen and Dickenson, 2000; Knabl et al., 2008). 
However, although anecdotal reports suggest some efficacy of classical BDZ in chronic 
pain patients, classical BDZ are usually not considered as first line therapeutics in these 
patients (Jasmin et al., 2004).  
 
Mammalian GABAAR form a heterogeneous family of heteropentameric ion channels 
composed from a repertoire of 19 subunits. The different GABAAR subtypes are best 
characterized by the type of α subunit present in the individual receptors (Olsen and 
Sieghart, 2008). Experiments in genetically modified mice demonstrated a particular 
relevance of GABAAR containing α2 and α3 subunits for antihyperalgesia mediated by 
spinally applied BDZ (Knabl et al., 2008). These and subsequent experiments (Knabl et 
al., 2009) from our group established that the antihyperalgesic actions of BDZ site 
agonists occur independent of the sedative actions mediated by α1 containing GABAAR 
(Rudolph et al., 1999). More recent experiments with novel BDZ site ligands with 
improved subunit specificity (i.e. reduced or even absent activity α1 GABAAR) have 
shown that such novel compounds are able to reduce nerve injury and inflammation-
induced hyperalgesia after systemic administration in the absence of sedation (Knabl et 
al., 2008; Munro et al., 2008; Knabl et al., 2009; Munro et al., 2009; Di Lio et al., 2011). 
While the contribution of spinal GABAAR to this antihyperalgesia has been studied in 
detail, much less is known about a possible role of supraspinal GABAAR. These receptors 
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might contribute to antihyperalgesia through a genuine antihyperalgesic effect, e.g. 
through GABAAR in the rostral agranular insular cortex (Jasmin et al., 2003), or through 
the reversal of anxiety-induced hyperalgesia (Andre et al., 2005). The latter possibility is 
particularly interesting as α2 and α3 GABAAR similarly contribute to antihyperalgesia 
and anxiolysis (Low et al., 2000; Morris et al., 2006). On the other hand, supraspinal 
GABAAR might partially counteract spinal antihyperalgesia for example through 
inhibiting antinociceptive tracts descending from the periaqueductal grey (PAG) or the 
rostroventromedial medulla (RVM) (Harris and Westbrook, 1995; Luger et al., 1995; 
Tatsuo et al., 1999). The subtypes of the GABAAR relevant to pain control at all these 
supraspinal sites are not known. It is thus possible that activation of supraspinal 
GABAAR either facilitates or impedes spinal antihyperalgesia. 
 
To address these questions, we generated two lines of GABAAR -mutated mice. The first 
of these lines (Hoxb8-α2-/-) carries a tissue-specific deletion of the α2 GABAAR subunit 
from all spinal neurons, astrocytes and primary sensory neurons up to the mid cervical 
level (about C4). This tissue-specific ablation was achieved by crossing mice which 
carried a GABAAR α2 (Gabra2) allele flanked by loxP sites (α2fl (Witschi et al., 2011)) with 
mice expressing the cre recombinase under the transcriptional control of the Hoxb8 
homeobox gene (Witschi et al., 2010). The second line can be viewed as a tissue-specific 
point-mutated α2 GABAAR mouse line (Hoxb8-α2R/-). This line carried the α2fl allele, a 
BDZ-insensitive H101R point-mutated allele (α2R; (Low et al., 2000)), and the Hoxb8-cre 
transgene. At supraspinal sites, this line expresses the point-mutated allele together with 
the fully functional (“wild-type”) α2fl allele, while in the peripheral and spinal nervous 
system only the point-mutated allele is expressed. For pharmacological analyses, we 
used the novel non-sedative partial BDZ site agonist HZ166 (Rivas et al., 2009; Di Lio et 
al., 2011). Analysis of the antihyperalgesic effects of HZ166 in the two mutated mouse 
lines and comparison of these effects with those obtained in wild-type mice and in mice, 
in which all α2 GABAA had been rendered BDZ-insensitive, revealed that activation of 
supraspinal α2 GABAAR did not contribute to the antihyperalgesic actions of HZ166.  
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Materials and Methods 
 
Generation of GABAA receptor mutated mice 
 Hoxb8-α2 /- and Hoxb8-α2R/- mice were generated by crossing α2fl/fl mice (Witschi et al., 
2011) and α2R/fl mice with mice which carried in addition the Hoxb8-cre transgene 
(Witschi et al.). All mice were maintained at a C57BL/6J background. During the 
breeding of Hoxb8-α2 -/- mice, a small number of mice were born carrying a non-
conditional loss of the GABAAR α2 allele which had probably occurred through 
undesired recombination events in the germ line. To ensure that these mice were 
excluded from further breeding and experiments we verified in all mice the absence of a 
knock-out allele in genomic DNA obtained from ear biopsies (where the Hoxb8-cre is not 
expressed during any developmental stage).  
 
Cell culture and transfection 
 HEK 293 cells were maintained in DMEM supplemented with 10% FBS and seeded to a 
density of 500,000 cells onto polylysine-coated 100 mm culture dishes one day before 
transfection. Cells were transfected with plasmids containing the subunit combination 
α2β3γ2 or α2(H101R) β3γ2 (7 mg total DNA, ratio 1:1:2) using jetPEI transfection reagent 
(Polyplus-transfection). Twenty-four hours after transfection, HEK 293 cells were 
harvested in PBS and used for [3H]Ro 15-4513 binding.  
 
[3H]Ro 15-4513 binding assay 
For [3H]Ro 15-4513 binding, HEK 293 cells were homogenized in 10 vol. 10 mM Tris pH 
7.5, 0.32 sucrose, protease inhibitor cocktail (complete Mini, Roche Applied Science) and 
centrifuged at 1,000 g for 10 min at 4°C. The supernatant was carefully removed and 
centrifuged again for 20 min at 25,000 g at 4°C. The crude membrane pellet was 
resuspended in 10 mM Tris-HCl pH 7.4, protease inhibitor cocktail and washed once by 
centrifugation and resuspension. Aliquots of the crude membranes prepared from 
HEK293 cells expressing the α2β3γ2 or α2(H101R)β3γ2 subunit combination (150-200 mg 
protein) were incubated with increasing concentrations of HZ-166 (10-8-10-4M) and 6.3 
nM [3H]Ro 15-4513 (22.7 Ci/mmol, PerkinElmer) in a total volume of 200 μl for 90 min. 
on ice. Subsequently, the samples were filtered onto glass fiber filters using a 12-
channnel semiautomated cell harvester (Scatron) and washed with ice-cold buffer (10 
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mM Tris-HCl pH 7.4). Non-specific [3H]Ro 15-4513 binding was measured using 10 mM 
flumazenil. The radioactivity of the filters was determined by liquid scintillation 
counting using a Tricarb 2500 liquid scintillation analyzer. Binding data were analyzed 
using the GraphPad Prism software (version 5.02, GraphPad Software, USA).  
 
Cell Culture, transfection and cDNA constructs 
 HEK 293 cells (CRL-1573; American Type Culture Collection, Manassas, VA, USA) were 
cultured using standard methods. The cells were transfected with α2/ α2(H101R), β3 
and γ2 rat GABAAR expression vectors (28) using lipofectamine LTX (Invitrogen, 
Carlsbad, CA, USA). The transfection mixture was composed of (in μg): 1 α2/β3, 3 γ2 
and 0.5 EGFP. Expression of EGFP was used as a marker of successfully transfected cells. 
All recordings were made 18 – 36 hours after transfection.  
 
Electrophysiology 
The effects of HZ166 on GABAAR were studied in electrophysiological experiments on 
HEK293 cells transiently expressing GABAAR. GABA-evoked currents were recorded in 
the whole-cell patch-clamp configuration at room temperature (20–24°C) at a holding 
potential of -60 mV. Patch electrodes were pulled from borosilicate glass and were filled 
with (in mM): 120 CsCl, 10 EGTA, 10 HEPES (pH 7.4), 4 MgCl2, 0.5 GTP and 2 ATP. The 
external solution contained (in mM) 150 NaCl, 10 KCl, 2.0 CaCl2, 1.0 MgCl2, 10 HEPES 
(pH 7.4), and 10 glucose. Recordings were performed with a HEKA EPC-7 amplifier and 
Patch Master v2.11 software (HEKA Elektronik, Lambrecht-Pfalz, Germany). GABA was 
applied to the recorded cell using a manually controlled pulse (4-6 s) of a sub-saturating 
GABA concentration (EC5) using an outlet tube (200 μm ID) of a custom-designed 
gravity-fed micro perfusion system positioned 50-120 μm away from the recorded cell. 
The corresponding EC5 values for wild-type α2β3γ2 or mutant α2(H101R)β3γ2 receptors 
were obtained experimentally after successive application of 0.1, 1, 5, 10, 30, 100, 300 and 
500 μM GABA. The concentration-response curve parameters (EC50 and Hill coefficients, 
nh) were obtained from the curve fits of normalized concentration–responses to the 
equation IGABA = Imax [GABA]nh / ([GABA]nh + [EC50]nh). The mean maximal current 
(Imax) indicated the average maximal current elicited by a concentration of 500 mM 
GABA. HZ166 was first dissolved in DMSO and subsequently diluted into the recording 
solution on the day of the experiment. HZ166 was co-applied together with GABA 
without preincubation. 
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Behavioral testing 
Experiments were performed in 7 - 10 week old mice of both sexes. Care was taken to 
ensure that equal numbers of male and female mice were used in all experiments since 
no gender differences were expected. Unilateral constriction injury of the left sciatic 
nerve just proximal to the trifurcation was performed as described previously (Bennett 
and Xie, 1988; Hosl et al., 2006). Anesthesia was induced and maintained by 2% 
isoflurane, combined with oxygen (30%). The sciatic nerve was exposed at the mid-thigh 
level proximal to the sciatic trifurcation by blunt dissection through the biceps femoris 
muscle. About 5 mm of the nerve were freed of adhering connective tissue and three 
chromic gut ligatures (4/0) (Ethicon) were loosely put around the nerve with about 1 
mm spacing. The ligatures were tied until they elicited a brief twitch in the hind limb. 
The surgical wound was closed in layers. Mechanical sensitivities were assessed before 
surgery and after 7 days when sensitization had reached its maximum. On day 7, the 
antihyperalgesic effects of HZ166 were assessed. Mechanical sensitivity was determined 
as the threshold mechanical force (g) that evoked an immediate withdrawal response 
upon stimulation of the plantar side of one hind paw with electronic von Frey filaments 
(IITC, Woodland Hills, CA). 4 - 5 measurements were made for each time point and 
animal. Measurements of paw withdrawal thresholds of the injured paw and of the 
contralateral paw were made alternately. Permission for the animal experiments was 
obtained from the Veterinäramt des Kantons Zürich (ref. no. 135/2009).  
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Results 
 
The cre/loxP system was employed to generate mice lacking the GABAAR α2 subunit 
from the peripheral nervous system and from the spinal cord (Hoxb8-α2 /- mice), and 
point-mutated (Hoxb8-α2R/-) mice, whose peripheral and spinal GABAAR were rendered 
BDZ-insensitive (for details of the breeding scheme and for abbreviations of the 
genotypes see Tab. 1). Hoxb8-α2 /- mice carried a Hoxb8-cre transgene and two floxed 
GABAAR α2 (α2fl) alleles, while Hoxb8-α2R/- mice carried the Hoxb8-cre transgene 
together with a α2fl allele and a point-mutated (H101R) GABAAR α2 (α2R) allele.  
 
Morphological analyses demonstrated that the supraspinal GABAAR α2 subunit 
distribution of Hoxb8-α2 /- mice was indistinguishable from that of Hoxb8-α2fl/fl (wild-
type) mice (fig. 1). Sagittal sections of the cervical spinal cord revealed the expected 
progressive rostral to caudal loss of GABAAR α2 subunits within the upper cervical 
segments. Transverse sections of the lower lumbar spinal cord did not show any 
GABAAR α2 immunoreactivity, indicating highly effective gene Hoxb8 cre-mediated 
recombination. The apparent lack of α2 GABAAR from the lumbar spinal cord of Hoxb8-
α2 /- mice indicates that only few, if any, spinal α2 GABAAR resided on processes of 
neurons descending from supraspinal areas. Conversely, unchanged GABAAR α2 
subunit expression in the brain indicates that neurons projecting from the spinal cord to 
supraspinal CNS areas made only a minor contribution to α2 GABAAR in the brain.  
 
To investigate the consequences of these two mutations for the antihyperalgesic action of 
BDZ site ligands, we used the novel non-sedative partial BDZ site agonist HZ166, which 
has an improved side effect profile compared to classical BDZ site ligands. Before we 
analyzed the antihyperalgesic actions of this compound in Hoxb8-α2 /- and Hoxb8-α2R/- 
mice, we verified that H101R α2 GABAAR currents were insensitive to modulation by 
HZ166. It has previously been shown that this point mutation dramatically reduces the 
binding of diazepam to GABAAR and completely abolishes their facilitation by diazepam 
(Wieland et al., 1992). This mutation can however have different effects on the action of 
other BDZ site ligands. The potentiating effect of bretazenil for example is enhanced in 
the point mutated receptors and the action of Ro 45-1513 is converted from negative to 
positive modulation (Benson et al., 1998).   
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Tab. 1: Genotypes and cell type-specific phenotypes of the mouse lines analyzed. Phenotypically, 
floxed alleles are regarded as wild-type in the absence of cre.  
 
 
 
 
 
Fig. 1. Distribution of α2 GABAAR in the brain and spinal cord of wild-type (α2fl/fl) and Hoxb8-α2 /- mice. 
Immunoperoxidase immunoreactivity (IR) for the GABAAR α2 subunit in brain and spinal cord. The sagittal 
brain sections from α2fl/fl (A) and Hoxb8-α2 /- (B) were stained for α2 subunit IR and no difference in 
distribution was apparent (n = 3 each genotype). In the cervical sections the rostral regions of 
both genotype had similar intensity (C, D) whereas caudally Hoxb8-α2 /- mice showed a decrease 
in IR. The staining for α2 subunit was normal in the lumbar sections of α2fl/fl mice but was absent 
in the lumbar sections of Hoxb8-α2 /- mice (E-H). E-F: the coronal plane, G-H: the sagittal plane. 
Scale bar, 100µm. 
genotype   Gabra2 phenotype 
Gabra2 
allele 1 
Gabra2 
allele 2 
Hoxb8-cre  
transgene 
Spinal sites Supraspinal 
sites 
designation (short) 
fl fl - wt / wt wt / wt α2fl/fl_Hoxb8-cretg- (α2fl/fl) 
fl fl + - / - wt / wt α2fl/fl_ Hoxb8-cretg+ (Hoxb8-α2 /-) 
fl R - wt / R wt / R α2fl/R_ Hoxb8-cretg- (α2fl/R) 
fl R + R/- wt / R α2fl/R_ Hoxb8-cretg+ (Hoxb8-α2R/-) 
R R - R / R R / R (α2R/R) 
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We therefore compared the binding affinity of HZ166 to wild-type α2/β3/γ2 and point-
mutated α2(H101R)/β3/γ2 GABAAR. We found that the introduction of the H101R point 
mutation almost completely abolished binding of HZ166 to α2/β3/γ2 GABAAR (fig. 2). 
Only at a very high HZ166 concentration (100μM) Ro 45-1513 binding was marginally 
affected (26±6%).  
 
 
 
Fig. 2. Binding of HZ166 to wild-type and H101R point mutated α2  GABAAR. Inhibition of 
[3H]Ro15-4513 binding to HEK293 cell transfected with either the α2β2γ2 (●) or α2(H101R)β3γ2 
subunit combination (○) by HZ166. Data represent the means ± standard deviation of 4 
independent experiments. Error bars smaller than the symbol are not depicted.  
 
 
 
 
 
 
Fig. 3. Potentiation of GABA-evoked currents by HZ166 on wild-type and α2(H101R)-mutated GABAAR. 
(A) Examples of current traces through wild-type α2β3γ2 or mutated α2(H101R)β3γ2 GABAAR in absence 
(black) or presence of HZ166 (1 μM, red) (B) Sensitivity to HZ166 of the normalized GABA-activated 
currents in wild-type and α2(H101R)-mutated GABAAR using equipotent (EC5) GABA concentrations (C) 
Summary of the current potentiation elicited by HZ166 in wild-type and α2(H101R)-mutated GABAAR. The 
potentiation was largely attenuated by the mutation (***, P<0.001). (D) Sensitivity to GABA of recombinant 
α2β3γ2 or α2(H101R)β3γ2 receptors expressed in HEK cells.  
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Accordingly, electrophysiological experiments in HEK-293 cells transfected with either 
wild-type or mutated α2/β3/γ2 GABAAR showed that HZ166 had completely lost its 
ability for positive allosteric modulation in the point-mutated receptors (fig. 3). While 
HZ166 (1µM) potentiated GABA (EC5) evoked currents through wild-type α2/β3/γ2 
GABAAR by 200%, potentiation was virtually absent in the point-mutated receptors.  
 
We then went on to investigate Hoxb8-α2-/- and Hoxb8-α2R/- mice in behavioral 
experiments and to address the susceptibility of these mice to antihyperalgesia by 
systemic HZ166. In this series of experiments we included in addition to Hoxb8-α2-/- and 
Hoxb8-α2R/- mice also wild-type (α2fl/fl) mice and homozygous α2 GABAAR H101R 
point-mutated mice (α2R/R). Comparison of wild-type with α2R/R mice allowed us to 
determine the total contribution of α2 GABAAR to antihyperalgesia by HZ166. Hoxb8- 
α2-/- mice, Hoxb8-α2R/- mice and α2fl/fl (wild-type) mice responded similarly to 
mechanical stimulation of their hind paws with electronic von Frey filaments and to 
thermal stimulation with a defined radiant heat source in the plantar test. Neuropathic 
pain sensitization induced by chronic constriction injury of the sciatic nerve developed 
similarly in (insert ‘in’) all genotypes (fig. 4).  
 
 
 
 
 
 
 
 
 
 
Fig. 4. Baseline nociceptive sensitivity. Neuropathic pain induced by chronic constriction injury 
(CCI) to the sciatic nerve of the left hind paw. (A) Thermal hyperalgesia (paw withdrawal 
latencies, s), and (B) mechanical sensitization (paw withdrawal thresholds, g) in wild-type (α2fl/fl), 
Hoxb8-α2 /-, and Hoxb8-α2 /- mice. Pre CCI and post CCI values are compared. n = 6 –10 mice / 
group. ANOVA F(df)= 1.4845 (pre CCI) and F(df) = 0.7107 (post CCI) for thermal hyperalgesia. 
ANOVA F(df) = 0.7242 (pre CCI) and F(df) = 0.5666 (post CCI) for mechanical hyperalgesia.  
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 No significant differences were observed in the degree of sensitization reached 7 days 
after surgery between the different genotypes for either mechanical or heat stimuli. We 
next compared the antihyperalgesic potential of HZ166 in the three types of mutant mice 
(Hoxb8-α2 /-, Hoxb8-α2R/- and α2R/R mice) with that in wild-type α2fl/fl mice. A dose of 16 
mg/kg body weight applied intraperitoneally (i.p.) was chosen because this dose has 
previously been shown to produce a maximal antihyperalgesic response in the absence 
of sedative actions (Di Lio et al., 2011). A maximal antihyperalgesic response was 
observed between 60 and 90 minutes after drug injection. In wild-type mice, HZ166 
reduced mechanical and thermal hyperalgesia by 61% and 52%, respectively (fig. 5). Both 
the time course and the degree of antihyperalgesia were very close to those reported 
previously by our group for wild-type C57BL/6 mice (Di Lio et al., 2011). This maximal 
possible effect was reduced in α2R/R mice to 25% indicating that about 60% of the 
antihyperalgesic actions of HZ166 were mediated by α2 GABAAR. The degree of 
antihyperalgesia observed in both Hoxb8-α2-/- and Hoxb8-α2R/- mice was virtually 
indistinguishable from that of global α2R/R point-mutated mice, indicating that 
supraspinal α2 GABAAR were not required for antihyperalgesia induced by systemic 
HZ166, indicating that supraspinal α2 GABAAR did not make a significant contribution 
to antihyperalgesia by systemic HZ166 neither through a direct action on the nociceptive 
system nor through other more indirect actions such as the reversal of anxiety-induced 
hyperalgesia. 
 
 
 
 
 
 
 
 
Fig. 5. Antihyperalgesic effects of HZ166. HZ166 was injected intraperitoneally at a dose of 16 
mg/kg body weight 7 days after CCI surgery. Effects on thermal (A, B) and mechanical (C, D) 
hyperalgesia are expressed as percentage maximum possible analgesia (%MPE) (mean ± SEM) 
determined for the time interval between 1 and 2 h after drug application. ANOVA followed by 
Bonferroni post hoc test, F = 37.55 and 19.61 for thermal and mechanical hyperalgesia, respectively. 
*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001, significant against vehicle-treated α2fl/fl mice; +, P ≤ 0.05; ++, 
P ≤ 0.01; +++, P ≤ 0.001, significant against HZ166-treated α2fl/fl mice.  
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This was also confirmed by additional experiments in which we investigated potential 
anxiolytic actions of two doses of HZ166 in the elevated plus maze test (fig. 6). Neither 8 
mg nor 16 mg HZ166 /kg body weight exerted a significant anxiolytic response as 
indicated by the absence of a significant effect on the time spent in the open arms of the 
plus maze. The lack of effect on the total number of entries in this test confirmed the 
absence of a sedative action of HZ166 at the doses tested. 
 
 
 
 
Fig. 6. Absence of anxiolytic effects of HZ166 in C57BL/6 mice in the elevated plus maze. 
Percentage of total entries and open arm entries in C57BL/6 mice treated with vehicle (veh) or 8 
or 16 mg/kg HZ166 (8, 16 respectively. Males V-n=6, 8-n=5, 16-n=6 and females V-n=9 and 16-
n=8. Data represent mean ± SEM. ANOVA - No significant difference was detected between the 
vehicle and any of the treated group. 
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Discussion 
 
Studies performed in mice carrying a point mutation in the GABAAR α2 subunit gene, 
which renders this subunit diazepam-insensitive, have provided compelling evidence 
for the relevance of α2 GABAAR for diazepam-induced spinal antihyperalgesia (Knabl et 
al., 2008). Similar compelling evidence was lacking for more recently developed BDZ site 
agonists with improved subtype specificity. Our present study focused on the novel BDZ 
site ligand HZ166 that shows compared to diazepam not only improved subunit 
specificity but also reduced sedative properties. Our biochemical and 
electrophysiological experiments demonstrate that the H101R point mutation renders α2 
GABAAR not only insensitive to diazepam but also to HZ166. The subsequent behavioral 
experiments, in which HZ166 was tested in point-mutated α2R/R mice, provided for the 
first time direct evidence that the antihyperalgesic action of a systemically applied non-
sedative agonist also occurs through α2 GABAAR.  
 
The reduced sedative properties of HZ166 and the availability of tissue-specific α2 
GABAA-deficient mice allowed us to address the role of the supraspinal CNS areas in 
BDZ-induced antihyperalgesia in the absence of sedation. This appeared to us as an 
important issue as α2 GABAAR are not only found in the spinal cord but also in 
supraspinal CNS areas where they mediate for example the anxiolytic effects of classical 
BDZ. It was hitherto unknown to what extent α2 GABAAR in the brain contribute to the 
apparent antihyperalgesic actions of BDZ site ligands.  
 
α2 GABAAR in the brain could contribute to BDZ-induced antihyperalgesia through a 
genuine effect on the supraspinal nociceptive system. However, alternatively their 
antihyperalgesic effects could also be secondary, reflecting for example, a reversal of 
anxiety-induced hyperalgesia. However, the actions of HZ166 on hyperalgesia were 
identical in α2R/R and Hoxb8-α2 /- (and Hoxb8-α2R/-) mice indicating that supraspinal α2 
GABAAR did have any detectable influence on HZ166-mediated antihyperalgesia. 
Together with our previous study (Witschi et al., 2011), in which we studied mice 
lacking α2 GABAAR specifically in primary nociceptors, the present data unambiguously 
demonstrate that the major (i.e. the α2 GABAAR-mediated) component of 
antihyperalgesia by BDZ occurs through a genuine effect on the spinal nociceptive 
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system and that this antihyperalgesia is not secondary to effects of BDZ on neuronal 
circuits in the brain. 
 
The data presented in this study do not completely rule out a possible contribution of 
GABAAR expressed outside the CNS. There is indeed evidence that GABAAR are also 
found on the peripheral terminals of nociceptive fibers and that exogenous activation of 
these receptors interferes with the excitability of these nerve fiber (Carlton et al., 1999) or 
with action potential propagation along these fibers (Carr et al.). However, both studies 
did not find evidence for an activation of these receptors by endogenous GABA, which 
would be a pre-requisite for a contribution of these GABAAR to pharmacological effects 
of BDZ. In line with this absence, experiments comparing systemically and intrathecally 
administered diazepam demonstrated similar degrees of antihyperalgesia (Ralvenius, 
Rudolph and Zeilhofer, in preparation) and hence render a contribution of peripheral 
GABAAR expressed outside the CNS unlikely.  
 
An unexpected finding of our study was that the complete deletion of all spinal α2 
GABAAR in Hoxb8-α2 /- mice did not lead to changes in baseline nociceptive thresholds 
or in the degree of neuropathic hyperalgesia. A possible explanation might be the 
compensatory up-regulation of other components of inhibitory neurotransmission. Such 
compensatory up- or down-regulations of gene expression are in fact frequently 
observed in mice carrying deletions of GABAAR genes (Rudolph and Mohler, 2004). 
However, a relevant compensation by BDZ-sensitive GABAA can be largely ruled out on 
the basis of our experiments with the tissue-specific point-mutated (Hoxb8-α2R/-) mice, 
which show unchanged levels of α2 GABAAR expression in the spinal cord. Conditional 
knock-out Hoxb8-α2 /- mice and the tissue-specific point-mutated mice showed virtually 
identical changes in their responsiveness to HZ166.  
 
Another surprising finding of our study was the absence of a clear anxiolytic effect of 
HZ166 at a dose which exerted a saturating antihyperalgesic response. This result is in 
clear contrast to previous findings on diazepam which showed that antihyperalgesia and 
sedation by diazepam occur at similar doses (Knabl et al., 2009), while anxiolysis is 
achieved already at much lower doses (Low et al., 2000). This is particularly surprising 
as the prominent contribution of α2 GABAAR to HZ166-mediated antihyperalgesia 
indicates that a highly level of α2 receptor activation was reached with the doses used in 
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our study. Although we cannot fully exclude differences in HZ166 tissue concentrations 
between spinal cord and brain as an underlying reason, it is possible that factors 
different from the nature of α subunit contained in the GABAAR complex determine 
differences in the susceptibility of GABAAR to different BDZ site ligands.  
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Abstract 
 
In the spinal cord dorsal horn, presynaptic GABAA receptors (GABAAR) in the terminals 
of nociceptors as well as postsynaptic receptors in spinal neurons regulate the 
transmission of nociceptive and somatosensory signals from the periphery. GABAAR are 
heterogeneous and distinguished functionally and pharmacologically by the type of  
subunit variant they contain. This heterogeneity raises the possibility that GABAAR 
subtypes differentially regulate specific pain modalities. Here, we characterized the 
subcellular distribution of GABAAR subtypes in nociceptive circuits using 
immunohistochemistry with subunit-specific antibodies combined with markers of 
primary afferents and dorsal horn neurons. Confocal laser scanning microscopy analysis 
revealed a distinct, partially overlapping laminar distribution of the 1-3 and 5 
subunit-immunoreactivity in laminae I-V. Likewise, a layer-specific pattern was evident 
for their distribution among glutamatergic, GABAergic, and glycinergic neurons 
(detected in transgenic mice expressing vGluT2-eGFP, GAD67-eGFP, and GlyT2-eGFP, 
respectively). Finally, all four subunits could be detected within primary afferent 
terminals. C-fibers predominantly contained either 2 or 3 subunit-immunoreactivity, 
terminals from myelinated (A/A fibers were co-labeled in roughly equal proportion 
with each subunit. Presence of axo-axonic GABAergic synapses was determined by co-
staining with gephyrin and vesicular inhibitory amino acid transporter to label 
GABAergic postsynaptic densities and terminals, respectively. Co-localization of 2 or 
3 subunit with these markers was observed in a subset of C-fiber synapses. 
Furthermore, gephyrin mRNA and protein expression was detected in dorsal root 
ganglia. Collectively, these results show that differential GABAAR distribution in 
primary afferent terminals and dorsal horn neurons allows for multiple, circuit-specific 
modes of regulation of nociceptive circuits. 
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Introduction 
 
Chronic pain is a frequent, strongly debilitating condition that is often resistant to 
pharmacotherapy and therefore a major socio-economic problem. Chronic pain can 
result from inflammation, nerve injury, or CNS lesion. Noxious stimuli evoking pain are 
detected by two major classes of nociceptors, Aδ and C nociceptors, whose cell bodies 
are located in dorsal root ganglia (DRG) and trigeminal ganglia. The central axons of 
DRG-residing nociceptors terminate mainly in the superficial layers of the spinal dorsal 
horn (laminae I and II) (Rexed, 1952), with peptidergic and non-peptidergic C fibers 
being segregated in lamina II outer (IIo) and II inner (IIi), respectively (Hunt and 
Mantyh, 2001; Todd, 2010). The spinal cord dorsal horn processes nociceptive signals 
and relays them to higher brain centers, where conscious pain sensation arises. Chronic 
pain is a pathological condition involving altered function of primary nociceptors and of 
central pain circuits, manifesting in primary hyperalgesia (exaggerated pain sensations 
at the site of injury) and secondary hyperalgesia in uninjured healthy tissue.  
 
In 1965, Melzack and Wall proposed the gate control theory of pain attributing a critical 
contribution of inhibitory interneurons (GABAergic and glycinergic) of the spinal dorsal 
horn in regulating nociceptive signal strength and keeping nociceptive and non-
nociceptive modalities apart (Melzack and Wall, 1965). Intrathecally-applied bicuculline 
and strychnine, blockers of GABAA receptors (GABAAR) and glycine receptors 
respectively, increase nociceptive reactions elicited by exposure to noxious stimuli 
(Roberts et al., 1986; Yaksh, 1989). Conversely, enhancing GABAAR function by spinal 
application of GABA or a positive allosteric modulator, such as midazolam, was shown 
to depress noxious stimulus-evoked activity in spinal cord neurons and to reverse 
neuropathic pain induced by nerve injury (Clavier et al., 1992; Eaton et al., 1999; Knabl et 
al., 2008; Sumida et al., 1995).  
 
GABAARs are ligand-gated heteropentameric ion channels assembled from a repertoire 
of 19 subunits (1-6, 1-3, 1-3, , , θ, π, 1-3). The most common subtype in the CNS is 
composed of two , two , and one  subunit (Möhler, 2006). GABAAR containing 1, 
2, 3, or 5 subunits associated with the 2 subunit are sensitive to diazepam (Wieland 
et al., 1992). In the spinal cord, morphological studies revealed a considerable 
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heterogeneity in the distribution of GABAAR subunits. Thus, in the rat, in situ 
hybridization studies detected strong signals for GABAAR 2, 3, 3 and 2 subunit 
mRNA, weak expression for 1, 5, 1, 2, 1 and 3, and could not detect  and 
subunits (Ma et al., 1993; Persohn et al., 1991; Wisden et al., 1991). Immunohistochemical 
analysis revealed distinct laminar distribution of major  subunit variants (Bohlhalter et 
al., 1996).  
 
GABAAR can modulate spinal nociceptive processing via at least two mechanisms. 
Postsynaptic GABAAR in spinal cord neurons directly reduce their excitability, while 
GABAAR located in afferent terminals of nociceptors cause presynaptic inhibition of 
transmitter release. Previous work has demonstrated that the 2 and 3 subunits are 
abundant in mouse dorsal horn neurons (Knabl et al., 2008), co-localized in part with 
substance P-positive terminals in lamina II and with NK1-receptor-positive lamina I 
neurons. In addition, there is extensive pharmacological and behavioral evidence 
indicating that both modes of inhibition contribute to physiological and pathological 
pain sensation (Jasmin et al., 2003; Knabl et al., 2008; Munro et al., 2011; Sastry, 1980; 
Zeilhofer et al., 2012b). However, the precise site of action of the different GABAAR 
subtypes in various pain modalities is not known.  
 
These uncertainties are due, in large part, to insufficient knowledge about the cellular 
and subcellular distribution of GABAAR subtypes in circuits of spinal dorsal horn 
(Zeilhofer et al., 2012b). Therefore, the aim of this study was to analyze 
immunohistochemically the molecular organization of GABAAR in identified intrinsic 
dorsal horn neurons and primary afferents in layers I-III, using immunofluorescence 
staining combined with specific neuronal and axonal markers.  
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Materials and Methods 
 
Animals  
Experiments were performed with 6-8 week old C57BL/6J male and female mice. For 
identification of glutamatergic, GABAergic and glycinergic neurons, transgenic mice 
expressing vGlut2-eGFP (www.gensat.org, (Gong et al., 2003), GAD67-eGFP (Tamamaki 
et al., 2003; Wang et al., 2009) and GlyT2-eGFP (Zeilhofer et al., 2005) on C57BL/6J 
background were used. Mice were bred in the animal facility of Institute of 
Pharmacology and Toxicology under the approval of local authorities. They were 
maintained under standard conditions with 12 h day/night cycle and ad libitum supply 
of food and water. All experimental procedures were approved by the Cantonal 
Veterinary Office of Zurich.  
 
Western blot analysis 
Mice (n=3) deeply anaesthetized by intraperitoneal administration of sodium 
pentobarbital (50 mg/kg) were decapitated and DRG were quickly dissected out, snap-
frozen with dry ice, and stored at -80◦C until further processing. 30-40 DRG were 
homogenized in ice-cold solubilization buffer (1 mM EDTA, 10 mM Tris Cl, 150 mM 
NaCl, 0.02% NaN3) followed by sonication. The protein content of the sonicated sample 
was determined by Bradford’s assay and was then denatured using 10% 
mercaptoethanol. The samples were then serially diluted to achieve the required protein 
concentration in 20 L loading volume. 7.5% SDS-polyacrylamide gels were used for 
electrophoresis and a wet-blot was developed on nitrocellulose acetate membrane. The 
membrane was then blocked using 5% western blocking reagent (Roche Diagnostics 
GmbH, Mannheim, Germany, Cat No. 11 921 673 001) in Tris buffered saline-Tween 20 
followed by overnight incubation in mouse monoclonal antibody 7a against gephyrin 
(Table 1). Following washing, the membrane was treated with secondary antibody goat 
anti-mouse conjugated to horseradish peroxidase (1:300 dilution) and the signal was 
enhanced using freshly prepared chemiluminescent mix (Super signal West Pico 
chemiluminescent substrate, Thermo, 3747N, Rockford, Cat No. 34087). The images were 
captured using Fujifilm scanner using the software Fujifilm-image reader LAS 100 Pro 
V2.51. Mouse crude brain homogenates were included in the test as positive control for 
gephyrin detection and albumin as a negative control. 
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Real-time PCR 
Lumbar DRG from adult mice were removed following decapitation and collected in a 
tube containing a lysis solution. Total RNA was isolated by using GenEluteTM 
Mammalian Total RNA Miniprep Kit (RTN70, Sigma-Aldrich). Genomic DNA was 
removed and cDNA was generated in a reaction mixture using QuantiTect® Reverse 
Transcription Kit (Qiagen® GmbH, Hilden, Germany, Cat. No. 205311), real-time 
quantitative PCR (qPCR) was performed and analyzed using TaqMan® gene expression 
master mix (Applied Biosystems International, Inc., Rotkreuz, Switzerland, Part No. 
4369016) with generated cDNA in a total reaction volume of 10 μL in 384-well arrays 
with 7900HT fast real-time PCR system and software (Applied Biosystems). mRNA 
expression of gephyrin was quantified using pre-designed coding assays (FAM™ dye-
labeled TaqMan® MGB probes; Applied Biosystems) (glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), cytoplasmic reference gene: assay ID: Mm99999915_g1, 
context sequence: GAACGGATTTGGCCGTATTGGGCGC; gephyrin: assay ID: 
Mm01297308_m1**, context sequence: AGAAAGGATC TCAGGAATGCTTTCA). The 
real-time qPCR cycling program consisted of 95°C for 10 min, followed by 40 cycles of 
95°C for 15 s and 60°C for 1 min. The expression level of gephyrin gene was normalized 
to that of the GAPDH gene, which was used as a reference. All qPCR reactions were 
carried out in triplicate. Relative quantification of transcript was determined using the 
comparative CT method (2−ΔCT) calibrated to β-actin. 
 
Immunohistochemistry 
Immunohistochemistry was performed using well characterized primary antibodies 
described in table 1. The distribution of  subunit variants in the lumbar spinal cord was 
analyzed in sections processed for immunoperoxidase staining. Mice were deeply 
anaesthetized with pentobarbital (nembutal, 50 mg/kg, i.p.) followed by transcardiac 
perfusion of saline (20 mL) and 70 mL ice-cold fixative containing 4% paraformaldehyde 
(PFA) and 15% saturated picric acid solution in 0.15 M sodium phosphate buffer, pH 7.4. 
The spinal cords were extracted immediately after the perfusion and post-fixed in the 
same solution for 5 h. Tissue was then processed for antigen retrieval as described 
(Kralic et al., 2006), cryo-protected with 30% sucrose in phosphate-buffered saline (PBS), 
and cut coronally at 40 μm from frozen blocks with a sliding microtome. Sections were 
collected in PBS and stored at -20°C in antifreeze solution (15% glucose and 30% 
ethylene glycol in 50 mM sodium phosphate buffer, pH 7.4) prior to use. Sections were 
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incubated free-floating overnight at 4°C with primary antibodies against GABAAR 
subunits (Table 1) in Tris buffer pH 7.7 containing 2% normal goat serum and 0.2% 
Triton X-100. Sections were then washed and incubated for 30 min at room temperature 
with biotinylated secondary antibodies (1:300; Jackson ImmunoResearch, West Grove, 
PA), followed by incubation in avidin-biotin complex (1:100 in Tris buffer, Vectastain 
Elite Kit; Vector Laboratories, Burlingame, CA), for 30 min, washed again and finally 
visualized with diaminobenzidine tetrahydrochloride (DAB; Sigma, St Louis, MO) in 
Tris buffer (pH 7.7) containing 0.015% hydrogen peroxide. The color reaction was 
stopped after 5–15 min with ice-cold PBS. Sections were then mounted on gelatin-coated 
slides and air-dried followed by dehydration with ethanol. The slides were then cleared 
in xylol and cover-slipped with Eukitt (Erne Chemie, Dallikon, Switzerland).  
 
The distribution of GABAAR subunits in identified spinal cord neurons were analyzed 
by immunofluorescence staining on coronal sections of transgenic eGFP-expressing 
mice. The sections were prepared from 2-3 male mice as described above. For staining, 
the sections were incubated overnight at 4°C with a mixture of primary antibodies 
diluted in Tris buffer containing 2% normal goat serum. Sections were washed 
extensively and incubated for 1h at room temperature with the corresponding secondary 
antibodies conjugated to Cy3 (1:500), Cy2 (1:200) (Jackson ImmunoResearch) and or 
Alexa488 (1:1000, Molecular Probes, Eugene, OR). Sections were washed again and 
cover-slipped with fluorescence mounting medium (DAKO, Carpinteria, CA). 
 
Distribution of GABAAR  subunits within primary afferent terminals was studied using 
a protocol developed for detection of postsynaptic proteins (Schneider Gasser et al., 
2006). Mice were deeply anaesthetized with pentobarbital (nembutal, 50 mg/kg, i.p.) and 
perfused with Ringer’s solution. Spinal cords were rapidly collected by pressure ejection 
and placed in oxygenated ice-cold artificial cerebrospinal fluid. 300 μm thick parasagittal 
slices were prepared from the lumbar spinal cord with a vibrating microtome and 
incubated for 45 min at 34°C. They were then fixed in 4% paraformaldehyde in 0.1 M 
sodium phosphate buffer for 10 min, extensively washed, and stored overnight in 30% 
sucrose in Tris buffer for cryo-protection. Slices were then flat-frozen and sections were 
cut at 14 μm with a cryostat, mounted on gelatin-coated glass slides and air-dried at 
room temperature for 45 min. Immunofluorescence staining was performed as described 
above.  
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Image acquisition and analysis 
The regional distribution of  subunit-immunoreactivity (-IR) analyzed by 
immunoperoxidase staining was visualized in sections from four mice with bright field 
microscopy (Axioplan; Zeiss) using MCID Elite 6.0 software (Imaging Research, GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden) for image acquisition. Images were 
cropped to the desired dimensions in Adobe Photoshop CS. Minimal adjustments of 
contrast and brightness were applied to entire images, if needed.  
 
Double and triple-immunofluorescence signals were visualized by confocal microscopy 
(LSM 710; Zeiss AG, Jena, Germany) using a 63× Plan-Apochromat objective (N.A. 1.4). 
The pinhole was set to 1 Airy unit for each channel and separate color channels were 
acquired sequentially. The acquisition settings were adjusted to cover the entire dynamic 
range of the photomultipliers. Typically, stacks of confocal images (1024×1024 pixels) 
spaced by 0.3 μm were acquired at a magnification of 56-130 m/pixel. For display, 
images were processed with the image analysis software Imaris (Bitplane; Zurich, 
Switzerland). Images from all channels were overlaid (maximal intensity projection) and 
background was subtracted, when necessary. A low-pass filter was used for images 
displaying  subunit staining.  
 
Analysis of the distribution of  subunit-IR in eGFP-positive neurons and dendrites was 
performed in single confocal sections from 2-3 mice per genotype  acquired at a 
magnification of 78 nm/pixel in 8-bit gray scale images, using a threshold segmentation 
algorithm (minimal intensity, 90–130; area >0.08 μm2). All structures with >70% overlap 
between both channels (co-localized area >0.056 m2, corresponding to 9 pixels) was 
apparent were considered as "colocalized" (Image J imaging software, NIH, Bethesda, 
MD).  
 
Quantification of colocalization of  subunit-IR within primary afferent terminals was 
likewise performed by confocal laser scanning microscopy in sections from five adult 
mice. The analysis was done in high magnification images acquired at the Nyquist rate 
(56 nm/pixel; 150 nm spacing). To minimize false-positive results, additional criteria 
were applied: (a) The  subunit staining is completely inside the axon terminal staining; 
(b) the area of colocalization >20 pixels (>0.063 m2); (c) co-localization was visible in 
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three consecutive confocal sections. The data were acquired in six sections per animal 
and analyzed statistically using non-parametric tests (Kruskal–Wallis followed by 
Dunn’s multiple comparison test; Prism, GraphPad Software, San Diego, CA, USA). All 
files were randomized and individual terminals were identified as isolated objects and 
counted automatically (Imaris; Bitplane).  
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Target  Immunogen Species Source Characterization References 
1 
subunit 
Rat N-terminal synthetic  
peptide 1–16 
(pGluPSQDE 
LKDNTTVFTR) 
Guinea pig 
serum 
In house 
 
Antibody and immunohistochemistry  
protocol were verified in mutant mice 
lacking the respective subunit 
 
 
(Fritschy et al., 1997; 
Panzanelli et al., 2011; 
Schneider Gasser et al., 
2007; Studer et al., 2006) 
 
2 
subunit 
Rat N-terminal synthetic 
peptide 1–9 
(NIQEDEAKN) 
Guinea pig 
affinity 
purified 
3 
subunit 
Rat N-terminal synthetic 
peptide 1–15 
(pGluGESRRQEPGDFV
KQ) 
Guinea pig 
serum 
5 
subunit
Rat N-terminal synthetic 
peptide 1–10 
(QMPTSSVQDE) 
Guinea pig 
serum 
 
subunit
Rat N-terminal synthetic 
peptide 1–14 
(LNESPGQNSKDEKL) 
Rabbit 
affinity 
purified 
Phosphosolutions, Aurora, 
CO; cat. no. 844-GA4N 
Antibody and immunohistochemistry  
protocol were verified in  4-/- mice 
(Bencsits et al., 1999; Peng 
et al., 2002); Fritschy, 
unpublished 
CGRP Synthetic calcitonin gene related peptide 
Rabbit 
polyclonal 
Chemicon, Temecula, CA; 
cat no. AB15360 
By immunohistochemistry both antibodies 
react with peptidergic primary afferent 
terminals. Specific reactivity of these antisera 
is eliminated by pre-incubation with excess 
peptide antigens 
(Chang et al., 2004; 
Dirmeier et al., 2008) Substanc
e P 
Substance P conjugated 
to BSA 
Rat 
monoclonal 
Bachem, St.Helen, UK; cat. 
no. T-1609 
Cholera 
toxin B 
 
cholera toxin B 
subunit (cholerogenoid) Goat serum 
List Biological Laboratories, 
Campbell, CA; cat. no. 
7032A6 
immunoprecipitation of cholera toxin B 
subunit; selective detection of CTB injected 
into peripheral nerves; co-localization with 
vGluT2 in primary afferent terminals 
(Todd et al., 2003) 
Gephyrin Affinity-purified rat glycine receptors 
Mouse 
monoclonal, 
clone 7a 
Synaptic Systems 
(Gottingen, Germany); cat. 
no. 147011 
Selective detection of gephyrin in inhibitory 
synapses; detection of recombinant gephyrin 
expressed in neurons 
(Pfeiffer et al., 1984; 
Sassoè-Pognetto et al., 
2000) 
GFP 
Purified recombinant 
green fluorescent 
protein 
Chicken IgY 
fraction from 
yolks 
Aves laboratories, Portland, 
OR; cat. no. GFP-1020 
Western blot analysis;  
immunohistochemistry using transgenic 
mice expression the GFP gene product. 
(Encinas et al., 2006) 
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     The nonpeptidergic fibers were identified by the marker Isolectin B4-alexa 488 conjugate from Molecular probes, Eugene, OR, USA, cat no. 121411.  
 
Tab. 1. Primary antibodies used.  
Protein 
kinase C 
Synthetic peptide 676-
689 of human PKC 
(VNPDFVHPDARSPT) 
Mouse 
monoclonal, 
clone 20 
BD Transduction 
laboratories; cat no.  611158 
Western blot analysis; 
immunohistochemistry (Neumann et al., 2008) 
Versican 
recombinant protein 
fragment of GAG- 
domain of mouse 
versican 
Rabbit 
affinity 
purified 
gift from Prof. Dieter 
Zimmermann 
Immunoblotting of the fusion protein and 
crude mouse brain extracts; co-localization 
with IB4 in primary afferent terminals 
(Schmalfeldt et al., 1998; 
Zimmermann et al., 1994) 
VIAAT 
Synthetic peptide 75-87 
of rat VIAAT 
(AEPPVEGDIHYQR) 
Rabbit 
affinity 
purified 
Synaptic Systems; cat. no. 
131003 
Specific for the mammalian vGAT 
demonstrated by Western blotting and 
immunohistochemistry; selective detection 
of GABAergic terminals in brain sections 
and primary neuron cultures 
(Brünig et al., 2002; 
Fritschy et al., 2006; 
Panzanelli et al., 2009) 
vGluT1 
Recombinant GST-
fusion protein 
containing amino acid 
residues 456-561 of rat 
vGluT1 
Rabbit serum Synaptic Systems; cat. no. 135002 
Specific for the mammalian vGluT1 
demonstrated by Western blotting and 
immunohistochemistry 
(Bellocchio et al., 2000; 
Fujiyama et al., 2001; 
Todd et al., 2003) 
vGluT2 
Recombinant GST-
fusion protein 
containing amino acid 
residues 510-582of rat 
vGluT2 
Rabbit serum Synaptic Systems; cat. no. 135102 
Specific for the mammalian vGluT2 
demonstrated by Western blotting and 
immunohistochemistry; selective detection 
of a subset of glutamatergic axon terminals 
in brain sections 
(Fremeau et al., 2004; 
Nahmani and Erisir, 2005) 
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Results 
 
Differential distribution of GABAAR  subunits in mouse spinal dorsal horn 
The distribution of  subunit variants was examined in transverse sections of the lumbar 
spinal cord using immunoperoxidase staining with subunit-specific antibodies. In order 
to visually enhance the differences in staining intensity across layers, images are 
displayed in false-colors ranging from dark blue for weak signals to red, pink, orange, 
yellow and white for maximal intensity (Fig. 1A-E). For each antibody, signals were 
normalized to display the strongest signals in white, except for the 4 subunit, where 
only background was detected. Higher magnification images of the dorsal horn are also 
shown in color photomicrographs of immunoperoxidase staining (Fig. 1F-I). At the 
macroscopic level, 1, 2, 3, and5 subunit immunoreactivity showed a widespread 
but differential laminar distribution pattern, whereas the 4 subunit was not detectable 
although a strong signal was observed in specific forebrain regions (e.g., thalamus) using 
the same staining conditions (not shown). As described previously in rat (Bohlhalter et 
al., 1996), IR was restricted to the grey matter except for dendrites extending radially into 
the white matter. In lamina I, mainly the 2 and 3 subunits were detected, along with a 
few 1 subunit-positive cells. Staining for the 2 and 3 subunits was most intense in 
lamina II, along with a moderate 5 subunit-IR. In addition, the 1 subunit was detected 
in the innermost lamina II. In lamina III, all four subunit variants were present with a 
peak staining intensity for the 3 and 5 subunit, a moderate 2 subunit staining and 
weak 1 subunit-IR. The latter was stronger in laminae IV-V in which 2, 3, and 5 
subunit-IR was also detected at moderate levels. A distinct gradient of intensity was 
evident medio-laterally, culminating with intense staining of lamina X, around the 
central canal, notably for the 1, 2, and 3 subunit. In summary, a roughly 
complementary distribution pattern was observed between the  and  subunit in 
laminae I-III, whereas the 3 and 5 subunit largely overlapped in lamina III. The 
overall strong IR of these four  subunits (which all contribute to assembly of diazepam-
sensitive GABAAR) in the superficial dorsal horn compared with the intermediate zone 
and ventral horn underscores the relevance of GABAAR for processing of nociceptive 
inputs in the spinal cord. 
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Neuron-specific expression of  subunit variants 
To determine whether these differential distribution patterns reflect possible neural 
circuit specificity, we investigated the distribution of the four  subunit variants in 
neurons identified by their transmitter phenotype (glutamatergic, GABAergic, 
glycinergic) using transgenic mice expressing vGluT2-eGFP, GlyT2-eGFP, and GAD67-
eGFP, respectively. To unambiguously determine the laminar distribution of these 
neuronal populations, CGRP was used as a marker to differentiate lamina I from lamina 
IIo (Fig. 2A) and IB4 for separating lamina IIo from lamina IIi. In preliminary 
experiments, we confirmed that IB4 labeling is limited to the outer part of lamina IIi (Fig. 
2A), using PKC as a specific marker of lamina II-III boundary (Neumann et al., 2008). 
Figure 2B-C illustrates in fluorescence microscopy the three classes of interneurons with 
respect to IB4 labeling. Both vGluT2-eGFP- and GAD67-eGFP-positive neurons were 
distributed evenly in laminae IIo, IIi and III, whereas GlyT2-eGFP-positive neurons were 
mainly located in laminae III-IV and scarcely in lamina IIo at the border with lamina I.  
 
We analyzed systematically each neuronal population to determine which proportion of 
them was immunopositive for the 2/3 subunits (most abundant in layer II) and 
1/5 subunits (most abundant in layers III-IV). Data are pooled from 2-3 mice per 
genotype, with ≈50 randomly selected eGFP-positive neurons per mouse being assessed 
in each lamina for colocalization with  subunit-IR. This analysis was performed in 
perfusion-fixed tissue, in which eGFP signals are optimally preserved, notably in thin 
dendritic profiles. Under these conditions, staining was rather uniform and diffuse in the 
neuropil and it was not possible to distinguish postsynaptic from extrasynaptic GABAAR 
subunit staining (Fritschy et al., 1998). Double-labeled dendrites were also seen, but were 
not quantified, as they could not be allocated to identified cells. Therefore, quantitative 
analysis was restricted to double-labeled cell bodies.  
 
 
Fig. 1. Differential distribution of GABAAR  subunit variants in adult mouse lumbar spinal cord. A-E: Each 
panel shows a color-coded photomicrograph of a coronal hemi-section processed for immunoperoxidase 
staining with subunit specific antibodies. The intensity of pixel was normalized using a custom-made look-
up table showing the strongest signal in white and the background in dark blue, except for the 4 subunit, 
where only background staining was detected. Comparisons between antibodies are not relevant. 
Immunoreactive dendrites penetrating into the white matter are indicated with arrows. Notice the intense 
2- (B) and 3 subunit (C) IR in lamina I and II, and 1 (A), 3 and  subunit-IR (E) in lamina III-V, 
whereas 4 subunit-IR (D) was not detectable. In addition, the 1, 2, and 3 subunit-IR was prominent 
around the central canal (lamina X). F: Schematic representation of spinal cord laminae.  G-J: Color 
photomicrographs of the dorsal horn, depicting the cellular distribution of the 1, 2, 3, and 5 subunit in 
the superficial laminae. Scale bars, 100 m. 
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Further, we could not determine whether multiple  subunit variants were present in 
the same cell; however, this information is inferred when the total percentage of 
colocalization exceeds 100%. Representative examples of each colocalization pattern are 
shown in Figure 2D-O and the quantitative results are provided in Figure 3A-C.  
vGluT2-eGFP-positive glutamatergic neurons 
Considerable laminar specificity was observed in the distribution of  subunit variants 
in vGluT2-eGFP-positive cells, with 2/3 subunit-IR being each present in about 40% 
of cells in lamina IIo, along with the 5 subunit in a small fraction of cells, whereas in 
lamina IIi, almost all eGFP-positive cells were double-labeled for the 3 subunit and 
>50% for the 2 subunit. In lamina III, vGluT2-eGFP-positive cells likely expressed more 
than one  subunit variant, the proportion of co-localization ranging from 25% for the 
2 subunit to 70% for the 3 subunit, with a significant contribution of 1 and 5 
subunit, as well (Fig. 3A). These percentages of colocalization well matched the fraction 
of dendritic profiles immunoreactive for each subunit in the various laminae (Fig. 2D, G, 
J, M), suggesting overall a somato-dendritic localization of GABAAR in glutamatergic 
dorsal horn interneurons and a major influence of 3-GABAAR, notably in lamina IIi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Layer-specific allocation of  subunit variants in identified subpopulations of eGFP-positive dorsal 
horn neurons. A-C: Images depicting vGluT2-eGFP (A-A’), GAD67-eGFP (B) and GlyT2-eGFP (C) neurons 
(green) in laminae I-III distinguished by IB4 (blue) labeling of non-peptidergic primary afferents, as well as 
PKC (red, panel A only). D-O: Double fluorescence labeling with antibodies to the 1, 2, 3, and 5 
subunit (magenta) and eGFP (green), depicting colocalized voxels in white. Each image represents a stack of 
13 confocal layers spaced by 0.3 μm. Each column represents a different neuronal marker; the lamina from 
which each image was taken is indicated in the lower right corner; neurons identified as double-labeled are 
shown with arrows, whereas arrowheads point to examples of double-labeled dendrites. Note that the 
majority of  subunit immunoreactive puncta are not associated with eGFP-positive dendrites; even in those 
cases when most somata are double-labeled (e.g., panels E or H). Scale bars: A-C 20 m; D-O 10 m. 
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GAD67-eGFP-positive GABAergic interneurons 
In contrast to the pattern shown by excitatory interneurons, only around 5% GAD67-
eGFP-positive cells in lamina IIo had 2 subunit-IR, along with 72% of cells in lamina IIi. 
Besides, 2 subunit-IR was present in around 40% cells located at the lamina IIi-III 
border. 3 subunit-IR was observed in 37 and 85% of GAD67-eGFP-positive cells in 
lamina IIo and IIi respectively. Therefore, in lamina IIi most of these cells have both 2- 
and 3-GABAAR. In lamina III, 3 subunit-IR was observed in 50% of GAD67-eGFP-
positive cells and the 5 subunit-IR in 60% of them, suggesting possible co-occurrence of 
these subunits in individual neurons. As seen for vGluT2-eGFP neurons, a large fraction 
of GAD67-eGFP-positive dendritic profiles were double-labeled for the 2 or 3 
subunits in these experiments (Fig. 2E, H, K, N), suggesting that GABAergic synapses 
are distributed onto both dendritic and perisomatic areas. 
GlyT2-eGFP-positive glycinergic neurons 
GlyT2-eGFP-positive glycinergic cell somata were strikingly rare lamina II (absent in 
lamina IIi) and were more frequently detected in laminae III-V. The majority of the few 
cells in lamina IIo contained both 2 and 3 subunits and almost all GlyT2-eGFP-
positive neurons in deeper laminae were positive for the 3 subunit-IR. The 1 and  
subunits were detected in a few fluorescent cells of lamina IIo, (around 10-15%) and 
about 25% in lamina III (Fig. 3C). The dendrites of glycinergic neurons were only 
occasionally labeled for a GABAAR subunit (Fig. 2F, I, L, O), suggesting a concentration 
of inputs in the perisomatic area. 
 
 
 
  
 
 
 
 
Fig. 3. Quantitative analysis of the distribution of  subunit variants in dorsal horn eGFP-positive neurons 
and in primary afferent terminals. A-C: Colocalization frequency of  subunit IR in vGluT2-eGFP (A), 
GAD67-GFP (B) and GlyT2-eGFP (C) neurons, subdivided by lamina. The data are pooled from 2-3 mice per 
genotype. D: Percentage colocalization (mean ± SD) of CGRP- (lamina IIo), IB4- (lamina IIi), and CTB- 
(lamina III) positive primary afferent profiles with  subunit variants in C57BL/6J mice. E: Density of  
subunit immunoreactive clusters (mean ± SD; n=3 mice/group) colocalized with CGRP-, IB4-, and CTB-
positive profiles. Colocalization was quantified in six sections per mouse.  
Results (Paper 3) 
 
111 
 
 
 
Results (Paper 3) 
 
112 
 
GABAAR subunit distribution in primary afferent terminals  
A large fraction of the neuropil staining seen for the various  subunit variants was not 
colocalized with dendritic profiles. Therefore, we investigated whether this pattern 
reflects the presence of GABAAR in primary afferent fiber terminals. CGRP and IB4 
labeling were used to reveal peptidergic and non-peptidergic C-fibers, respectively. The 
specificity of these markers was confirmed by double labeling with antibodies against 
substance P to label peptidergic fibers and against the extracellular matrix proteoglycan 
versican 2, an identified IB4-binding glycoconjugate (Bogen et al., 2005; Gibbins et al., 
1987) (data not shown). Myelinated fibers in the dorsal horn were labeled by 
transganglionic tracing of cholera toxin subunit B (CTB) injected into the sciatic nerve 
(Fig. 4A), as well as by immunofluorescence against vGluT1 (data not shown) (Todd et 
al., 2003). Triple labeling experiments performed using antibodies against CGRP and 
CTB along with either anti-PKC or fluorescently-tagged IB4 to confirm the distinct 
laminar distribution of these markers in primary afferent terminals in the dorsal horn 
(Fig. 4B-B'). CGRP, IB4 and CTB were then analyzed separately for colocalization of  
subunit-immunofluorescence. 
 
For all  subunit variants, we observed at high magnification that the punctate staining 
of the neuropil was partially colocalized with each of the three markers of primary 
afferents. For quantification, colocalization was defined by an intensity threshold 
algorithm using stringent criteria (see Materials and Methods). It is of note, however, 
that the region containing the presynaptic active zone could not be identified in primary 
afferent profiles, because neither vGluT1 nor vGluT2 are detectable in the terminals of C-
fibers. Quantitative results are presented in Fig. 3D-E, representing average data (± SD) 
from 5 mice per group. 
 
 
 
 
Fig. 4. Immunohistochemical identification of  subunit-IR inside primary afferent terminals.  A: Illustration 
of transganglionic and retrograde transport of CTB injected into the sciatic nerve. Note the extensive labeling 
of axons in the ipsilateral dorsal horn and neuronal somata in the ventral horn. B: Lamina-specific 
distribution of the three classes of primary afferents in the superficial dorsal horn, demonstrated by triple 
labeling for CGRP (peptidergic fibers; blue) in lamina IIo, IB4 (non-peptidergic fibers; green) in lamina Iii, 
and CTB-positive myelinated fiber terminals (magenta) in lamina III. B’: Triple labeling for CGRP (green), 
IB4 (blue) and PKC (magenta) confirmed the localization of non-peptidergic afferents in the outer part of 
lamina IIi. C-F: Representative images for double staining experiments depicting with high resolution the 
punctate distribution of  subunit IR (magenta) relative to afferent terminals (green), as well as their 
colocalization (white). Framed areas are enlarged in panels G-J. Scale, A, 200 m; B: 20 m; C-F: 5 m; G-I: 
0.5 m.  
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In lamina IIo, a large fraction of CGRP-positive profiles, 28% and 59%, respectively, 
contained 2 and 3 subunit-IR (Fig. 4A-J). Likewise, 43% and 46% of IB4-labeled 
profiles in lamina IIi, and 18% and 21% of CTB-positive profiles in lamina III were 
colocalized with 2 and 3 subunit-IR (Fig. 3D). The density of puncta immunoreactive 
for each subunit was also analyzed (Fig. 3E). Lamina IIo showed a density of 38 and 85 
2 and 3 subunit puncta, respectively, colocalized with CGRP-IR per 1000 m2. In 
lamina IIi and III, 56 2 subunit and 58 3 subunit puncta were co-localized with IB4 
labeling, and 28 and 40 with CTB-IR.  
 
The 1 subunit was scarcely detected in CGRP- and IB4-positive profiles in lamina II, 
suggesting that it is not associated with C-fibers (Fig. 3D, E), in spite of the moderate 
staining intensity for this subunit in lamina IIi (Fig. 1). In contrast, 1 subunit-IR was 
detected in 13% CTB-positive profiles in lamina III, representing 15 puncta per 1000 m2 
(Fig. 3E). 
 
The 5 subunit showed high colocalization rate with CGRP-positive profiles (15%), but 
less than 3% with IB4-labeled profiles (Fig. 3D). The highest colocalization rate for the 5 
subunit was detected in CTB-IR profiles, reaching 44%. The density analysis showed 17, 
1 and 22 puncta per 1000 m2 in CGRP, IB4 and CTB staining, respectively (Fig. 3E). 
 
 
 
 
 
 
Fig. 5. Evidence for axo-axonic GABAergic synapses on primary afferent terminals. A: Postsynaptic 
distribution of gephyrin clusters (green) in the mouse spinal dorsal horn demonstrated by extensive 
apposition to presynaptic terminals positive for VIAAT (blue; arrow). B: Western blot analysis of gephyrin 
in crude mouse brain extracts and dorsal root ganglia. All bands, loaded with three different protein 
amounts, are from a single blot. C-G: Representative image showing the postsynaptic localization of 3 
subunit and gephyrin clusters in primary afferent terminals apposed to a VIAAT-positive terminal. 
Quadruple labeling was performed in fresh-frozen tissue to optimize detection of postsynaptic proteins. C: 
Quadruple staining for the 3 subunit (red), gephyrin (green), IB4 (blue) and VIAAT (orange); the stack of 
confocal images is displayed in the 3 Cartesian planes, with arrowheads pointing to axo-axonic synapses and 
the arrow to a terminal containing the 3 subunit, but not gephyrin, shown in 3D. D: Distribution of pixels 
depicting 3 subunit/gephyrin (yellow) and 3 subunit-IB4 (magenta) co-localization relative to primary 
afferents and VIAAT-positive terminals, showing quadruple labeling of axo-axonic synapses (white; 
arrowheads). E-G: Patterns of colocalization between pairs of markers depicted in color-separated panels, as 
indicated. Scale, A: 5 m; C-G: 3 m. 
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These data reveal a clear specificity in the occurrence of GABAAR subtype markers in 
primary afferent terminals of the superficial dorsal horn, with peptidergic and non-
peptidergic fibers being associated mainly with the 3 and 2 subunits; in addition, 
some peptidergic fibers contain 5-GABAAR, whereas CTB-positive profiles, 
representing myelinated fiber terminals, are associated with the four diazepam-sensitive 
 subunit variants.  
 
Identification of putative GABAergic synapses on primary afferent terminals 
The presence of GABAAR in primary afferent suggests a major role for filtering incoming 
nociceptive sensory information. To determine whether this function is assumed by 
GABAergic synapses, we carried our analysis further to visualize postsynaptic 2 and 
3 subunit clusters, apposed to presumptive presynaptic terminals identified by staining 
for vesicular inhibitory transporter (VIAAT) and colocalized with gephyrin within 
labeled primary afferent terminals. These two markers allow for a selective 
discrimination of pre- and postsynaptic components of inhibitory synapses. These 
experiments were performed in weakly fixed tissue to maximize the detection of 
postsynaptic proteins (see Materials and Methods). As a prerequisite, double 
immunofluorescence experiments showed a systematic apposition of VIAAT-positive 
profile to gephyrin clusters, indicating the presence of postsynaptic GABAAR (Fig. 5A). 
While a large fraction of these gephyrin clusters likely are located postsynaptically in 
dendrites and neuronal somata, confocal laser scanning microscopy analysis showed 
gephyrin clusters also in a subset of peptidergic and non-peptidergic C-fibers in laminae 
I-II, as well as myelinated fibers in laminae III-V (data not shown). A substantial fraction 
(≈30%) of these gephyrin clusters was colocalized with the 2 and 3 subunit-IR.  
 
Quadruple immunohistochemistry was performed eventually with the combination of 
VIAAT, gephyrin, a primary afferent marker and 2 or3 subunit antibody (Fig. 5C-G), 
using primary antibodies raised in different species. We detected gephyrin along with 
either 2 or 3 subunit-IR in individual primary afferent terminal profiles from all three 
classes apposed to a VIAAT-profile, suggestive of a synaptic contact. A representative 
example is shown for the 3 subunit in IB4-positive terminals (Fig. 5C-G). These 
observations provide a proof-of-principle for the presence of 2- and 3-GABAAR 
associated with gephyrin in axo-axonic synapses onto primary afferent terminals.  
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Gephyrin mRNA and protein expression in DRG neurons 
To validate the presence of gephyrin-IR inside primary afferent terminals, we verified 
that gephyrin is expressed in the DRG using qRT-PCR and Western blotting. Thus, qPCR 
analysis using Taqman assays using -actin as reference confirmed the detection of 
gephyrin mRNA in DRG lysate. Relative to GAPDH, gephyrin mRNA copy number 
detected was 2.25±1.1%.  Likewise, Western blot analysis of gephyrin in crude extracts of 
lumbar DRG and adult mouse brain homogenate as control confirmed the presence of 
gephyrin protein in both preparations, detected as a band with apparent molecular 
weight of 95 kDa (Fig. 5B). 
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Discussion 
The present results demonstrate that the differential laminar distribution of GABAAR 
subtypes in the dorsal horn, distinguished by their  subunit variant, corresponds to a 
complex cell-specific and primary afferent-specific expression pattern. These findings 
provide a framework to investigate how GABAAR subtypes differentially regulate 
sensory processing and pain by controlling the activity of different neuronal networks. 
The highest degree of GABAAR heterogeneity occurs in lamina III, suggesting the 
existence with multiple parallel circuits controlled by distinct GABAAR, as well as 
convergence of circuits impinging onto spinal cord neurons that express multiple 
GABAAR subtypes. GABAAR in glutamatergic primary afferents and neurons likely 
mediate inhibition by controlling transmitter release and postsynaptic excitation, 
respectively. In contrast, GABAA-mediated inhibition of GABAergic interneurons might 
be of particular relevance for disinhibition of specific neuronal circuits (Labrakakis et al., 
2009). Pharmacologically, GABAAR heterogeneity in spinal cord circuits is of immediate 
relevance for the treatment of distinct pain modalities with subtype-selective ligands. 
Methodological considerations 
Compelling evidence from morphological, functional, and pharmacological studies 
indicates that the six  subunit variants correspond to distinct GABAAR subtypes 
(Fritschy and Brunig, 2003; Olsen and Sieghart, 2008; Rudolph et al., 2001; Sieghart, 2006) 
and, therefore, can be used as subtype markers for immunohistochemistry. Importantly, 
because an  subunit is required for assembly and cell surface expression of most 
GABAAR (Kralic et al., 2006; Panzanelli et al., 2011; Studer et al., 2006; Sur et al., 2001; 
Vicini et al., 2001), their detection by immunofluorescence implies the presence of  and 
 subunit variants in the same cells. However, one cannot distinguish in neurons 
expressing two different  subunit variants whether they are part of the same receptor 
complex or correspond to two receptor subtypes intermingled within the same synapse 
(Panzanelli et al., 2011). Therefore, it is not possible to define morphologically or 
functionally all neuronal circuits controlled by a given GABAAR subtype. 
 
Despite the importance of inhibitory neurotransmission for nociception, there is only 
limited information available on the cellular and subcellular distribution of GABAAR in 
the spinal cord dorsal horn, in part due to technical limitations. First, the small size of 
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neurons and thin diameter of their dendrites, combined with their high packing density 
and the presence of numerous immunopositive primary afferent terminals, makes it very 
difficult to assign an immunopositive profile to an identified cell. In particular, the 
distinction between postsynaptic and extrasynaptic GABAAR, which in brain sections 
can be achieved in mildly-fixed tissue (Schneider Gasser et al., 2006), is obscured in the 
spinal cord by the extensive labeling of primary afferent terminals. Furthermore, using 
transgenic mouse lines, which express eGFP in a neurotransmitter-specific manner, it is 
not certain that all neurons using this neurotransmitter are labeled. In particular, 
GABAergic neurons expressing only GAD65-only are not visible in GAD67-eGFP mice 
(Tamamaki et al., 2003; Wang et al., 2009). Likewise, while vGluT2-eGFP is expressed 
selectively in glutamatergic neurons, it is not known which fraction of these cells express 
this marker. A further limitation of the method is that it did allow us to quantify double 
labeled cells only on the basis of somatic, but not dendritic labeling. 
 
With regard to primary afferent terminals, colocalization analysis is limited by the 
resolution of confocal microscopy, in particular along the z-axis. We have taken a 
conservative approach based on stringent criteria for assessing the presence of  
subunit-IR inside labeled primary afferent terminals (see Materials and Methods). The 
validity of this approach was confirmed recently by the analysis of the 2 subunit in 
mice carrying a conditional deletion of Gabra2 selectively in nociceptors (Witschi et al., 
2011). However, in the absence of a marker of the presynaptic active zone or presynaptic 
vesicles in primary afferent terminals, it was not possible to determine the localization of 
 subunit-IR relative to these structures. To overcome this problem, we attempted to 
determine the presence of axo-axonic GABAergic synapses onto primary afferent 
terminals, using VIAAT and gephyrin as markers. This approach provided strong 
evidence that such synapses exist in principle, in line with ultrastructural evidence for 
the presence of axo-axonic GABAergic synapses on primary afferent glomeruli (Ribeiro-
da-Silva and Coimbra, 1982; Ribeiro-da-Silva et al., 1985; Todd, 1996). However, 
although our approach did not allow a reliable quantification of their abundance, only a 
minority of profiles immunopositive for CGRP or IB4, as well as those labeled with CTB 
appeared to contain a gephyrin cluster. Such negative results may not be fully 
conclusive, especially when presynaptic terminals cannot be distinguished from 
preterminal axons, but they still suggest that in the majority of cases, GABAAR in C-fiber 
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terminals or in myelinated nociceptor terminals are activated by GABA spillover in the 
extracellular space, rather than by phasic GABA release.  
Organization of GABAAR subtypes in intrinsic spinal dorsal horn neurons 
Despite these limitations, our results clearly show that the four  subunit variants 
contributing to the assembly of diazepam-sensitive GABAAR (Rudolph and Mohler, 
2006) are present in the spinal cord dorsal horn with distinct laminar, cellular and 
subcellular distributions. Therefore, modulation of distinct pain modalities and/or 
functional alterations of GABAergic inhibition in specific neuronal circuits in the dorsal 
horn can be expected from our results in models of chronic pain. Moreover, the failure to 
detect the 4 subunit indicates that this diazepam-insensitive GABAAR subtypes likely 
plays only a minor role in the spinal cord.  
 
We observed a distinct laminar distribution of the 1, 2, 3, and 5 subunit-IR with 
considerable overlap within individual laminae. These findings imply that some neurons 
express multiple  subunit variants (notably 2/3 in lamina IIo), whereas others have 
a single  subunit (notably in lamina IIi and III). A striking overall feature is the 
prominent 2 subunit staining in lamina II  also observed in the rat (Bohlhalter et al., 
1996), which contrasts with the lack of 2 subunit mRNA expression reported in the 
dorsal horn (Persohn et al., 1991; 1992; Wisden et al., 1991). However, our present data 
demonstrate the presence of eGFP-positive cells immunoreactive for the 2 and 3 
subunit in lamina II, with a predominance of the 3 subunit-IR (Knabl et al., 2008). 
Therefore, in situ hybridization with radiolabeled oligonucleotides might lack sensitivity 
for detecting 2 subunit mRNA in lamina II neurons. Nevertheless, most 2 subunit-IR 
was located in the neuropil, presumably on primary afferent terminals and possibly also 
on dendrites from neurons located in deeper layers.  
 
Glutamatergic neurons identified by vGluT2-eGFP expression likely express different  
subunits in lamina IIo (either 2 or 3 subunit) and III (1, 5, 3), and both 2/3 
subunits in lamina IIi, providing a clear example of differential control by distinct 
GABAAR subtypes. The implications of such observations are that subtype-selective 
GABAAR ligands would produce distinct effects on glutamatergic neuronal circuits in 
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these three laminae, which are innervated by different subpopulations of primary 
afferent terminals. 
 
It is most remarkable that at least 40% GAD67-eGFP neurons apparently lack labeling for 
any GABAAR subunit on their soma in lamina IIo (Figure 3), despite the abundant 2 
and 3 subunit-IR in this sublamina, suggesting that these GABAergic neurons receive 
only limited perisomatic GABAergic inhibitory input. As noted above, our study 
provides no data on cells selectively expressing GAD65 in the spinal cord. Such cells are 
rare in the forebrain, where GAD67-eGFP labels the vast majority of GABAergic cells 
(Tamamaki et al., 2003). In case of spinal cord, GAD65 has been shown to be expressed in 
a specific GABAergic interneuronal population, which is specifically presynaptic to the 
proprioceptive terminals (Betley et al., 2009; Hughes et al., 2005).  
 
Glycinergic neurons, which are rare in lamina IIo but abundant in lamina III, widely 
express the 3 subunit, along with either 2 in lamina IIo, or, in equal proportion 1, 2 
or 5 subunit in lamina III. These features provide a substrate for possible cross-talk 
between the two inhibitory systems.  
Functional organization of GABAA receptor subtypes on primary afferent 
terminals 
Primary afferent depolarization is well known to occur in spinal cord, and GABAAR 
have been shown long ago to mediate the inhibition of potassium-stimulated CGRP 
release in spinal cord tissue (Bourgoin et al., 1992). Overall, the presence of presynaptic 
GABAAR in major brain regions, including cerebral cortex, hippocampus, and 
cerebellum, is undisputed (Hutcheon et al., 2000; Trigo et al., 2010; Vautrin et al., 1994). 
However, immunohistochemical studies have largely failed so far to reveal their 
distribution and subunit composition. Therefore, the spinal cord appears to be unique 
for the prominent labeling of multiple GABAAR subunits in terminals of both myelinated 
and non-myelinated sensory afferents. The present study confirms our previous 
observations (Knabl et al., 2008; Witschi et al., 2011) and provides proof-of-principle 
evidence that these GABAAR correspond, at least in part, to axo-axonic synapses, with a 
postsynaptic density containing the scaffolding protein gephyrin. Moreover, our results 
show an IR pattern of the various  subunit variants compatible with a complementary 
distribution (one GABAAR subtype per afferent terminal); C-fiber terminals containing 
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either 2- or 3-GABAAR, whereas myelinated terminals in layer III containing in 
roughly equal proportion one of the four diazepam-sensitive GABAAR subtypes. These 
results are compatible with the notion that distinct GABAAR subtypes modulate the 
function of primary afferent carrying specific pain modalities and/or being differentially 
involved in various forms of chronic pain (Zeilhofer et al., 2012a; Zeilhofer et al., 2009). 
Moreover, while diazepam can be expected to potentiate the action of GABAAR in 
primary afferents, subtype-selective ligands would potentially exert more selective 
effects. 
 
There is increasing evidence for the existence of segregated circuits mediating specific 
pain-related modalities in the dorsal horn (Neumann et al., 2008; Todd, 2010; Zylka et al., 
2005). For instance, a differential distribution of- and -opioid receptors in subsets of 
peptidergic and non-peptidergic nociceptors, respectively, regulating distinct pain 
modalities (heat and mechanical pain) has been reported (Scherrer et al., 2009). TRPV1 
receptors, critical for the development of thermal hyperalgesia, also have been found to 
be restricted to a subset of peptidergic nociceptors in lamina IIo (Cavanaugh et al., 2011) 
whereas TRPV2, which is expressed non-peptidergic and myelinated nociceptors 
terminating in lamina IIi and in deeper laminae was conclusively shown to be 
dispensable for progression of thermal hyperalgesia (Park et al., 2011). In line with these 
observations, we have shown that mice lacking 2-GABAAR specifically in primary 
nociceptors (sns-2/ mice) exhibit reduced potentiation of dorsal root potentials and 
impaired thermal and mechanical anti-hyperalgesia by diazepam in a model of 
inflammatory pain (Witschi et al., 2011).  
 
The role of 3-GABAAR in lamina II neurons and primary afferents for the control of 
hyperalgesia is less well established. They contribute in part to thermal and mechanical 
hyperalgesia in models of inflammatory and neuropathic pain, possibly along with a 
contribution by 5-GABAAR (Knabl et al., 2008; Munro et al., 2011). Finally, based on 
their distribution on myelinated fibers and lamina III neurons, 5-GABAAR could have a 
major role in regulation of allodynia.  
 
The relevance of our finding possibility extends beyond pain control, notably if primary 
afferent depolarization were involved in other pathological sensory modalities, such as 
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itch. Both C-fibers and A-fibers have been shown to convey this sensation elicited by 
histamine (Andrew and Craig, 2001; Potenzieri and Undem, 2012; Schmelz et al., 1997). 
In addition, decreased inhibitory synaptic input to nociceptive terminals in lamina I-II 
elicits itch (Ross et al., 2010), in line with our findings.  
Conclusions 
Collectively, the present results show that GABAAR distribution in the primary afferent 
terminals and intrinsic dorsal horn neurons of the dorsal horn allows for multiple, 
circuit-specific modes of regulation of neuronal networks. This conclusion confirms 
previous evidence for a differential contribution of 2- and 2/3/5-GABAAR for 
thermal and mechanical anti-hyperalgesia, respectively (Knabl et al., 2008). The likely 
existence of parallel and serial connections involving GABAergic neurons allows for 
both inhibition and disinhibition in a pain modality-specific manner. This organization 
pattern of GABAARs in the adult spinal cord might be altered morphologically and 
functionally in chronic pain conditions. Identifying these alterations in mouse models of 
chronic inflammatory and neuropathic pain, will facilitate the design of novel 
therapeutic avenues based on GABAAR subtype-selective ligands.  
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 The studies presented in this thesis address the contribution of spinal GABAAR 
subtypes to BDZ-induced analgesia. Results from morphological, electrophysiological 
and behavioral experiments provide compelling evidence for the existence of a genuine 
analgesic, or better antihyperalgesic, action of spinal α2 GABAAR. Morphological 
experiments showed that spinal nociceptor terminals express α2 GABAAR together with 
α3 GABAAR. Specific ablation of the GABAAR α2 subunits from these nociceptor 
terminals partially prevented the antihyperalgesic action of intrathecally applied 
diazepam (chapter 3.1), while complete ablation of GABAAR α2 subunits from the spinal 
cord and periphery completely blocked the α2 GABAAR-dependent component of 
antihyperalgesia by the novel non-sedative BDZ site ligand HZ166 (chapter 3.2). These 
results are in perfect agreement with previous studies from our group (Knabl et al., 
2008), which attributed to α2 GABAAR a critical role in the spinal antihyperalgesic effects 
of intrathecally injected diazepam in inflammatory and neuropathic pain states – at least 
in rodents.  
 
While the dominant contribution of α2 GABAAR is widely accepted (Knabl et al., 2008; 
Knabl et al., 2009; Munro et al., 2009), it is less clear whether additional activity at α3 or 
α5 GABAAR is also needed (Munro et al., 2011). In two previous publications (Knabl et 
al., 2008, Knabl et al., 2009), our group has reported that α3 and α5 GABAAR also 
contribute to antihyperalgesia but less than α2 GABAAR and that their contribution 
varies depending on the sensory quality (heat, cold or mechanical) and on the type of 
pain model used (zymosan A, chronic constriction injury and formalin). In these studies, 
the contribution of α2 GABAAR was strongest for relief from heat hyperalgesia both after 
inflammation and neuropathy consistent with the prominent expression of GABAAR  α2  
subunits on nociceptor terminals in lamina IIo, as demonstrated in chapter 3.3 of this 
thesis. By contrast, myelinated sensory terminals in the deeper laminae, whose activation 
is responsible for touch-evoked pain (allodynia), expressed mainly  α5  and α3 subunits. 
In line with this differential expression, α3 and α5 GABAAR made stronger contributions 
to antihyperalgesia against mechanical allodynia than heat hyperalgesia (Knabl et al., 
2008). So far, our conclusions on the contribution of the different GABAAR subtypes 
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were mainly based on the loss of antihyperalgesic activity in GABAAR point-mutated or 
knock-out mice. These experiments provided important information on the GABAAR 
necessary for antihyperalgesia. It is however difficult to conclude from these 
experiments whether additional efficacy at α3  and α5 GABAAR would provide better 
antihyperalgesia than activity at α2 GABAAR alone. Work with the recently developed 
subtype-selective agonist NS 11394 (Mirza et al., 2008) points at a significant contribution 
of α5 GABAAR to antihyperalgesia (Munro et al., 2008). At present there are not enough 
subtype-selective compounds available that would allow addressing all possible subunit 
combinations. Alternatively, the generation of mice carrying point mutations in more 
than one α subunit would allow clarifying this issue in reasonable time span.  
 
The results of such studies will have important implications for the development of 
novel therapeutic approaches to chronic pain. Since several years, drug companies are 
working on the development of novel subtype-specific GABAAR modulators with 
improved tolerability or novel therapeutic indications (Griebel et al., 2001; Knabl et al., 
2009; Munro et al., 2008; Nickolls et al., 2011). Several such compounds have been 
developed in the last decade demonstrating that subtype-selective targeting of GABAAR 
is possible in principle. Most of these drug discovery and drug development programs 
aimed at compounds with improved selectivity at α2  and α3 GABAAR over 
α1 GABAAR. In most cases, the development of non-sedative anxiolytic drugs was the 
primary intention. However, several of these subtype-selective BDZ site ligands have 
meanwhile also been tested for potential antihyperalgesic activity in a wide variety of 
rodent pain models (Di Lio et al., 2011; Knabl et al., 2008; Munro et al., 2008; Nickolls et 
al., 2011). Most of these compounds exhibited significant antihyperalgesic effects in rat 
and mouse neuropathic pain models (tab. 1). In some studies, the efficacy reached was 
similar to that of gabapentin or pregabalin, drugs frequently used for the treatment of 
painful neuropathies in human patients (Di Lio et al., 2011; Nickolls et al., 2011). For 
several of these compounds, efficacy was also seen in inflammatory models, but efficacy 
was generally less than in neuropathic models. Comparison of the antihyperalgesic and 
anxiolytic efficacies of several subtype-selective compounds suggests that 
antihyperalgesia requires, in general, higher intrinsic activity than anxiolysis. This was 
also obvious from a previous study of our group (Knabl et al., 2009), which showed 
antihyperalgesic and sedative actions of systemic diazepam occur with similar dose-
dependencies, while anxiolysis can be reached already at 10-fold lower doses. 
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The positive results from our rodent studies and from those of other groups are in 
apparent contrast to clinical experience with classical BDZ. Although there are several 
anecdotal reports of beneficial effects in chronic pain patients (Tucker et al., 2004), 
classical BDZ do in general not exert analgesic actions after systemic treatment. 
Treatment guidelines include them typically as co-medications for their anxiolytic and 
muscle relaxant effects (Gold and Dribben, 1964; Højsted  et al., 2010; Khanderia and 
Pandit, 1987; Nordbø et al., 2012).  
There are several possible explanations for the discrepancies between the promising 
results from rodent studies and the lack of evidence from clinical experience in human 
pain patients. Although species differences in the distribution and the function of 
GABAAR subtypes in nociceptive pathways cannot be excluded at present, a recent 
study by Waldvogel et al. (2010) did not reveal major differences in the brain. An 
alternative explanation could be the higher susceptibility of the human brain to the 
sedative effects of BDZ site agonists. It has in fact been demonstrated that several 
compounds with reduced efficacy at α1 GABAAR caused sedation in human volunteers, 
although such sedative effects had not been found in preclinical rodent studies (De Haas  
et al., 2007). Antihyperalgesic action of classical non-selective BDZ might therefore only 
occur at concentrations, which induce already strong sedation in humans. Compounds 
suitable as antihyperalgesic agents for human treatment should therefore have a high 
intrinsic activity at α2 GABAAR (and perhaps also at α3 or α5 GABAAR) but very little 
activity at α1 GABAAR. Such compounds are not yet available for human testing.  
 
Part of the discrepancy of preclinical rodent data and clinical experience in human 
patients might also come from the different routes of administration. In most of our 
studies (including the study described in chapter 3.1 of this thesis) diazepam was given 
locally to the spinal cord, whereas under clinical conditions BDZ are usually given 
systemically. A few studies performed with intrathecal midazolam did in fact find 
evidence for the existence of BDZ-mediated analgesia also in human patients (Prochazka  
et al., 2011; Tucker et al., 2004). It is therefore possible that supraspinal GABAAR might 
counteract a spinal antihyperalgesic effect of BDZ. Results from chapter 3.2 of this thesis 
argue against a significant effect of supraspinal α2 GABAAR on antihyperalgesia, but 
similar evidence is not yet available for the other GABAAR subtypes.  
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L-838417 which almost completely lacks activity at α1 GABAAR and which exhibits 
moderate activity at α2, α3, and α5 GABAAR, is antihyperalgesic in different rodent 
models of inflammatory and neuropathic pain (Knabl et al., 2008; Nickolls et al., 2011), 
but has very poor pharmacokinetic properties in man preventing its testing in human 
volunteers or patients (tab.1). Another highly selective compound is TPA023 (low 
intrinsic activity at α2  and α3 GABAAR, negligible activity at α1 and α5 GABAAR shows 
only moderate antihyperalgesic activity in some but not all rodent pain models most 
likely due to its low intrinsic activity (Nickolls et al., 2011). HZ166 is another recently 
developed BDZ site ligand with high activity at α2 and α5 GABAAR but reduced 
sedative properties (Rivas et al., 2009; Fischer et al., 2010; Di Lio et al., 2011). In mice it 
exerts antihyperalgesic activity comparable to that of non-sedative doses of gabapentin. 
This compound has not yet gone through human tolerability screening and is therefore 
not available for human studies. Whether its therapeutic window is sufficiently broad to 
allow antihyperalgesic activity in the absence of sedation is not clear.  
 
The question whether subtype-selective GABAAR agonists exert antihyperalgesic activity 
in humans cannot be answered conclusively at this stage but will depend on the future 
availability of compounds with high intrinsic activity at α2 GABAAR (and perhaps α3 
and α5 GABAAR) and high selectivity over α1 GABAAR in addition to suitable 
pharmacokinetic properties and good tolerability in humans. Hopefully such 
compounds will become available soon from on-going drug development programs at 
several pharmaceutical and biotechnological companies (Rogawski, 2006). 
 
In summary, using the classical BDZ, diazepam, and the more recently developed BDZ 
site ligand, HZ166, and a combination of anatomical, electrophysiological and behavioral 
tools, this dissertation has provided proof-of-principle evidence that spinal α2 GABAAR, 
which are abundant in the primary afferent terminals and dorsal horn interneurons, are 
the predominant contributors to the antihyperalgesic actions of GABAAR. 
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*Compound 2 in Rivas et al., 2009 
Tab 1. Subtype selectivity of BDZ Site Ligands.  
 
Relative potentiation (%) 
 
Compound 
α1 α2 α3 α4 
 
Reference 
 
Effects in pain models 
 
 
NS11394 
 
7.8 
 
26 
 
52 
 
78 
 
Munro et al., 2008 
antinociceptive in rat formalin and capsaicin test; 
antihyperalgesic in CFA inflammation, CCI and SNI. 
 
HZ166* 
 
27 
 
52 
 
36 
 
23 
 
Di Lio et al., 2011 
 
antihyperalgesic in mouse zymosan A and CCI 
 
 
SL651498 
 
70 
 
>100 
 
83 
 
50 
Griebel et al., 2001 
 
Knabl et al., 2009 
reduced electrically evoked flexor responses in rats; 
antinociceptive in mouse formalin test 
 
L-838,417 
 
1 
 
15 
 
12 
 
32 
 
Knabl et al., 2008 
 
Nickolls et al., 2011 
antihyperalgesic in rat zymosan A and CCI, 
antiallodynic in rat SNL but not TNT; 
antihyperalgesic but no antiallodynic effect in rat CFA 
 
TPA023 
 
0.6 
 
4 
 
9 
 
5 
 
Nickolls et al., 2011 
antiallodynic in rat SNL; no antihyperalgesic effect in 
rat CFA 
 
Zolpidem 
 
153 
 
75 
 
78 
 
13 
 
Munro et al., 2008 
effective in rat formalin and capsaicin, but only at 
sedative doses 
 
Bretazenil 
 
73 
 
21 
 
33 
 
42 
 
Munro et al., 2008 
no antihyperalgesia in rat  CCI and SNI at non-
sedative doses 
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6 Appendices 
 
6.1  Abbreviations 
 
ACC    Anterior cingulate cortex  
aCSF    artificial cerebrospinal fluid  
BDNF    Brain derived neurotrophic factor  
BDZ   Benzodiazepines  
CCI   Chronic constriction injury  
CGRP   Calcitonin-gene related peptide  
COX-2   Cyclooxygenase-2  
CVLM   Caudal ventrolateral medulla  
DAB    Diaminobenzidine tetrahydrochloride  
DRG    Dorsal root ganglion  
DRPs    Dorsal root potentials  
DZP    Diazepam  
EPSC    Excitatory postsynaptic currents  
ERKs   Extracellular signal-regulated kinases  
GABAAR   GABAA receptors 
GABABR   GABAB receptors 
GAD    Glutamate decarboxylase  
GAPDH   Glyceraldehyde-3-phosphate dehydrogenase  
GDNF    Glial-derived neurotrophic factor  
GLYT2   Glycine transporter type 2  
i.p.   Intraperitonial 
i.t.   Intrathecal  
IB4   Isolectin B4  
IR    Immunoreactivity  
LPb    Lateral parabrachial area  
LTP    Long term potentiation  
mPGES-1  microsomal prostaglandin E synthase-1 
153
Appendices 
 
 
MRGPRD   Mas-related G-protein-coupled receptor member D  
NGF    Nerve growth factor  
NK1R    Neurokinin 1  receptor 
NKCC1  Sodium-potassium-chloride transporter  
NO    Nitric oxide  
NTS    Nucleus of the solitary tract  
PAD   Primary afferent depolarization  
PAG    Periaqueductal grey matter  
PBS    Phosphate-buffered saline  
PFA    Paraformaldehyde  
PGE2   Prostaglandin E2  
PWL    Paw withdrawal latencies 
PWT   Paw withdrawal thresholds  
qRT-PCR   quantitative reverse transcriptase polymerase chain reaction  
RVM    Rostroventromedial medulla  
SNI   Spared nerve injury  
sns    sensory neuron specific sodium channel  
TBST    Tris buffered saline-Tween 20  
TRPV-1  Transient receptor potential vanilloid- 1 receptor 
TTX   Tetrodotoxin 
VGCCs   Voltage-gated calcium channels  
VGLUT1  Vesicular glutamate transporter 1  
VIAAT  Vesicular inhibitory amino acid transporter  
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